CN104220058A - 丝氨酸消旋酶抑制剂 - Google Patents
丝氨酸消旋酶抑制剂 Download PDFInfo
- Publication number
- CN104220058A CN104220058A CN201380017021.8A CN201380017021A CN104220058A CN 104220058 A CN104220058 A CN 104220058A CN 201380017021 A CN201380017021 A CN 201380017021A CN 104220058 A CN104220058 A CN 104220058A
- Authority
- CN
- China
- Prior art keywords
- group
- atom
- nmr
- general formula
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940122833 Serine racemase inhibitor Drugs 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 86
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- -1 N-(substituted)-2-(substituted sulfamoylamino)-acetamide Chemical class 0.000 claims description 103
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 87
- 125000001424 substituent group Chemical group 0.000 claims description 85
- 125000000217 alkyl group Chemical group 0.000 claims description 77
- 125000005843 halogen group Chemical group 0.000 claims description 70
- 125000003545 alkoxy group Chemical group 0.000 claims description 58
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 57
- 125000004429 atom Chemical group 0.000 claims description 50
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 44
- 125000003118 aryl group Chemical group 0.000 claims description 38
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 33
- 229910052717 sulfur Inorganic materials 0.000 claims description 20
- 125000004434 sulfur atom Chemical group 0.000 claims description 19
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 125000002252 acyl group Chemical group 0.000 claims description 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 14
- 150000008331 benzenesulfonamides Chemical class 0.000 claims description 13
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 5
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000006413 ring segment Chemical group 0.000 claims description 4
- 125000005504 styryl group Chemical group 0.000 claims description 4
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 160
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 135
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 126
- 238000002844 melting Methods 0.000 description 123
- 230000008018 melting Effects 0.000 description 123
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 110
- 239000002904 solvent Substances 0.000 description 104
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 98
- 239000000243 solution Substances 0.000 description 68
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 63
- 238000001953 recrystallisation Methods 0.000 description 46
- 238000006243 chemical reaction Methods 0.000 description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- 239000012300 argon atmosphere Substances 0.000 description 35
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 239000013078 crystal Substances 0.000 description 26
- 238000010898 silica gel chromatography Methods 0.000 description 23
- 108010006152 Serine racemase Proteins 0.000 description 19
- 102100035717 Serine racemase Human genes 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 239000012044 organic layer Substances 0.000 description 16
- 238000010992 reflux Methods 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 235000019441 ethanol Nutrition 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 description 12
- 235000011152 sodium sulphate Nutrition 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- 238000000605 extraction Methods 0.000 description 11
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 10
- 150000001408 amides Chemical class 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 125000004494 ethyl ester group Chemical group 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 7
- 0 CC(CNC(COC(CC#CC[C@@](C)*)=CC=*C)=O)N* Chemical compound CC(CNC(COC(CC#CC[C@@](C)*)=CC=*C)=O)N* 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- KUBDPQJOLOUJRM-UHFFFAOYSA-N 2-(chloromethyl)oxirane;4-[2-(4-hydroxyphenyl)propan-2-yl]phenol Chemical compound ClCC1CO1.C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 KUBDPQJOLOUJRM-UHFFFAOYSA-N 0.000 description 5
- 229930195711 D-Serine Natural products 0.000 description 5
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 4
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 4
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 4
- 229960001153 serine Drugs 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- VITFJKNVGRZRKB-UHFFFAOYSA-N acetyl isothiocyanate Chemical compound CC(=O)N=C=S VITFJKNVGRZRKB-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000002540 isothiocyanates Chemical class 0.000 description 3
- BZCKRPHEZOHHBK-UHFFFAOYSA-N methyl 2-phenoxyacetate Chemical compound COC(=O)COC1=CC=CC=C1 BZCKRPHEZOHHBK-UHFFFAOYSA-N 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 3
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- AYLDOKPNLDKXEO-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-3-[2-[(4-methylphenyl)sulfonylamino]phenyl]urea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=CC=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 AYLDOKPNLDKXEO-UHFFFAOYSA-N 0.000 description 2
- TWFSYIOOAAYYAL-UHFFFAOYSA-N 2,4,6-trichlorobenzaldehyde Chemical compound ClC1=CC(Cl)=C(C=O)C(Cl)=C1 TWFSYIOOAAYYAL-UHFFFAOYSA-N 0.000 description 2
- LWRSYTXEQUUTKW-UHFFFAOYSA-N 2,4-dimethoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(OC)=C1 LWRSYTXEQUUTKW-UHFFFAOYSA-N 0.000 description 2
- ODUZJBKKYBQIBX-UHFFFAOYSA-N 2,6-difluoroaniline Chemical compound NC1=C(F)C=CC=C1F ODUZJBKKYBQIBX-UHFFFAOYSA-N 0.000 description 2
- PJOZXAWMYSOWKU-UHFFFAOYSA-N 2-[[2-(3-methylphenoxy)acetyl]amino]-N-(4-phenylmethoxyphenyl)acetamide Chemical compound C(C1=CC=CC=C1)OC1=CC=C(C=C1)NC(=O)CNC(COC=1C=C(C=CC1)C)=O PJOZXAWMYSOWKU-UHFFFAOYSA-N 0.000 description 2
- XNBBFUUGTXSLBZ-UHFFFAOYSA-N 2-amino-n-(3-bromophenyl)acetamide Chemical compound NCC(=O)NC1=CC=CC(Br)=C1 XNBBFUUGTXSLBZ-UHFFFAOYSA-N 0.000 description 2
- PDAHECGJIFZDMD-UHFFFAOYSA-N 2-amino-n-(4-methoxy-2-methylphenyl)acetamide Chemical compound COC1=CC=C(NC(=O)CN)C(C)=C1 PDAHECGJIFZDMD-UHFFFAOYSA-N 0.000 description 2
- ZFJOLNZPELDZNC-UHFFFAOYSA-N 2-phenylacetyl isothiocyanate Chemical compound S=C=NC(=O)CC1=CC=CC=C1 ZFJOLNZPELDZNC-UHFFFAOYSA-N 0.000 description 2
- WYWPHTYDTACEPL-UHFFFAOYSA-N 3-(2,4,6-trichlorophenyl)prop-2-enoic acid Chemical compound OC(=O)C=CC1=C(Cl)C=C(Cl)C=C1Cl WYWPHTYDTACEPL-UHFFFAOYSA-N 0.000 description 2
- IKFNHLHERQPDLD-UHFFFAOYSA-N 4-amino-2,7-difluorofluoren-9-one Chemical compound O=C1C2=CC(F)=CC=C2C2=C1C=C(F)C=C2N IKFNHLHERQPDLD-UHFFFAOYSA-N 0.000 description 2
- GXLIFJYFGMHYDY-ZZXKWVIFSA-N 4-chlorocinnamic acid Chemical compound OC(=O)\C=C\C1=CC=C(Cl)C=C1 GXLIFJYFGMHYDY-ZZXKWVIFSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 102000018899 Glutamate Receptors Human genes 0.000 description 2
- 108010027915 Glutamate Receptors Proteins 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- MLEOQTXZDVCDDT-UHFFFAOYSA-N N-(2,6-difluorophenyl)-2-[[2-(4-phenylmethoxyphenoxy)acetyl]amino]acetamide Chemical compound Fc1cccc(F)c1NC(=O)CNC(=O)COc1ccc(OCc2ccccc2)cc1 MLEOQTXZDVCDDT-UHFFFAOYSA-N 0.000 description 2
- GHLZYSRDUAKRIK-UHFFFAOYSA-N N-(4-bromophenyl)-2-[2-(2-methylphenyl)ethylsulfonylamino]acetamide Chemical compound BrC1=CC=C(C=C1)NC(CNS(=O)(=O)CCC1=C(C=CC=C1)C)=O GHLZYSRDUAKRIK-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyl acetate Chemical compound CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- LJOODBDWMQKMFB-UHFFFAOYSA-N cyclohexylacetic acid Chemical compound OC(=O)CC1CCCCC1 LJOODBDWMQKMFB-UHFFFAOYSA-N 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JATMCAQQSXISOR-UHFFFAOYSA-N n-(2-aminoethyl)-4-methylbenzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)NCCN)C=C1 JATMCAQQSXISOR-UHFFFAOYSA-N 0.000 description 2
- SFAOLWKGJFXPND-UHFFFAOYSA-N n-benzylsulfamoyl chloride Chemical compound ClS(=O)(=O)NCC1=CC=CC=C1 SFAOLWKGJFXPND-UHFFFAOYSA-N 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000006340 racemization Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- BELSFEPLZUYGGF-UHFFFAOYSA-N (4-fluorophenoxy)methyl acetate Chemical compound CC(=O)OCOC1=CC=C(F)C=C1 BELSFEPLZUYGGF-UHFFFAOYSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- YIKHDPHTFYWYJV-GQCTYLIASA-N (e)-3-(2,4-dimethoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C(OC)=C1 YIKHDPHTFYWYJV-GQCTYLIASA-N 0.000 description 1
- WILLCJDOWRLEMC-VOTSOKGWSA-N (e)-3-(2,6-dimethoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=CC(OC)=C1\C=C\C(O)=O WILLCJDOWRLEMC-VOTSOKGWSA-N 0.000 description 1
- SJDOOXOUSJDYFE-VMPITWQZSA-N (e)-3-(4-propan-2-ylphenyl)prop-2-enoic acid Chemical compound CC(C)C1=CC=C(\C=C\C(O)=O)C=C1 SJDOOXOUSJDYFE-VMPITWQZSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- YBNSMPPYEXCMFO-UHFFFAOYSA-N 1-(2,4-dichlorophenyl)-3-[2-[(4-fluorophenyl)sulfonylamino]phenyl]urea Chemical compound C1=CC(F)=CC=C1S(=O)(=O)NC1=CC=CC=C1NC(=O)NC1=CC=C(Cl)C=C1Cl YBNSMPPYEXCMFO-UHFFFAOYSA-N 0.000 description 1
- AIJDNHWEAOPJGK-UHFFFAOYSA-N 1-(2,4-dichlorophenyl)-3-[2-[(4-methylphenyl)sulfonylamino]ethyl]urea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NCCNC(=O)NC1=CC=C(Cl)C=C1Cl AIJDNHWEAOPJGK-UHFFFAOYSA-N 0.000 description 1
- VGPONFMIHWCODF-UHFFFAOYSA-N 1-(2-chlorophenyl)-3-[2-[(4-methylphenyl)sulfonylamino]ethyl]thiourea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NCCNC(=S)NC1=CC=CC=C1Cl VGPONFMIHWCODF-UHFFFAOYSA-N 0.000 description 1
- ZAMCPHKLGVAGMF-UHFFFAOYSA-N 1-(2-ethoxyphenyl)-3-[2-[(4-methylphenyl)sulfonylamino]ethyl]urea Chemical compound CCOC1=CC=CC=C1NC(=O)NCCNS(=O)(=O)C1=CC=C(C)C=C1 ZAMCPHKLGVAGMF-UHFFFAOYSA-N 0.000 description 1
- CWICQEWJRBZKTF-UHFFFAOYSA-N 1-(2-methoxy-5-methylphenyl)-3-[2-[(4-methylphenyl)sulfonylamino]ethyl]thiourea Chemical compound COC1=CC=C(C)C=C1NC(=S)NCCNS(=O)(=O)C1=CC=C(C)C=C1 CWICQEWJRBZKTF-UHFFFAOYSA-N 0.000 description 1
- HKXCJYQGJNRSIQ-UHFFFAOYSA-N 1-(2-methoxyphenyl)-3-[2-[(4-methylphenyl)sulfonylamino]ethyl]thiourea Chemical compound COC1=C(C=CC=C1)NC(NCCNS(=O)(=O)C1=CC=C(C=C1)C)=S HKXCJYQGJNRSIQ-UHFFFAOYSA-N 0.000 description 1
- FMKCIXMBCOPRRZ-UHFFFAOYSA-N 1-(2-methoxyphenyl)-3-[2-[(4-methylphenyl)sulfonylamino]ethyl]urea Chemical compound COC1=CC=CC=C1NC(=O)NCCNS(=O)(=O)C1=CC=C(C)C=C1 FMKCIXMBCOPRRZ-UHFFFAOYSA-N 0.000 description 1
- SLVZGWWEHACCPT-UHFFFAOYSA-N 1-(2-methoxyphenyl)-3-[2-[(4-methylphenyl)sulfonylamino]phenyl]urea Chemical compound COC1=C(C=CC=C1)NC(NC1=C(C=CC=C1)NS(=O)(=O)C1=CC=C(C=C1)C)=O SLVZGWWEHACCPT-UHFFFAOYSA-N 0.000 description 1
- VAEKVGIGZOXJCA-UHFFFAOYSA-N 1-(2-methylphenyl)-3-[2-[(4-methylphenyl)sulfonylamino]ethyl]urea Chemical compound CC1=CC=C(C=C1)S(=O)(=O)NCCNC(=O)NC1=C(C=CC=C1)C VAEKVGIGZOXJCA-UHFFFAOYSA-N 0.000 description 1
- JIIREBIRKYLVNX-UHFFFAOYSA-N 1-(2-methylphenyl)sulfonyl-3-[2-[(4-methylphenyl)sulfonylamino]ethyl]urea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NCCNC(=O)NS(=O)(=O)C1=CC=CC=C1C JIIREBIRKYLVNX-UHFFFAOYSA-N 0.000 description 1
- BASUNNHJMWUOIY-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-3-[1-[(4-methylphenyl)sulfonylamino]propan-2-yl]urea Chemical compound CC(CNS(=O)(=O)c1ccc(C)cc1)NC(=O)Nc1ccc(Cl)c(Cl)c1 BASUNNHJMWUOIY-UHFFFAOYSA-N 0.000 description 1
- XEUYULZCPCHDLV-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-3-[2-[(4-fluorophenyl)sulfonylamino]ethyl]urea Chemical compound C1=CC(F)=CC=C1S(=O)(=O)NCCNC(=O)NC1=CC=C(Cl)C(Cl)=C1 XEUYULZCPCHDLV-UHFFFAOYSA-N 0.000 description 1
- KWYYAPXXDBEHNR-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-3-[2-[(4-fluorophenyl)sulfonylamino]phenyl]urea Chemical compound C1=CC(F)=CC=C1S(=O)(=O)NC1=CC=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 KWYYAPXXDBEHNR-UHFFFAOYSA-N 0.000 description 1
- YPLGJYFPAOSWPH-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-3-[2-[(4-methoxyphenyl)sulfonylamino]ethyl]urea Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NCCNC(=O)NC1=CC=C(Cl)C(Cl)=C1 YPLGJYFPAOSWPH-UHFFFAOYSA-N 0.000 description 1
- KTECLDDPOWTCNQ-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-3-[2-[(4-methoxyphenyl)sulfonylamino]phenyl]urea Chemical compound COc1ccc(cc1)S(=O)(=O)Nc1ccccc1NC(=O)Nc1ccc(Cl)c(Cl)c1 KTECLDDPOWTCNQ-UHFFFAOYSA-N 0.000 description 1
- KHLUWGIVHZEWSW-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-3-[2-[(4-methylphenyl)sulfonylamino]ethyl]urea Chemical compound ClC=1C=C(C=CC=1Cl)NC(NCCNS(=O)(=O)C1=CC=C(C=C1)C)=O KHLUWGIVHZEWSW-UHFFFAOYSA-N 0.000 description 1
- MNCGNDLLVMVBAL-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-3-[3-[(4-fluorophenyl)sulfonylamino]propyl]urea Chemical compound C1=CC(F)=CC=C1S(=O)(=O)NCCCNC(=O)NC1=CC=C(Cl)C(Cl)=C1 MNCGNDLLVMVBAL-UHFFFAOYSA-N 0.000 description 1
- UBPMOAODMPNQIR-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-3-[3-[(4-methoxyphenyl)sulfonylamino]propyl]urea Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NCCCNC(=O)NC1=CC=C(Cl)C(Cl)=C1 UBPMOAODMPNQIR-UHFFFAOYSA-N 0.000 description 1
- PRQCELRHRBBHME-UHFFFAOYSA-N 1-(3-methylphenyl)-3-[2-[(4-methylphenyl)sulfonylamino]ethyl]urea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NCCNC(=O)NC1=CC=CC(C)=C1 PRQCELRHRBBHME-UHFFFAOYSA-N 0.000 description 1
- JTAUOSVDVCIJQN-UHFFFAOYSA-N 1-(4-bromo-2-chlorophenyl)-3-[2-[(4-methylphenyl)sulfonylamino]ethyl]urea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NCCNC(=O)NC1=CC=C(Br)C=C1Cl JTAUOSVDVCIJQN-UHFFFAOYSA-N 0.000 description 1
- FBHSBMYOPJPRFJ-UHFFFAOYSA-N 1-(4-fluorophenyl)-3-[2-[(4-methylphenyl)sulfonylamino]phenyl]urea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=CC=CC=C1NC(=O)NC1=CC=C(F)C=C1 FBHSBMYOPJPRFJ-UHFFFAOYSA-N 0.000 description 1
- QBSNMDZOJMHATI-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonyl-3-[2-[(4-methylphenyl)sulfonylamino]ethyl]urea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 QBSNMDZOJMHATI-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- HEQCUEOZTPFATQ-UHFFFAOYSA-N 1-[2-[(4-bromophenyl)sulfonylamino]ethyl]-3-(3,4-dichlorophenyl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(=O)NCCNS(=O)(=O)C1=CC=C(Br)C=C1 HEQCUEOZTPFATQ-UHFFFAOYSA-N 0.000 description 1
- JFVSLYUHMAMOKY-UHFFFAOYSA-N 1-[2-[(4-bromophenyl)sulfonylamino]phenyl]-3-(2,4-dichlorophenyl)urea Chemical compound ClC1=CC(Cl)=CC=C1NC(=O)NC1=CC=CC=C1NS(=O)(=O)C1=CC=C(Br)C=C1 JFVSLYUHMAMOKY-UHFFFAOYSA-N 0.000 description 1
- MLGWNWBDRNPYGS-UHFFFAOYSA-N 1-[2-[(4-bromophenyl)sulfonylamino]phenyl]-3-(3,4-dichlorophenyl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(=O)NC1=CC=CC=C1NS(=O)(=O)C1=CC=C(Br)C=C1 MLGWNWBDRNPYGS-UHFFFAOYSA-N 0.000 description 1
- VFVRIFNAYPAVNA-UHFFFAOYSA-N 1-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-3-(3,4-dichlorophenyl)urea Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)NCCNC(=O)NC1=CC=C(Cl)C(Cl)=C1 VFVRIFNAYPAVNA-UHFFFAOYSA-N 0.000 description 1
- NXHVUGHRJBAYEL-UHFFFAOYSA-N 1-[2-[(4-chlorophenyl)sulfonylamino]phenyl]-3-(2,4-dichlorophenyl)urea Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)NC1=CC=CC=C1NC(=O)NC1=CC=C(Cl)C=C1Cl NXHVUGHRJBAYEL-UHFFFAOYSA-N 0.000 description 1
- FKPRDWVXTUVQOV-UHFFFAOYSA-N 1-[2-[(4-chlorophenyl)sulfonylamino]phenyl]-3-(3,4-dichlorophenyl)urea Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)NC1=CC=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 FKPRDWVXTUVQOV-UHFFFAOYSA-N 0.000 description 1
- OQVRLLKNMCKABJ-UHFFFAOYSA-N 1-[2-[(4-methylphenyl)sulfonylamino]ethyl]-3-phenylurea Chemical compound Cc1ccc(cc1)S(=O)(=O)NCCNC(=O)Nc1ccccc1 OQVRLLKNMCKABJ-UHFFFAOYSA-N 0.000 description 1
- KIDAGDXZUOIHQR-UHFFFAOYSA-N 1-[3-[(4-bromophenyl)sulfonylamino]propyl]-3-(3,4-dichlorophenyl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(=O)NCCCNS(=O)(=O)C1=CC=C(Br)C=C1 KIDAGDXZUOIHQR-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- ISSWVIZTKDLJFQ-UHFFFAOYSA-N 2-(2,4-difluorophenyl)-N-[[[2-(4-fluorophenyl)acetyl]amino]carbamothioyl]acetamide Chemical compound Fc1ccc(CC(=O)NNC(=S)NC(=O)Cc2ccc(F)cc2F)cc1 ISSWVIZTKDLJFQ-UHFFFAOYSA-N 0.000 description 1
- FUGDCKXBUZFEON-UHFFFAOYSA-N 2-(2,6-difluorophenyl)acetic acid Chemical compound OC(=O)CC1=C(F)C=CC=C1F FUGDCKXBUZFEON-UHFFFAOYSA-N 0.000 description 1
- KPLDZIFASCMMQC-UHFFFAOYSA-N 2-(2,6-difluorophenyl)acetyl isothiocyanate Chemical compound FC1=CC=CC(F)=C1CC(=O)N=C=S KPLDZIFASCMMQC-UHFFFAOYSA-N 0.000 description 1
- FJXSCIXIDOBTDP-UHFFFAOYSA-N 2-(4-bromophenoxy)-n-[2-(2,6-difluoroanilino)-2-sulfanylideneethyl]acetamide Chemical compound FC1=CC=CC(F)=C1NC(=S)CNC(=O)COC1=CC=C(Br)C=C1 FJXSCIXIDOBTDP-UHFFFAOYSA-N 0.000 description 1
- HEUZAFXSCKUENO-UHFFFAOYSA-N 2-(benzylsulfonylamino)-n-(3-bromophenyl)acetamide Chemical compound BrC1=CC=CC(NC(=O)CNS(=O)(=O)CC=2C=CC=CC=2)=C1 HEUZAFXSCKUENO-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- RIBGZQOQQXQJJA-UHFFFAOYSA-N 2-[(4-methylphenyl)sulfonylamino]-N-(4-phenylmethoxyphenyl)acetamide Chemical compound C(C1=CC=CC=C1)OC1=CC=C(C=C1)NC(CNS(=O)(=O)C1=CC=C(C=C1)C)=O RIBGZQOQQXQJJA-UHFFFAOYSA-N 0.000 description 1
- VFHKXAIMOFHXNY-UHFFFAOYSA-N 2-[(4-methylphenyl)sulfonylamino]-n-(3-nitrophenyl)acetamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NCC(=O)NC1=CC=CC([N+]([O-])=O)=C1 VFHKXAIMOFHXNY-UHFFFAOYSA-N 0.000 description 1
- IYWJAMGUHPUNJH-UHFFFAOYSA-N 2-[2-(2-methylphenyl)ethylsulfonylamino]-N-(4-phenylmethoxyphenyl)acetamide Chemical compound C(C1=CC=CC=C1)OC1=CC=C(C=C1)NC(CNS(=O)(=O)CCC1=C(C=CC=C1)C)=O IYWJAMGUHPUNJH-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- XIKXNBMBNNOLHR-UHFFFAOYSA-N 2-[[2-(4-bromophenoxy)acetyl]amino]-n-(2,6-difluorophenyl)acetamide Chemical compound FC1=CC=CC(F)=C1NC(=O)CNC(=O)COC1=CC=C(Br)C=C1 XIKXNBMBNNOLHR-UHFFFAOYSA-N 0.000 description 1
- SAYPULPWYMESHS-UHFFFAOYSA-N 2-[[2-(4-bromophenoxy)acetyl]amino]-n-(3-bromophenyl)acetamide Chemical compound C1=CC(Br)=CC=C1OCC(=O)NCC(=O)NC1=CC=CC(Br)=C1 SAYPULPWYMESHS-UHFFFAOYSA-N 0.000 description 1
- FTSWKUBFMQPZBC-UHFFFAOYSA-N 2-[[2-(4-bromophenoxy)acetyl]amino]-n-(3-chlorophenyl)acetamide Chemical compound ClC1=CC=CC(NC(=O)CNC(=O)COC=2C=CC(Br)=CC=2)=C1 FTSWKUBFMQPZBC-UHFFFAOYSA-N 0.000 description 1
- VYGOLXRKGJDNAR-UHFFFAOYSA-N 2-[[2-(4-bromophenoxy)acetyl]amino]-n-(3-nitrophenyl)acetamide Chemical compound [O-][N+](=O)C1=CC=CC(NC(=O)CNC(=O)COC=2C=CC(Br)=CC=2)=C1 VYGOLXRKGJDNAR-UHFFFAOYSA-N 0.000 description 1
- CDTIQUVXGSCGDQ-UHFFFAOYSA-N 2-[[2-(4-bromophenoxy)acetyl]amino]-n-(4-fluorophenyl)acetamide Chemical compound C1=CC(F)=CC=C1NC(=O)CNC(=O)COC1=CC=C(Br)C=C1 CDTIQUVXGSCGDQ-UHFFFAOYSA-N 0.000 description 1
- MAUNETDQYVHLDP-UHFFFAOYSA-N 2-[[2-(4-bromophenoxy)acetyl]amino]-n-(4-iodophenyl)acetamide Chemical compound C1=CC(Br)=CC=C1OCC(=O)NCC(=O)NC1=CC=C(I)C=C1 MAUNETDQYVHLDP-UHFFFAOYSA-N 0.000 description 1
- OCCKGEJURKCBTP-UHFFFAOYSA-N 2-[[2-(4-bromophenoxy)acetyl]amino]-n-(4-methoxy-2-methylphenyl)acetamide Chemical compound CC1=CC(OC)=CC=C1NC(=O)CNC(=O)COC1=CC=C(Br)C=C1 OCCKGEJURKCBTP-UHFFFAOYSA-N 0.000 description 1
- CROQLWAQSYRBNC-UHFFFAOYSA-N 2-[[2-(4-bromophenoxy)acetyl]amino]-n-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1NC(=O)CNC(=O)COC1=CC=C(Br)C=C1 CROQLWAQSYRBNC-UHFFFAOYSA-N 0.000 description 1
- KCPLTZCLXOMTSL-UHFFFAOYSA-N 2-[[2-(4-bromophenoxy)acetyl]amino]-n-[(2-methylphenyl)methyl]acetamide Chemical compound CC1=CC=CC=C1CNC(=O)CNC(=O)COC1=CC=C(Br)C=C1 KCPLTZCLXOMTSL-UHFFFAOYSA-N 0.000 description 1
- IFJLEMUQBYJNKJ-UHFFFAOYSA-N 2-[[2-(4-bromophenoxy)acetyl]amino]-n-[(4-bromophenyl)methyl]acetamide Chemical compound C1=CC(Br)=CC=C1CNC(=O)CNC(=O)COC1=CC=C(Br)C=C1 IFJLEMUQBYJNKJ-UHFFFAOYSA-N 0.000 description 1
- BZPLYYVIPPHZAW-UHFFFAOYSA-N 2-[[2-(4-bromophenoxy)acetyl]amino]-n-cyclohexylacetamide Chemical compound C1=CC(Br)=CC=C1OCC(=O)NCC(=O)NC1CCCCC1 BZPLYYVIPPHZAW-UHFFFAOYSA-N 0.000 description 1
- JBPUXMDRSACSQW-UHFFFAOYSA-N 2-[[2-(4-chlorophenoxy)acetyl]amino]-n-(2,6-difluorophenyl)acetamide Chemical compound FC1=CC=CC(F)=C1NC(=O)CNC(=O)COC1=CC=C(Cl)C=C1 JBPUXMDRSACSQW-UHFFFAOYSA-N 0.000 description 1
- YLXKIONIWUXQSS-UHFFFAOYSA-N 2-[[2-(4-chlorophenoxy)acetyl]amino]-n-(4-iodophenyl)acetamide Chemical compound C1=CC(Cl)=CC=C1OCC(=O)NCC(=O)NC1=CC=C(I)C=C1 YLXKIONIWUXQSS-UHFFFAOYSA-N 0.000 description 1
- OWFAQOQQBJVQLN-UHFFFAOYSA-N 2-[[2-(4-chlorophenoxy)acetyl]amino]-n-(4-methoxy-2-methylphenyl)acetamide Chemical compound CC1=CC(OC)=CC=C1NC(=O)CNC(=O)COC1=CC=C(Cl)C=C1 OWFAQOQQBJVQLN-UHFFFAOYSA-N 0.000 description 1
- RVTKWZSFGNPCMV-UHFFFAOYSA-N 2-[[2-(4-fluorophenoxy)acetyl]amino]-n-(4-fluorophenyl)acetamide Chemical compound C1=CC(F)=CC=C1NC(=O)CNC(=O)COC1=CC=C(F)C=C1 RVTKWZSFGNPCMV-UHFFFAOYSA-N 0.000 description 1
- WNGSSDZTXRXFJZ-UHFFFAOYSA-N 2-[[2-(4-fluorophenoxy)acetyl]amino]-n-(4-iodophenyl)acetamide Chemical compound C1=CC(F)=CC=C1OCC(=O)NCC(=O)NC1=CC=C(I)C=C1 WNGSSDZTXRXFJZ-UHFFFAOYSA-N 0.000 description 1
- CEVDRPUZPCFAOV-UHFFFAOYSA-N 2-[[2-(4-fluorophenoxy)acetyl]amino]-n-(4-methoxy-2-methylphenyl)acetamide Chemical compound CC1=CC(OC)=CC=C1NC(=O)CNC(=O)COC1=CC=C(F)C=C1 CEVDRPUZPCFAOV-UHFFFAOYSA-N 0.000 description 1
- IRRCDPPKFXWFPU-UHFFFAOYSA-N 2-[[2-(4-fluorophenoxy)acetyl]amino]-n-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1NC(=O)CNC(=O)COC1=CC=C(F)C=C1 IRRCDPPKFXWFPU-UHFFFAOYSA-N 0.000 description 1
- JTJQIUJKAQDRJR-UHFFFAOYSA-N 2-[benzyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]acetic acid Chemical compound CC(C)(C)OC(=O)N(CC(O)=O)CC1=CC=CC=C1 JTJQIUJKAQDRJR-UHFFFAOYSA-N 0.000 description 1
- VIWPOLVBBUYYCD-UHFFFAOYSA-N 2-amino-n-(2,6-difluorophenyl)acetamide Chemical compound NCC(=O)NC1=C(F)C=CC=C1F VIWPOLVBBUYYCD-UHFFFAOYSA-N 0.000 description 1
- KPWHTYAODUPVMY-UHFFFAOYSA-N 2-cyclohexyl-n-[[[2-(4-fluorophenyl)acetyl]amino]carbamothioyl]acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NNC(=S)NC(=O)CC1CCCCC1 KPWHTYAODUPVMY-UHFFFAOYSA-N 0.000 description 1
- AVDJRZSRUGHQHN-UHFFFAOYSA-N 2-cyclohexylacetyl isothiocyanate Chemical compound S=C=NC(=O)CC1CCCCC1 AVDJRZSRUGHQHN-UHFFFAOYSA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- KIAALEIKTWTEBB-UHFFFAOYSA-N 2-phenyl-n-[[(2-thiophen-2-ylacetyl)amino]carbamothioyl]acetamide Chemical compound C=1C=CC=CC=1CC(=O)NC(=S)NNC(=O)CC1=CC=CS1 KIAALEIKTWTEBB-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- SMJRBWINMFUUDS-UHFFFAOYSA-N 2-thienylacetic acid Chemical compound OC(=O)CC1=CC=CS1 SMJRBWINMFUUDS-UHFFFAOYSA-N 0.000 description 1
- AJYXPNIENRLELY-UHFFFAOYSA-N 2-thiophen-2-ylacetyl chloride Chemical compound ClC(=O)CC1=CC=CS1 AJYXPNIENRLELY-UHFFFAOYSA-N 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- GMFKMSVCLZDWHC-UHFFFAOYSA-N 3-(2,4,6-trichlorophenyl)prop-2-enoyl isothiocyanate Chemical compound Clc1cc(Cl)c(C=CC(=O)N=C=S)c(Cl)c1 GMFKMSVCLZDWHC-UHFFFAOYSA-N 0.000 description 1
- JARROIJACNTGOM-UHFFFAOYSA-N 3-(2,4,6-trifluorophenyl)prop-2-enoic acid Chemical compound OC(=O)C=CC1=C(F)C=C(F)C=C1F JARROIJACNTGOM-UHFFFAOYSA-N 0.000 description 1
- FCFNWFAQOMAFCV-UHFFFAOYSA-N 3-(2,4,6-trifluorophenyl)prop-2-enoyl isothiocyanate Chemical compound Fc1cc(F)c(C=CC(=O)N=C=S)c(F)c1 FCFNWFAQOMAFCV-UHFFFAOYSA-N 0.000 description 1
- NAHHIDFSVKWMKA-UHFFFAOYSA-N 3-(2,4-dimethoxyphenyl)-N-[[(2-thiophen-2-ylacetyl)amino]carbamothioyl]prop-2-enamide Chemical compound COc1ccc(C=CC(=O)NC(=S)NNC(=O)Cc2cccs2)c(OC)c1 NAHHIDFSVKWMKA-UHFFFAOYSA-N 0.000 description 1
- YAOVMHLRARFXLY-UHFFFAOYSA-N 3-(2,4-dimethoxyphenyl)prop-2-enoyl isothiocyanate Chemical compound COc1ccc(C=CC(=O)N=C=S)c(OC)c1 YAOVMHLRARFXLY-UHFFFAOYSA-N 0.000 description 1
- ZEAMXYYEGUCMIX-UHFFFAOYSA-N 3-(2,6-dimethoxyphenyl)-N-[[(2-thiophen-2-ylacetyl)amino]carbamothioyl]prop-2-enamide Chemical compound COc1cccc(OC)c1C=CC(=O)NC(=S)NNC(=O)Cc1cccs1 ZEAMXYYEGUCMIX-UHFFFAOYSA-N 0.000 description 1
- YCTKHKWLURCXDC-UHFFFAOYSA-N 3-(2,6-dimethoxyphenyl)prop-2-enoyl isothiocyanate Chemical compound COc1cccc(OC)c1C=CC(=O)N=C=S YCTKHKWLURCXDC-UHFFFAOYSA-N 0.000 description 1
- VXWMHVFFLLIRAC-UHFFFAOYSA-N 3-(3,5-dibromophenyl)-N-[[(2-phenylacetyl)amino]carbamothioyl]prop-2-enamide Chemical compound BrC=1C=C(C=C(C=1)Br)C=CC(=O)NC(=S)NNC(CC1=CC=CC=C1)=O VXWMHVFFLLIRAC-UHFFFAOYSA-N 0.000 description 1
- VMCLLLFTVMTWJC-UHFFFAOYSA-N 3-(3,5-dibromophenyl)-N-[[(2-thiophen-2-ylacetyl)amino]carbamothioyl]prop-2-enamide Chemical compound Brc1cc(Br)cc(C=CC(=O)NC(=S)NNC(=O)Cc2cccs2)c1 VMCLLLFTVMTWJC-UHFFFAOYSA-N 0.000 description 1
- YHQAKQMFFUZLKL-UHFFFAOYSA-N 3-(3,5-dibromophenyl)prop-2-enoic acid Chemical compound OC(=O)C=CC1=CC(Br)=CC(Br)=C1 YHQAKQMFFUZLKL-UHFFFAOYSA-N 0.000 description 1
- WSKNMTNJCOYFBB-UHFFFAOYSA-N 3-(4-chlorophenyl)-n-[[(2-thiophen-2-ylacetyl)amino]carbamothioyl]prop-2-enamide Chemical compound C1=CC(Cl)=CC=C1C=CC(=O)NC(=S)NNC(=O)CC1=CC=CS1 WSKNMTNJCOYFBB-UHFFFAOYSA-N 0.000 description 1
- RQQSVSIYWAXBBG-UHFFFAOYSA-N 3-(4-chlorophenyl)prop-2-enoyl isothiocyanate Chemical compound ClC1=CC=C(C=CC(=O)N=C=S)C=C1 RQQSVSIYWAXBBG-UHFFFAOYSA-N 0.000 description 1
- KTQUTKMDIMWOGM-UHFFFAOYSA-N 3-(4-fluorophenyl)prop-2-enoyl isothiocyanate Chemical compound Fc1ccc(C=CC(=O)N=C=S)cc1 KTQUTKMDIMWOGM-UHFFFAOYSA-N 0.000 description 1
- DROXWCKLMKAZAK-UHFFFAOYSA-N 3-(4-methylphenyl)prop-2-enoyl isothiocyanate Chemical compound Cc1ccc(C=CC(=O)N=C=S)cc1 DROXWCKLMKAZAK-UHFFFAOYSA-N 0.000 description 1
- YPOCGFLBPITFQR-UHFFFAOYSA-N 3-(4-nitrophenyl)-n-[[(2-thiophen-2-ylacetyl)amino]carbamothioyl]prop-2-enamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1C=CC(=O)NC(=S)NNC(=O)CC1=CC=CS1 YPOCGFLBPITFQR-UHFFFAOYSA-N 0.000 description 1
- NSQSXSLGLVLESP-UHFFFAOYSA-N 3-(4-nitrophenyl)prop-2-enoyl isothiocyanate Chemical compound [O-][N+](=O)c1ccc(C=CC(=O)N=C=S)cc1 NSQSXSLGLVLESP-UHFFFAOYSA-N 0.000 description 1
- FUMTWCXDYYOBEV-UHFFFAOYSA-N 3-(4-phenylphenyl)-N-[[(2-thiophen-2-ylacetyl)amino]carbamothioyl]prop-2-enamide Chemical compound O=C(Cc1cccs1)NNC(=S)NC(=O)C=Cc1ccc(cc1)-c1ccccc1 FUMTWCXDYYOBEV-UHFFFAOYSA-N 0.000 description 1
- DMJDEZUEYXVYNO-UHFFFAOYSA-N 3-(4-phenylphenyl)prop-2-enoic acid Chemical compound C1=CC(C=CC(=O)O)=CC=C1C1=CC=CC=C1 DMJDEZUEYXVYNO-UHFFFAOYSA-N 0.000 description 1
- SEHZRWFCOFVAIB-UHFFFAOYSA-N 3-(4-phenylphenyl)prop-2-enoyl isothiocyanate Chemical compound O=C(C=Cc1ccc(cc1)-c1ccccc1)N=C=S SEHZRWFCOFVAIB-UHFFFAOYSA-N 0.000 description 1
- CSEQAGQZZZTDDN-UHFFFAOYSA-N 3-(4-propan-2-ylphenyl)-N-[[(2-thiophen-2-ylacetyl)amino]carbamothioyl]prop-2-enamide Chemical compound CC(C)c1ccc(C=CC(=O)NC(=S)NNC(=O)Cc2cccs2)cc1 CSEQAGQZZZTDDN-UHFFFAOYSA-N 0.000 description 1
- DLEZOSKQLNNCEL-UHFFFAOYSA-N 3-(4-propan-2-ylphenyl)prop-2-enoyl isothiocyanate Chemical compound CC(C)c1ccc(C=CC(=O)N=C=S)cc1 DLEZOSKQLNNCEL-UHFFFAOYSA-N 0.000 description 1
- ANRMAUMHJREENI-UHFFFAOYSA-N 3-[4-(trifluoromethyl)phenyl]prop-2-enoic acid Chemical compound OC(=O)C=CC1=CC=C(C(F)(F)F)C=C1 ANRMAUMHJREENI-UHFFFAOYSA-N 0.000 description 1
- ONFMRIQIIFBGJI-UHFFFAOYSA-N 3-[4-(trifluoromethyl)phenyl]prop-2-enoyl isothiocyanate Chemical compound FC(F)(F)c1ccc(C=CC(=O)N=C=S)cc1 ONFMRIQIIFBGJI-UHFFFAOYSA-N 0.000 description 1
- HJBLUNHMOKFZQX-UHFFFAOYSA-N 3-hydroxy-1,2,3-benzotriazin-4-one Chemical compound C1=CC=C2C(=O)N(O)N=NC2=C1 HJBLUNHMOKFZQX-UHFFFAOYSA-N 0.000 description 1
- YVIWODWWGFHTIU-UHFFFAOYSA-N 3-phenylpropanoyl isothiocyanate Chemical compound S=C=NC(=O)CCC1=CC=CC=C1 YVIWODWWGFHTIU-UHFFFAOYSA-N 0.000 description 1
- ISMMYAZSUSYVQG-ZZXKWVIFSA-N 4-Fluorocinnamic acid Chemical compound OC(=O)\C=C\C1=CC=C(F)C=C1 ISMMYAZSUSYVQG-ZZXKWVIFSA-N 0.000 description 1
- JLBJTVDPSNHSKJ-UHFFFAOYSA-N 4-Methylstyrene Chemical compound CC1=CC=C(C=C)C=C1 JLBJTVDPSNHSKJ-UHFFFAOYSA-N 0.000 description 1
- ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 4-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1 ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 0.000 description 1
- VLJQDHDVZJXNQL-UHFFFAOYSA-N 4-methyl-n-(oxomethylidene)benzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)N=C=O)C=C1 VLJQDHDVZJXNQL-UHFFFAOYSA-N 0.000 description 1
- XMMRNCHTDONGRJ-ZZXKWVIFSA-N 4-nitrocinnamic acid Chemical compound OC(=O)\C=C\C1=CC=C([N+]([O-])=O)C=C1 XMMRNCHTDONGRJ-ZZXKWVIFSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- JUISOLVQDBILQO-QPJJXVBHSA-N C=C(C=C=S)C(/C=C/c(cc1)ccc1Cl)=O Chemical compound C=C(C=C=S)C(/C=C/c(cc1)ccc1Cl)=O JUISOLVQDBILQO-QPJJXVBHSA-N 0.000 description 1
- MYEVKYYLWJXASZ-UHFFFAOYSA-N CC1=CC=C(CCS(NC(C=CC=C2)=C2NC(NC(C=CC(Cl)=C2)=C2Cl)=O)(=O)=O)C=C1 Chemical compound CC1=CC=C(CCS(NC(C=CC=C2)=C2NC(NC(C=CC(Cl)=C2)=C2Cl)=O)(=O)=O)C=C1 MYEVKYYLWJXASZ-UHFFFAOYSA-N 0.000 description 1
- BSXSJYBBILQLAS-UHFFFAOYSA-N COC(COc(cc1)ccc1OC)=O Chemical compound COC(COc(cc1)ccc1OC)=O BSXSJYBBILQLAS-UHFFFAOYSA-N 0.000 description 1
- OAJXJMNRDXPXOF-UHFFFAOYSA-N COC(COc(cc1)ccc1Oc1ccccc1)=O Chemical compound COC(COc(cc1)ccc1Oc1ccccc1)=O OAJXJMNRDXPXOF-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 101710088653 D-serine dehydratase 1 Proteins 0.000 description 1
- 125000000734 D-serino group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ICRBZWJCPOTZSS-UHFFFAOYSA-N N-(4-bromo-2-fluorophenyl)-2-[2-(2-methylphenyl)ethylsulfonylamino]acetamide Chemical compound BrC1=CC(=C(C=C1)NC(CNS(=O)(=O)CCC1=C(C=CC=C1)C)=O)F ICRBZWJCPOTZSS-UHFFFAOYSA-N 0.000 description 1
- VRVIIPKDEWXBKZ-UHFFFAOYSA-N N-[(4-bromo-2-fluorophenyl)methyl]-2-[[2-(4-bromophenoxy)acetyl]amino]acetamide Chemical compound Fc1cc(Br)ccc1CNC(=O)CNC(=O)COc1ccc(Br)cc1 VRVIIPKDEWXBKZ-UHFFFAOYSA-N 0.000 description 1
- UGYHOEZKKNZVRD-UHFFFAOYSA-N N-[[(2-thiophen-2-ylacetyl)amino]carbamothioyl]-3-(2,4,6-trichlorophenyl)prop-2-enamide Chemical compound S1C(=CC=C1)CC(=O)NNC(=S)NC(C=CC1=C(C=C(C=C1Cl)Cl)Cl)=O UGYHOEZKKNZVRD-UHFFFAOYSA-N 0.000 description 1
- CKRYZOYXPPUKHI-UHFFFAOYSA-N N-[[(2-thiophen-2-ylacetyl)amino]carbamothioyl]-3-(2,4,6-trifluorophenyl)prop-2-enamide Chemical compound S1C(=CC=C1)CC(=O)NNC(=S)NC(C=CC1=C(C=C(C=C1F)F)F)=O CKRYZOYXPPUKHI-UHFFFAOYSA-N 0.000 description 1
- CJUMAFVKTCBCJK-UHFFFAOYSA-N N-benzyloxycarbonylglycine Chemical compound OC(=O)CNC(=O)OCC1=CC=CC=C1 CJUMAFVKTCBCJK-UHFFFAOYSA-N 0.000 description 1
- ZFOVCSTVYYYRSU-ZZXKWVIFSA-N O=C(/C=C/c(cc1)ccc1Cl)Cl Chemical compound O=C(/C=C/c(cc1)ccc1Cl)Cl ZFOVCSTVYYYRSU-ZZXKWVIFSA-N 0.000 description 1
- BOBGVSGLRNWBFF-ONEGZZNKSA-N O=C(/C=C/c1cc(Br)cc(Br)c1)N=C=C1CC1 Chemical compound O=C(/C=C/c1cc(Br)cc(Br)c1)N=C=C1CC1 BOBGVSGLRNWBFF-ONEGZZNKSA-N 0.000 description 1
- PCILUCOGYFHSCR-ZZXKWVIFSA-N OC(/C=C/C(CC1)=CC=C1Cl)=O Chemical compound OC(/C=C/C(CC1)=CC=C1Cl)=O PCILUCOGYFHSCR-ZZXKWVIFSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229940007550 benzyl acetate Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- SKKTUOZKZKCGTB-UHFFFAOYSA-N butyl carbamate Chemical compound CCCCOC(N)=O SKKTUOZKZKCGTB-UHFFFAOYSA-N 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003028 enzyme activity measurement method Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000004611 light stabiliser Substances 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- FHTPLYLDLXLRSC-UHFFFAOYSA-N n-(2,6-difluorophenyl)-2-[[2-(4-fluorophenoxy)acetyl]amino]acetamide Chemical compound C1=CC(F)=CC=C1OCC(=O)NCC(=O)NC1=C(F)C=CC=C1F FHTPLYLDLXLRSC-UHFFFAOYSA-N 0.000 description 1
- JAUGWNNXMFSBJY-UHFFFAOYSA-N n-(2,6-difluorophenyl)-2-[[2-(4-methoxyphenoxy)acetyl]amino]acetamide Chemical compound C1=CC(OC)=CC=C1OCC(=O)NCC(=O)NC1=C(F)C=CC=C1F JAUGWNNXMFSBJY-UHFFFAOYSA-N 0.000 description 1
- GRVNQNJFQOJWCB-UHFFFAOYSA-N n-(2,6-difluorophenyl)-2-[[2-(4-phenoxyphenoxy)acetyl]amino]acetamide Chemical compound FC1=CC=CC(F)=C1NC(=O)CNC(=O)COC(C=C1)=CC=C1OC1=CC=CC=C1 GRVNQNJFQOJWCB-UHFFFAOYSA-N 0.000 description 1
- VSTXANIIZJECGG-UHFFFAOYSA-N n-(2-aminoethyl)-4-bromobenzenesulfonamide Chemical compound NCCNS(=O)(=O)C1=CC=C(Br)C=C1 VSTXANIIZJECGG-UHFFFAOYSA-N 0.000 description 1
- MWEBCGQFQBAAJP-UHFFFAOYSA-N n-(2-aminoethyl)-4-chlorobenzenesulfonamide Chemical compound NCCNS(=O)(=O)C1=CC=C(Cl)C=C1 MWEBCGQFQBAAJP-UHFFFAOYSA-N 0.000 description 1
- CJTFAYYPQRBCMV-UHFFFAOYSA-N n-(2-aminoethyl)-4-fluorobenzenesulfonamide Chemical compound NCCNS(=O)(=O)C1=CC=C(F)C=C1 CJTFAYYPQRBCMV-UHFFFAOYSA-N 0.000 description 1
- DXJTYJVSEICHGS-UHFFFAOYSA-N n-(2-aminoethyl)-4-methoxybenzenesulfonamide Chemical compound COC1=CC=C(S(=O)(=O)NCCN)C=C1 DXJTYJVSEICHGS-UHFFFAOYSA-N 0.000 description 1
- XYFSMHPARYXICK-UHFFFAOYSA-N n-(2-aminophenyl)-4-bromobenzenesulfonamide Chemical compound NC1=CC=CC=C1NS(=O)(=O)C1=CC=C(Br)C=C1 XYFSMHPARYXICK-UHFFFAOYSA-N 0.000 description 1
- JNMXTMNGVYNSPE-UHFFFAOYSA-N n-(2-aminophenyl)-4-fluorobenzenesulfonamide Chemical compound NC1=CC=CC=C1NS(=O)(=O)C1=CC=C(F)C=C1 JNMXTMNGVYNSPE-UHFFFAOYSA-N 0.000 description 1
- DCILZFXMLGNOBT-UHFFFAOYSA-N n-(2-aminophenyl)-4-methoxybenzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=CC=C1N DCILZFXMLGNOBT-UHFFFAOYSA-N 0.000 description 1
- AQUNQTJQZYZXMR-UHFFFAOYSA-N n-(2-aminophenyl)-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=CC=CC=C1N AQUNQTJQZYZXMR-UHFFFAOYSA-N 0.000 description 1
- JWIARYFHWGQSGJ-UHFFFAOYSA-N n-(3-aminopropyl)-4-bromobenzenesulfonamide Chemical compound NCCCNS(=O)(=O)C1=CC=C(Br)C=C1 JWIARYFHWGQSGJ-UHFFFAOYSA-N 0.000 description 1
- WCCVAJAWAUVPCD-UHFFFAOYSA-N n-(3-aminopropyl)-4-fluorobenzenesulfonamide Chemical compound NCCCNS(=O)(=O)C1=CC=C(F)C=C1 WCCVAJAWAUVPCD-UHFFFAOYSA-N 0.000 description 1
- HVOVYSKTNDZLMX-UHFFFAOYSA-N n-(3-aminopropyl)-4-methoxybenzenesulfonamide Chemical compound COC1=CC=C(S(=O)(=O)NCCCN)C=C1 HVOVYSKTNDZLMX-UHFFFAOYSA-N 0.000 description 1
- CYKXMJPJALYMBC-UHFFFAOYSA-N n-(3-aminopropyl)-4-methylbenzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)NCCCN)C=C1 CYKXMJPJALYMBC-UHFFFAOYSA-N 0.000 description 1
- HMBGIRBXNSUFKO-UHFFFAOYSA-N n-(3-bromophenyl)-2-[(4-methoxyphenyl)sulfonylamino]acetamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NCC(=O)NC1=CC=CC(Br)=C1 HMBGIRBXNSUFKO-UHFFFAOYSA-N 0.000 description 1
- OUNSTZOJBOXBPS-UHFFFAOYSA-N n-(3-bromophenyl)-2-[(4-methylphenyl)sulfonylamino]acetamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NCC(=O)NC1=CC=CC(Br)=C1 OUNSTZOJBOXBPS-UHFFFAOYSA-N 0.000 description 1
- OALDUKJKOBYUPT-UHFFFAOYSA-N n-(3-bromophenyl)-2-[[2-(4-methoxyphenoxy)acetyl]amino]acetamide Chemical compound C1=CC(OC)=CC=C1OCC(=O)NCC(=O)NC1=CC=CC(Br)=C1 OALDUKJKOBYUPT-UHFFFAOYSA-N 0.000 description 1
- NPWZXLQPERORHA-UHFFFAOYSA-N n-(4-bromophenyl)-2-[[2-(4-fluorophenoxy)acetyl]amino]acetamide Chemical compound C1=CC(F)=CC=C1OCC(=O)NCC(=O)NC1=CC=C(Br)C=C1 NPWZXLQPERORHA-UHFFFAOYSA-N 0.000 description 1
- MNDPMTWPBSRDEY-UHFFFAOYSA-N n-(4-hydroxyphenyl)-2-[[2-(3-methylphenoxy)acetyl]amino]acetamide Chemical compound CC1=CC=CC(OCC(=O)NCC(=O)NC=2C=CC(O)=CC=2)=C1 MNDPMTWPBSRDEY-UHFFFAOYSA-N 0.000 description 1
- GTYMRFDJQTYLNB-UHFFFAOYSA-N n-(4-iodophenyl)-2-[[2-(3-methylphenoxy)acetyl]amino]acetamide Chemical compound CC1=CC=CC(OCC(=O)NCC(=O)NC=2C=CC(I)=CC=2)=C1 GTYMRFDJQTYLNB-UHFFFAOYSA-N 0.000 description 1
- MHUIAGUYMSUWRF-UHFFFAOYSA-N n-(4-methoxy-2-methylphenyl)-2-[[2-(3-methoxyphenoxy)acetyl]amino]acetamide Chemical compound CC1=CC(OC)=CC=C1NC(=O)CNC(=O)COC1=CC=CC(OC)=C1 MHUIAGUYMSUWRF-UHFFFAOYSA-N 0.000 description 1
- VOQAHLAOKSVCGK-UHFFFAOYSA-N n-(4-methoxy-2-methylphenyl)-2-[[2-(4-methoxyphenoxy)acetyl]amino]acetamide Chemical compound C1=CC(OC)=CC=C1OCC(=O)NCC(=O)NC1=CC=C(OC)C=C1C VOQAHLAOKSVCGK-UHFFFAOYSA-N 0.000 description 1
- MHVIDTZXQDHLII-UHFFFAOYSA-N n-[(4-bromo-2-fluorophenyl)methyl]-2-[(4-methylphenyl)sulfonylamino]acetamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NCC(=O)NCC1=CC=C(Br)C=C1F MHVIDTZXQDHLII-UHFFFAOYSA-N 0.000 description 1
- COEQDOYPLSEBAB-UHFFFAOYSA-N n-[(4-bromophenyl)methyl]-2-[(4-methylphenyl)sulfonylamino]acetamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NCC(=O)NCC1=CC=C(Br)C=C1 COEQDOYPLSEBAB-UHFFFAOYSA-N 0.000 description 1
- YKPNOQFLEPGHCY-UHFFFAOYSA-N n-[(4-methylphenyl)methyl]-2-[(4-methylphenyl)sulfonylamino]acetamide Chemical compound C1=CC(C)=CC=C1CNC(=O)CNS(=O)(=O)C1=CC=C(C)C=C1 YKPNOQFLEPGHCY-UHFFFAOYSA-N 0.000 description 1
- KZJVTHRLQWUVTC-UHFFFAOYSA-N n-[2-(2,6-difluoroanilino)-2-sulfanylideneethyl]-2-(4-methoxyphenoxy)acetamide Chemical compound C1=CC(OC)=CC=C1OCC(=O)NCC(=S)NC1=C(F)C=CC=C1F KZJVTHRLQWUVTC-UHFFFAOYSA-N 0.000 description 1
- LRNFRYOYWVLESW-UHFFFAOYSA-N n-[[[2-(2,6-difluorophenyl)acetyl]amino]carbamothioyl]-2-phenylacetamide Chemical compound FC1=CC=CC(F)=C1CC(=O)NNC(=S)NC(=O)CC1=CC=CC=C1 LRNFRYOYWVLESW-UHFFFAOYSA-N 0.000 description 1
- DHHPPPCZZNSQPS-UHFFFAOYSA-N n-[[[2-(3,5-difluorophenyl)acetyl]amino]carbamothioyl]-2-phenylacetamide Chemical compound FC1=CC(F)=CC(CC(=O)NNC(=S)NC(=O)CC=2C=CC=CC=2)=C1 DHHPPPCZZNSQPS-UHFFFAOYSA-N 0.000 description 1
- IAEQITXIJYXORZ-UHFFFAOYSA-N n-[[[2-(4-fluorophenyl)acetyl]amino]carbamothioyl]-2-phenylacetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NNC(=S)NC(=O)CC1=CC=CC=C1 IAEQITXIJYXORZ-UHFFFAOYSA-N 0.000 description 1
- UZBMHKPTEHSGLE-UHFFFAOYSA-N n-[[[2-(4-fluorophenyl)acetyl]amino]carbamothioyl]-2-thiophen-2-ylacetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NNC(=S)NC(=O)CC1=CC=CS1 UZBMHKPTEHSGLE-UHFFFAOYSA-N 0.000 description 1
- QCJAWQJTVUVYOJ-UHFFFAOYSA-N n-[[[2-(4-fluorophenyl)acetyl]amino]carbamothioyl]-3-phenylpropanamide Chemical compound C1=CC(F)=CC=C1CC(=O)NNC(=S)NC(=O)CCC1=CC=CC=C1 QCJAWQJTVUVYOJ-UHFFFAOYSA-N 0.000 description 1
- AYETZTKNSIPSPE-UHFFFAOYSA-N n-benzyl-2-[[2-(4-bromophenoxy)acetyl]amino]acetamide Chemical compound C1=CC(Br)=CC=C1OCC(=O)NCC(=O)NCC1=CC=CC=C1 AYETZTKNSIPSPE-UHFFFAOYSA-N 0.000 description 1
- YWYFDOIYOGAWEM-UHFFFAOYSA-N n-benzyl-2-[[2-(4-fluorophenoxy)acetyl]amino]acetamide Chemical compound C1=CC(F)=CC=C1OCC(=O)NCC(=O)NCC1=CC=CC=C1 YWYFDOIYOGAWEM-UHFFFAOYSA-N 0.000 description 1
- KNZIJMBIPACGPS-UHFFFAOYSA-N n-cyclohexyl-2-[[2-(4-fluorophenoxy)acetyl]amino]acetamide Chemical compound C1=CC(F)=CC=C1OCC(=O)NCC(=O)NC1CCCCC1 KNZIJMBIPACGPS-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical group 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- JBJWASZNUJCEKT-UHFFFAOYSA-M sodium;hydroxide;hydrate Chemical compound O.[OH-].[Na+] JBJWASZNUJCEKT-UHFFFAOYSA-M 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- SBNUJBWEKZWGRH-UHFFFAOYSA-N tert-butyl n-[2-(2,6-difluoroanilino)-2-oxoethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC(=O)NC1=C(F)C=CC=C1F SBNUJBWEKZWGRH-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C337/00—Derivatives of thiocarbonic acids containing functional groups covered by groups C07C333/00 or C07C335/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C337/06—Compounds containing any of the groups, e.g. thiosemicarbazides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C07C311/58—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/38—Amides of thiocarboxylic acids
- C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C327/42—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
- C07C335/08—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C335/18—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明的目的在于提供一种具有令人满意的活性和特异性的新的丝氨酸消旋酶抑制剂。本发明的丝氨酸消旋酶抑制剂以选自下述通式[MM_1]、[DR_1]、[DR'_1]、[LW_1]和[ED_1]的任意化合物组中的一个以上的化合物作为有效成分。
Description
技术领域
本发明涉及表现出丝氨酸消旋酶的抑制活性的非肽类的酰胺衍生物。
背景技术
NMDA(N-甲基-D-天冬氨酸:N-methyl-D-aspartate)型谷氨酸受体(以下称为NMDAR)是谷氨酸受体的一种。
被认为是与记忆和学习相关的受体,是阿尔茨海默型痴呆的治疗药物的靶标之一。
另一方面,哺乳类动物脑内存在着D-丝氨酸,作为内源性共激动剂(Co-agonist)参与NMDAR的功能控制。
D-丝氨酸可以利用丝氨酸消旋酶(SR)由L-丝氨酸合成。
已知在SR敲除(KO)小鼠中,NMDA诱发的神经变性减轻(非专利文献1)、PTZ致癫痫发作减轻等。
因此,考虑将SR作为对于伴随神经过度兴奋的病症的新的药物靶点,关于SR的已知药物,已有二肽类等的报道(非专利文献2)。
在先技术文献
非专利文献
非专利文献1:J.Neurosci.,2008,28(53),14486-14491.
非特許文献2:J.Med.Chem.,2006,49,2388-2397.
发明内容
发明要解决的技术问题
有报道指出二肽类表现出抑制效果的有效浓度范围窄、且具有细胞毒性,并不是特异性高的药物。
本发明的目的在于开发出具有令人满意的活性和特异性的新的SR抑制剂。
并且,本发明的另一目的在于开发出对于神经变性疾患和过度兴奋的脑病症的新的候选治疗药物。
用于解决技术问题的手段
本发明的发明人以SR的立体结构信息为基础,根据由虚拟筛选(insilico screening)发现的SR抑制药的先导化合物候选的结构信息,有机合成了新的低分子化合物,评价对于SR的效果,发现了新的具有SR抑制活性的化合物,从而完成了本发明。
下面,对本发明进行详细说明。
在本说明书中,只要没有特别说明,各术语具有下述含义。
卤原子意指氟原子、氯原子、溴原子或碘原子;烷基意指甲基、乙基、丙基、异丙基、丁基、异丁基、叔丁基、戊基和己基等直链状或支链状的C1-12烷基;低级烷基意指甲基、乙基、丙基、异丙基、丁基、异丁基、叔丁基、戊基和己基等直链状或支链状的C1-6烷基;环烷基意指环丙基、环丁基、环戊基和环己基等C3-8环烷基;芳基意指苯基、萘基、茚满基和茚基等;芳烷基意指苄基、苯乙基、α-甲基苯乙基、二苯甲基、三苯甲基等芳基-低级烷基;烷氧基意指甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基、异丁氧基、叔丁氧基、戊氧基、己氧基、庚氧基和辛氧基等直链状或支链状的C1-12烷氧基;低级烷氧基意指甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基、异丁氧基、叔丁氧基、戊氧基和己氧基等直链状或支链状的C1-6烷氧基;亚烷基意指亚甲基、亚乙基、亚丙基等直链状或支链状的C1-6亚烷基。
作为羟基保护基,包括通常能够用作羟基的保护基的所有的基团,例如可以列举苄氧羰基、4-硝基苄氧羰基、4-溴苄氧羰基、4-甲氧基苄氧羰基、3,4-二甲氧基苄氧羰基、甲氧基羰基、乙氧基羰基、叔丁氧基羰基、1,1-二甲基丙氧基羰基、异丙氧基羰基、异丁氧基羰基、二苯基甲氧基羰基、2,2,2-三氯乙氧基羰基、2,2,2-三溴乙氧基羰基、2-(三甲基甲硅烷基)乙氧基羰基、2-(苯基磺酰基)乙氧基羰基、2-(三苯基磺酰基)乙氧基羰基、2-糠氧基羰基、1-金刚烷氧基羰基、乙烯氧基羰基、烯丙氧基羰基、S-苄硫羰基、4-乙氧基-1-萘氧基羰基、8-喹啉氧基羰基、乙酰基、甲酰基、氯乙酰基、二氯乙酰基、三氯乙酰基、三氟乙酰基、甲氧基乙酰基、苯氧基乙酰基、三甲基乙酰基和苯甲酰基等酰基;甲基、叔丁基、2,2,2-三氯乙基和2-三甲基甲硅烷基乙基等低级烷基;烯丙基等低级烯基;苄基、对甲氧基苄基、3,4-二甲氧基苄基、二苯甲基和三苯甲基等低级烷基;四氢呋喃基、四氢吡喃基和四氢噻喃基等含氧杂环基和含硫杂环基;甲氧基甲基、甲硫基甲基、苄氧基甲基、2-甲氧基乙氧基甲基、2,2,2-三氯乙氧基甲基、2-(三甲基甲硅烷基)乙氧基甲基、1-乙氧基乙基和1-甲基-1-甲氧基乙基等低级烷氧基-和低级烷硫基-低级烷基;甲磺酰基和对甲苯磺酰基等低级烷基-和芳基-磺酰基;以及三甲基甲硅烷基、三乙基甲硅烷基、三异丙基甲硅烷基、二乙基异丙基甲硅烷基、叔丁基二甲基甲硅烷基、叔丁基二苯基甲硅烷基、二苯基甲基甲硅烷基和叔丁基甲氧基苯基甲硅烷基等取代甲硅烷基等。
本发明的丝氨酸消旋酶抑制剂,以一个以上的选自下述通式[MM_1]、通式[DR_1]、通式[DR′_1]、通式[LW_1]、通式[ED_1]的化合物组中的非肽性的酰胺衍生物作为有效成分。
下述通式[MM_1]表示苯氧基-(N-取代氨基甲酰基甲基)-乙酰胺衍生物,
式中,R1m表示选自氢原子、卤原子、烷基、烷氧基和可以被保护的羟基中的一个以上的原子或取代基;R2m表示可以具有取代基的芳基、芳烷基或环烷基;Xm表示氧原子或硫原子。
下述通式[DR_1]表示N-(取代)-2-(取代氨磺酰氨基)-乙酰胺衍生物,
式中,R1d表示选自氢原子、卤原子、烷基、烷氧基和可以被保护的羟基中的一个以上的原子或取代基;R2d表示可以具有取代基的芳基、芳烷基或芳基乙酰胺基;Xd表示氧原子或亚氨基,nd表示0或1。
下述通式[DR′_1]表示N-(取代)-2-(取代氨磺酰氨基)-乙酰胺衍生物,
式中,R1d′表示选自氢原子、卤原子、烷基、烷氧基和可以被保护的羟基中的一个以上的原子或取代基;R2d′表示可以具有取代基的芳基、芳烷基或芳基乙酰胺基;Xd′表示氧原子或亚氨基。
下述通式[LW_1]表示N-[(酰基)肼基硫代羰基]-乙酰胺衍生物,
式中,R1w表示可以具有取代基的苯乙烯基、苄基或环己基甲基;R2w表示可以具有取代基的芳基、含有氧原子或硫原子作为成环原子的杂环基;nw表示0、1或2。
下述通式[ED_1]表示苯磺酰胺衍生物,
式中,R1e相同或不同,表示选自氢原子、卤原子、烷基、烷氧基中的一个以上的原子或取代基;R2e表示可以具有取代基的苯基或甲苯磺酰基;Ae表示亚烷基或亚苯基。
并且,本发明提供一种具有丝氨酸消旋酶阻害活性的以下通式所示的新的非肽性的酰胺衍生物。
一种下述通式[MM_2]所示的苯氧基-(N-取代氨基甲酰基甲基)-乙酰胺衍生物,
式中,R1m表示选自氢原子、卤原子、烷基、烷氧基和可以被保护的羟基中的一个以上的原子或取代基;R2Am表示可以具有选自卤原子、烷基、烷氧基、硝基和可以被保护的羟基中的1~2个原子或取代基作为取代基的芳基、芳烷基或环烷基;Xm表示氧原子或硫原子。
一种下述通式[DR_1a]所示的N-(取代)-2-(取代氨磺酰氨基)-乙酰胺衍生物,
式中,R1d表示选自氢原子、卤原子、烷基、烷氧基和可以被保护的羟基中的一个以上的原子或取代基;R2d表示可以具有取代基的芳基、芳烷基或芳基乙酰胺基;Xd表示氧原子或亚氨基。
一种下述通式[DR_1b]所示的N-(取代)-2-(取代氨磺酰氨基)-乙酰胺衍生物,
式中,R1d表示选自氢原子、卤原子、烷基、烷氧基和可以被保护的羟基中的一个以上的原子或取代基;R2ad表示可以具有取代基的苄基或可以具有取代基的芳基乙酰胺基。
一种下述通式[DR′_1]所示的N-(取代)-2-(取代氨磺酰氨基)-乙酰胺衍生物,
式中,R1d′表示选自氢原子、卤原子、烷基、烷氧基和可以被保护的羟基中的一个以上的原子或取代基;R2d′表示可以具有取代基的芳基、芳烷基或芳基乙酰胺基;Xd′表示氧原子或亚氨基。
一种下述通式[LW_1d]所示的N-[(酰基)肼基硫代羰基]-乙酰胺衍生物,
式中,R13w表示卤原子;R12w、R14w、R15w和R16w相同或不同,表示选自氢原子、卤原子、烷基、烷氧基、硝基中的一个以上的原子或取代基;R2bw表示可以具有取代基的芳基、含有氧原子或硫原子作为成环原子的杂环基。
一种下述通式[LW_1e]所示的N-[(酰基)肼基硫代羰基]-乙酰胺衍生物,
式中,R2cw表示可以具有取代基的氧原子或含有氧原子作为成环原子的杂环基,取代基R12w~R16w表示以下的组合,
(1)R12w、R14w和R16w为氢原子,R13w和R15w为卤原子;
(2)R13w、R14w和R15w为氢原子,R12w和R16w为烷氧基。
一种下述通式[LW_1g]所示的N-[(酰基)肼基硫代羰基]-乙酰胺衍生物,
式中,R1aw表示选自卤原子、烷基、烷氧基、硝基和可以被保护的羟基中的一个以上的原子或取代基;取代基R22w~R26w表示以下的组合,
(1)R24w为卤原子,R22w、R23w、R25w和R26w为氢原子;
(2)R23w为烷基,R22w、R24w、R25w和R26w为氢原子;
(3)R22w和R26w为卤原子,R23w、R24w和R26w为氢原子;
(4)R23w和R25w为卤原子,R22w、R24w和R26w为氢原子。
一种下述通式[LW_1c]所示的N-[(酰基)肼基硫代羰基]-乙酰胺衍生物,
式中,R2w表示可以具有取代基的芳基、氧原子或含有氧原子作为成环原子的杂环基;nw表示0、1或2。
一种下述通式[ED_1aa]所示的苯磺酰胺衍生物,
式中,R11e表示氢原子、烷基或烷氧基;R21e表示氢原子、卤原子或烷基;R22e表示氢原子或卤原子;R23e表示氢原子或卤原子;R24e表示氢原子、烷基或烷氧基;Xe表示氧原子或硫原子;ne表示整数2或3,
但是,不包括R11e为烷基、R21e和R23e为卤原子、R22e和R24e为氢、Xe为氧原子、ne为2的情况。
一种下述通式[ED_1ab]所示的苯磺酰胺衍生物,
式中,R11e表示氢原子、烷基或烷氧基;R25e和R26e相同或不同,表示氢原子或烷基;ne表示整数2或3。
一种下述通式[ED_1ba]所示的苯磺酰胺衍生物,
式中,R11e表示氢原子、烷基或烷氧基;R22e和R23e相同或不同,表示氢原子或烷基。
在上述通式所示的非肽性的酰胺衍生物中,在存在异构体(例如光学异构体、几何异构体和互变异构体等)的情况下,本发明包括这些所有的异构体,还包括水合物、溶剂合物和所有的晶型。
并且,通式所示的非肽性的酰胺衍生物可以形成盐,作为这些盐,可以列举通常已知的亚氨基或羟基的盐。
具体而言,例如作为DR化合物和ED化合物的盐,可以列举与钠和钾等碱金属的盐。
作为优选的盐,可以列举药理学上可接受的盐。
本发明中具有丝氨酸消旋酶抑制活性的优选的化合物,例如可以列举以下的化合物。
<MM化合物>
下述通式[MM_1a]所示的苯氧基-(N-取代氨基甲酰基甲基)-乙酰胺衍生物,
式中,R1am表示氢原子、卤原子、烷氧基、可以被保护的羟基;R1bm表示氢原子或烷基;R2am表示可以具有取代基的芳基或环烷基;Xm表示氧原子或硫原子;nm表示0或整数1。
并且,优选的化合物例如可以列举以下的化合物。
下述通式[MM_1b]所示的苯氧基-(N-取代氨基甲酰基甲基)-乙酰胺衍生物,
式中,R1am表示氢原子、卤原子、烷氧基、可以被保护的羟基;R1bm表示氢原子或烷基;R2bm表示选自氢原子、卤原子、烷基、硝基和羟基中的一个以上的原子或取代基。
<DR化合物和DR′化合物>
下述通式[DR_1c]所示的N-(取代)-2-(取代氨磺酰氨基)-乙酰胺衍生物,
式中,R1ad表示选自氢原子、卤原子、烷基和烷氧基中的一个以上的原子或取代基;R2bd表示可以具有取代基的烷基;nd表示0或1。
下述通式[DR_1d]所示的N-(取代)-2-(取代氨磺酰氨基)-乙酰胺衍生物,
式中,R1ad表示选自氢原子、卤原子、烷基和烷氧基中的一个以上的原子或取代基;R2cd表示可以具有取代基的芳基或烷基。
下述通式[DR_1e]所示的N-(取代)-2-(取代氨磺酰氨基)-乙酰胺衍生物,
式中,R1ad表示选自氢原子、卤原子、烷基和烷氧基中的一个以上的原子或取代基;R2aad表示选自氢原子、卤原子、烷基、烷氧基和可以被保护的羟基中的一个以上的原子或取代基。
式中,R1d′表示选自氢原子、卤原子、烷基、烷氧基和可以被保护的羟基中的一个以上的原子或取代基;R2d′表示可以具有取代基的芳基、芳烷基或芳基乙酰胺基;Xd′表示氧原子或亚氨基。
<LW化合物>
式中,R1aw表示选自卤原子、烷基、烷氧基、硝基和可以被保护的羟基中的一个以上的原子或取代基;R2w和R2aw表示可以具有取代基的芳基、含有氧原子或硫原子作为成环原子的杂环基;nw表示0、1或2。
并且,优选的化合物例如可以列举以下的化合物。
下述通式[LW_1d]所示的N-[(酰基)肼基硫代羰基]-乙酰胺衍生物,
式中,R13w表示卤原子;R12w、R14w、R15w和R16w相同或不同,表示选自氢原子、卤原子、烷基、烷氧基、硝基中的一个以上的原子或取代基;R2bw表示可以具有取代基的芳基、含有氧原子或硫原子作为成环原子的杂环基。
下述通式[LW_1e]所示的N-[(酰基)肼基硫代羰基]-乙酰胺衍生物,
式中,R2cw表示可以具有取代基的氧原子或含有氧原子作为成环原子的杂环基,取代基R12w~R16w表示以下的组合:
(1)R12w、R14w和R16w为氢原子,R13w和R15w为卤原子;
(2)R13w、R14w和R15w为氢原子,R12w和R16w为烷氧基。
下述通式[LW_1f]所示的N-[(酰基)肼基硫代羰基]-乙酰胺衍生物,
式中,R12w~R16w表示以下的组合:
(1)R12w、R14w和R16w为氢原子,R13w和R15w为卤原子;
(2)R13w、R14w和R15w为氢原子,R12w和R16w为烷氧基。
下述通式[LW_1g]所示的N-[(酰基)肼基硫代羰基]-乙酰胺衍生物,
式中,R1aw表示选自卤原子、烷基、烷氧基、硝基和可以被保护的羟基中的一个以上的原子或取代基;取代基R22w~R26w表示以下的组合:
(1)R24w为卤原子,R22w、R23w、R25w和R26w为氢原子;
(2)R23w为烷基,R22w、R24w、R25w和R26w为氢原子;
(3)R22w和R26w为卤原子,R23w、R24w和R26w为氢原子;
(4)R23w和R25w为卤原子,R22w、R24w和R26w为氢原子。
<ED化合物>
下述通式[ED_1a]和[ED_1b]所示的苯磺酰胺衍生物,
式中,R1e相同或不同,表示氢原子、卤原子、烷基、烷氧基中的一个以上的原子或取代基;R2e表示可以具有取代基的苯基或甲苯磺酰基;R2ae表示可以具有取代基的苯基;ne表示整数2或3。
并且,优选的化合物例如可以列举以下的化合物。
下述通式[ED_1aa]所示的苯磺酰胺衍生物,
式中,R11e表示氢原子、烷基或烷氧基;R21e表示氢原子、卤原子或烷基;R22e表示氢原子或卤原子;R23e表示氢原子或卤原子;R24e表示氢原子、烷基或烷氧基;Xe表示氧原子或硫原子;ne表示整数2或3。
但是,不包括R11e为烷基、R21e和R23e为卤原子、R22e和R24e为氢原子、Xe为氧原子、ne为2的情况。
下述通式[ED_1ab]所示的苯磺酰胺衍生物,
式中,R11e表示氢原子、烷基或烷氧基;R25e和R25e相同或不同,表示氢原子或烷基;ne表示整数2或3。
下述通式[ED_1ba]所示的苯磺酰胺衍生物,
式中,R11e表示氢原子、烷基或烷氧基;R22e和R23e相同或不同,表示氢原子或卤原子。
本发明的非肽性酰胺衍生物例如可以通过以下方法制造。
·制造方法1<MM化合物>
式中,R1m表示选自氢原子、卤原子、烷基、烷氧基和可以被保护的羟基中的一个以上的原子或取代基;R2m表示可以具有取代基的芳基、芳烷基或环烷基;Xm表示氧原子或硫原子。
在存在缩合剂的条件下,使通式[MM_4]化合物与通式[MM_3]化合物反应,由此能够制造通式[MM_1]化合物。
该反应所使用的溶剂,只要不对反应造成不良影响则没有特别限定,例如可以列举二氯甲烷、氯仿等卤化碳类;四氢呋喃等醚类;N,N-二甲基甲酰胺等酰胺类。
作为该反应所使用的缩合剂,例如可以列举羰基二咪唑(carbonyldiimidazole)、1-乙基-3-(3-二甲氨基丙基)碳二亚胺(EDC)等。
并且,还可以同时使用添加剂1-羟基苯并三唑(HOBt)、3,4-二氢-3-羟基-4-氧-1,2,3-苯并三嗪(HOOBt)。
缩合剂的使用量只要在通式[3]化合物的等摩尔以上即可,优选为1~10倍摩尔。
该反应通常可以以0~200℃、优选10~150℃实施10分钟~24小时。
通式[MM_3]化合物可以利用其本身公知的方法制造,例如可以参照以下的文献等。
·Synth.Commun.2004,34,377-382.
·Lett.Org.Chem.2011,8,234-241.
·Org.Lett.2010,12,4571-4575.
·U.S.Pat.Appl.Publ.,20070141113,21Jun2007.
·Faming Zhuanli Shenqing Gongkai Shuomingshu,101314576,03Dec2008.
·J.Am.Chem.Soc.2007,129,3981-3929.
通式[MM_4]化合物可以利用其本身公知的方法制造,例如可以参照以下的文献等。
·Eur.J.Org.Chem.2008,23,3976-3983.
·Eur.J.Med.Chem.1996,31,497-505.
·PCT Int.Appl.(2000),WO 2000071507A220001130.
·J.Org.Chem.2011,76,9278-9293.
·J.Med.Chem.2009,52,5005-5008.
·Org.Lett.2010,12,2718-2721.
·PCT Int.Appl.(2010),WO 2010067067A120100617.
·PCT Int.Appl.,2007141473,13Dec2007.
在通式[MM_3]、[MM_4]化合物存在异构体(例如光学异构体、几何异构体和互变异构体等)的情况下,可以使用它们所有的异构体,还可以使用水合物、溶剂合物以及所有的晶型。
并且,这些化合物可以不经离析而直接用于后续的反应。
这样操作得到的通式[MM_1]化合物可以通过提取、结晶、蒸馏和柱色谱等常规方法进行离析精制。
·制造方法2<DR和DR′化合物>
式中,R1d表示选自氢原子、卤原子、烷基、烷氧基和可以被保护的羟基中的一个以上的原子或取代基;R2d表示可以具有取代基的芳基、芳烷基或芳基乙酰胺基;Xd表示氧原子或亚氨基;nd表示0或1。
在存在碱的条件下,使通式[DR_3]化合物与通式[DR_2]或通式[DR′_2]化合物反应,由此能够分别制造通式[DR_1]或通式[DR′_1]化合物。
该反应所使用的溶剂,只要不对反应造成不良影响则没有特别限定,例如可以列举二氯甲烷、氯仿等卤化碳类;四氢呋喃等醚类等。
作为该反应所使用的碱,例如可以列举二乙胺、三乙胺、N,N-二甲基-4-氨基吡啶等有机碱。
碱的使用量可以相对于通式[3]化合物为0.1~2倍摩尔。
该反应通常可以以0~200℃、优选10~150℃实施10分钟~24小时。
通式[DR_2]或通式[DR′_2]化合物可以利用其本身公知的方法制造,例如可以参照以下的文献等。
·J.Med.Chem.,2011,54,2738-2744.
·ACS Chem.Neurosci.,2010,1,155-164.
·US2008/0269280A1
通式[DR_3]化合物可以利用其本身公知的方法制造,例如可以参照以下的文献等。
·Tetrahedron Lett.,2011,52,2579-2582.
在通式[DR_2]、[DR′_2]、[3]化合物存在异构体(例如光学异构体、几何异构体和互变异构体等)的情况下,可以使用它们所有的异构体,还可以使用水合物、溶剂合物以及所有的晶型。
并且,这些化合物可以不经离析而直接用于后续的反应。
这样操作得到的通式[DR_1]或通式[DR′_1]化合物可以通过提取、结晶、蒸馏和柱色谱等常规方法进行离析精制。
·制造方法3<LW化合物>
式中,R1w表示可以具有取代基的苯乙烯基、苄基或环己基甲基;R2w表示可以具有取代基的芳基、含有氧原子或硫原子作为成环原子的杂环基;nw表示0、1或2。
通过使通式[LW_2]化合物与通式[LW_3]化合物反应,能够制造通式[LW_1]化合物。
该反应所使用的溶剂,只要不对反应造成不良影响则没有特别限定,例如可以列举二氯甲烷、氯仿等卤化碳类;四氢呋喃等醚类等。
该反应通常可以以0~200℃、优选10~150℃实施10分钟~24小时。
通式[LW_2]化合物及其原料化合物可以利用其本身公知的方法制造,例如可以参照以下的文献等。
·Tetrahedron,2011,67,8120-8130.
·Bioorg.Med.Chem.,2004,13,433-441.
·Synthesis,2008,279-285.
·J.Org.Chem.,2008,73,5766-5775.
·Org.Biomol.Chem.,2009,7,4062-4066.
·Chem.Eur.J.,2000,6,3386-3390.
·Synth.Commun.,1980,10,37-42.
·Synth.Commun.,2002,32,195-201.
·J.Med.Chem.,1993,36,2381-9.
·J.Org.Chem.,1995,60,1981-4.
·J.Org.Chem.,1999,64,3975-3978.
·WO 2004046122A2.
·WO 2001092239A1.
·Bioorg.Med.Chem.Lett.,2011,21,1102-1104.
·Chem.Pep.Chem.Zvesti,1974,28,693-6.
·Chem.Pep.Chem.Zvesti,1969,23,173-80.
·J.Med.Chem.,2006,49,2186-2192.
·Bioorg.Med.Chem.Lett.,2008,18,1945-1951.
·WO 2009125597A1.
·WO 2007054831A2.
通式[LW_3]化合物可以利用其本身公知的方法制造,例如可以使一水合肼与羧酸酯反应。
式中,R2w表示可以具有取代基的芳基、含有氧原子或硫原子作为成环原子的杂环基;R′表示烷基;nw表示0、1或2。
在通式[LW_2]、[LW_3]化合物存在异构体(例如光学异构体、几何异构体和互变异构体等)的情况下,可以使用它们所有的异构体,还可以使用水合物、溶剂合物以及所有的晶型。
并且,这些化合物可以不经离析而直接用于后续的反应。
这样操作得到的通式[LW_1]化合物可以通过提取、结晶、蒸馏和柱色谱等常规方法进行离析精制。
·制造方法4<ED化合物>
式中,R1e相同或不同,表示选自氢原子、卤原子、烷基、烷氧基中的一个以上的原子或取代基;R2e表示可以具有取代基的苯基或甲苯磺酰基;Ae表示亚烷基或亚苯基。
通过使通式[ED_2]化合物与通式[ED_3]化合物反应,能够制造通式[ED_1]化合物。
该反应所使用的溶剂,只要不对反应造成不良影响则没有特别限定,例如可以列举二氯甲烷、氯仿等卤化碳类;四氢呋喃等醚类等。
该反应通常可以以0~200℃、优选10~100℃实施10分钟~24小时。
通式[ED_2]化合物及其原料化合物可以利用其本身公知的方法制造,例如可以如下所述,通过使通式[ED_4]的苯磺酰氯与通式[ED_5]的二胺在公知的条件下反应来制造。
式中,R1e相同或不同,表示选自氢原子、卤原子、烷基、烷氧基中的一个以上的原子或取代基;Ae表示亚烷基或亚苯基。
在通式[ED_2]、[ED_3]、[ED_4]、[ED_5]化合物存在异构体(例如光学异构体、几何异构体和互变异构体等)的情况下,可以使用它们所有的异构体,还可以使用水合物、溶剂合物以及所有的晶型。
并且,这些化合物可以不经离析而直接用于后续的反应。
这样操作得到的通式[ED_1]化合物可以通过提取、结晶、蒸馏和柱色谱等常规方法进行离析精制。
本发明化合物可以配合溶剂、增量剂、等渗剂、助溶剂、乳化剂、助悬剂、增粘剂、吸收促进剂、凝胶化-凝固促进剂、光稳定剂、保存剂、乳化-悬浊-分散稳定剂、抗着色剂、消泡剂、无痛剂、缓冲剂、pH调节剂等各种医药添加物,能够制成注射剂、栓剂等医药制剂。
上述制剂的给药方法没有特别限定,可以根据制剂形态、患者年龄、性别以及其他条件、患者症状的程度适当确定。
本发明制剂的有效成分的给药量可以根据用法、患者年龄、性别、疾患状态、以及其他条件等适当选择,通常对于成人可以将1天0.1~500mg分成1次至几次给药。
下面,对本发明的代表化合物的药理作用进行说明。
试验例1
<酶活性测定方法>
化合物对于丝氨酸消旋酶(SR)的活性的抑制效果,通过以下的(1)L-丝氨酸的消旋化反应、和(2)生产的D-丝氨酸的量的测定来求出。
(1)L-丝氨酸的消旋化反应
按照Strisovsky等人的方法(Biochemistry,44:13091-13100,2005.),使在大肠杆菌中表达并纯化的重组SR(3.7μg)在含有100mM HEPES(pH8.0)、1mM MgCl2、10μM PLP、1mM ATP、20mM L-丝氨酸、5mM DTT和溶解于DMSO的化合物(1~0.01mM)的反应液125μL中,以37℃反应8小时以上。
(2)D-丝氨酸的量的测定
按照Ito等人的方法(Analytical Biochemistry,371:167-172,2007.)进行。
在(1)的反应液25μL中加入25μL含有100mM HEPES(pH8.0)、20μM PLP、2μg重组D-丝氨酸脱水酶1(Dsd1)的溶液,以30℃反应30分钟。
接着,为了利用比色反应测定由D-丝氨酸通过Dsd1生产的丙酮酸,在反应溶液50μL中加入50μL的0.05%DNP/2M HCl,以30℃反应5分钟,之后,加入100μL乙醇,接着加入125μL的10M NaOH,充分混和,以室温反应10分钟,利用分光光度计测定515nm波长的吸光度。
将结果示于表1和表2。
其中,表1~表8的括号内的数值是对照的丙二酸。
[表1]
[表2]
[表3]
[表4]
[表5]
[表6]
[表7]
[表8]
发明效果
非肽性酰胺衍生物具有丝氨酸消旋酶抑制活性。因此这些化合物能够实现NMDAR的活性调节,能够制成对于神经变性疾患和过度兴奋的脑病症的新的治疗药物。
具体实施方式
下面,列举参考例和实施例,进一步对本发明进行说明。
而这些完全不对本发明有任何限定。
其中,化学结构式中的简写符号如下。
Me:甲基、Ph:苯基、Bn:苄基、Boc:丁氧基羰基
<参考例1>
在氩气氛下,在苯酚体(1.0mmol)的二甲基甲酰胺(3mL)溶液中,依次加入溴乙酸甲酯(0.10mL,1mmol)、碳酸钾(207mg,1.5mmol),以80℃搅拌整夜。
之后,用乙酸乙酯(10mL)将反应液稀释,进行硅藻土过滤,蒸馏除去溶剂。
利用二氧化硅凝胶柱色谱(15g,己烷︰丙酮=50︰1~40︰1)对得到的残渣进行精制,得到甲酯体。
·(4-溴苯氧基)乙酸甲酯
收率:100%
参考文献:Synth.Commun.,2004,34,377-382
·(4-氯苯氧基)乙酸甲酯
收率:90%
参考文献:Synth.Commun.,2004,34,377-382.
·(4-氟苯氧基)乙酸甲酯
收率:84%
参考文献:Lett.Org.Chem.,2011,8,234-241.
·(4-甲氧基苯氧基)乙酸甲酯
收率:97%
参考文献:Org.Lett.,2010,12,4571-4575.
·(4-苄氧基苯氧基)乙酸甲酯
收率:89%
参考文献:US20070141113
·(4-苯氧基苯氧基)乙酸甲酯
收率:97%
参考文献:Faming Zhuanli Shenqing Gongkai Shuomingshu,101314576,03Dec2008
·(3-甲氧基苯氧基)乙酸甲酯
收率:92%
参考文献:J.Am.Chem.Soc.,2007,129,3981-3929.
·m-甲基苯氧基乙酸甲酯
收率:89%
参考文献:J.Am.Chem.Soc.,2007,129,3981-3929.
·苯氧基乙酸甲酯
收率:85%
参考文献:Lett.Org.Chem.,2011,8,234-241.
<参考例2>
在氩气氛下,在2-甲基-4-甲氧基苯胺(0.13mL,1.0mmol)的二氯甲烷(5mL)溶液中依次加入三乙胺(0.21mL,1.5mmol)、N-叔丁氧基羰基·甘氨酸(175mg,1.0mmol)、EDC(192mg,1.0mmol)、DMAP((12mg,0.1mmol),以室温搅拌5小时。
蒸馏除去溶剂,利用二氧化硅凝胶柱色谱(20g,己烷︰丙酮=30︰1~2︰1)对得到的残渣进行精制,以无色油状物质的形态得到[(4-甲氧基-2-甲基-苯基氨基甲酰基)甲基]氨基甲酸叔丁酯(290mg)。
1H-NMR(400MHz,CDCl3):δ1.48(9H,s),2.22(3H,s),3.78(3H,s),3.93(2H,d,J=6.1Hz),5.21(1H,br),6.73-6.75(2H,m),7.59(1H,d,J=9.3Hz),7.79(1H,br)
13C-NMR(100MHz,CDCl3):δ17.85,28.21,45.09,55.23,80.32,111.34,115.82,125.26,128.09,132.42,156.44,157.17,168.34
IR(neat):1680,3290cm-1
MS(EI):m/z294(M+)
收率:99%
利用同样的反应获得以下化合物。
·[(4-碘-苯基氨基甲酰基)甲基]氨基甲酸叔丁酯
收率:98%
参考文献:Eur.J.Org.Chem.,2008,23,3976-3983.
·[(4-氟-苯基氨基甲酰基)甲基]氨基甲酸叔丁酯
收率:100%
参考文献:Eur.J.Med.Chem.,1996,31,497-505.
·[(4-溴-苯基氨基甲酰基)甲基]氨基甲酸叔丁酯
收率:97%
参考文献:WO2000/071507
·[(4-甲氧基-苯基氨基甲酰基)甲基]氨基甲酸叔丁酯
收率:68%
参考文献:J.Org.Chem.,2011,76,9278-9293.
·环己基氨基甲酰基甲基-氨基甲酸叔丁酯
收率:81%
参考文献:J.Med.Chem.,2009,52,5005-5008.
·苄基氨基甲酰基甲基-氨基甲酸叔丁酯
收率:86%
参考文献:Org.Lett.,2010,12,2718-2721.
<参考例3>
在氩气氛下,在N-叔丁氧基羰基·甘氨酸(1.36g,7.74mmol)的二氯甲烷(10mL)溶液加入1,1-羰基咪唑(1.38g,8.51mmol),以室温搅拌1小时后,加入2,6-二氟苯胺(0.78mL,7.74mml),以室温搅拌整夜。
蒸馏除去溶剂,利用二氧化硅凝胶柱色谱(15g,己烷︰丙酮=6︰~3︰1)对得到的残渣进行精制,以无色晶体物质的形态得到[(2,6-二氟苯基氨基甲酰基)甲基]氨基甲酸叔丁酯(1.73g)。
收率:78%
1H-NMR(400MHz,CDCl3):δ1.47(9H,s),4.00(2H,d,J=4.6Hz),5.22(1H,br),6.96,(2H,t,J=8.1Hz),7.18-7.27(1H,m),7.74(1H,br)
IR(KBr):1684,3281cm-1
MS(EI):m/z286(M+)
熔点:119-120℃
利用同样的反应获得以下化合物。
·(2-甲基-苄基氨基甲酰基)甲基]氨基甲酸叔丁酯
收率:98%
1H-NMR(400MHz,CDCl3):δ1.43(9H,s),2.31(3H,s),3.82(2H,d,J=6.1Hz),4.46(2H,d,J=5.6Hz),5.10(1H,br),6.22(1H,br),7.18-7.20(4H,m)
·[(4-溴-苄基氨基甲酰基)甲基]氨基甲酸叔丁酯
收率:85%
1H-NMR(400MHz,CDCl3):δ1.43(9H,s),3.82(2H,d,J=6.1Hz),4.41(2H,d,J=5.9Hz),5.12(1H,br),6.50(1H,br),7.15(2H,d,J=8.4Hz),7.45(2H,d,J=8.4Hz)
·[(4-溴-2-氟-苄基氨基甲酰基)甲基]氨基甲酸叔丁酯
收率93%
1H-NMR(400MHz,CDCl3):δ1.44(9H,s),3.80(2H,d,J=6.1Hz),4.45(2H,d,J=6.1Hz),5.07(1H,br),6.51(1H,br),7.20-7.29(3H,m)
·[(3-溴-苯基氨基甲酰基)甲基]氨基甲酸叔丁酯
收率:89%
1H-NMR(400MHz,CDCl3):δ1.47(9H,s),3.90(2H,d,J=6.1Hz),5.20(1H,br),7.16(1H,t,J=8.1Hz),7.22-7.25(1H,m),7.39(1H,d,J=8.1Hz),7.75(1H,s),8.25(1H,br)
·[(3-硝基-苯基氨基甲酰基)甲基]氨基甲酸叔丁酯
收率:92%
1H-NMR(400MHz,CDCl3):δ1.48(9H,s),3.94(2H,d,J=5.9Hz),5.25(1H,br),7.47(1H,t,J=7.9Hz),7.88(1H,d,J=7.9Hz),7.94(1H,d,J=7.9Hz),8.37(1H,s),8.67(1H,br)
·[(3-氯-苯基氨基甲酰基)甲基]氨基甲酸叔丁酯
收率:71%
参考文献:WO2010/067067
·[(4-苄氧基-苯基氨基甲酰基)甲基]氨基甲酸叔丁酯
收率:68%
参考文献:WO2007/141473
<参考例4>
在氩气氛下,在[(2,6-二氟苯基氨基甲酰基)甲基]氨基甲酸叔丁酯(52mg,0.18mmol)的THF(2mL)溶液中加入劳氏试剂(Lawesson′s Reagent)(50mg0.12mmol),整夜加热回流。蒸馏除去溶剂,利用二氧化硅凝胶柱色谱(13g,己烷︰丙酮=10︰~8︰1)对得到的残渣进行精制,以无色晶体物质的形态得到[(2,6-二氟苯基硫代氨基甲酰基)甲基]氨基甲酸叔丁酯(23mg)。
收率:42%
1H-NMR(400MHz,CDCl3):δ1.55(9H,s),4.34(2H,d,J=6.1Hz),5.40(1H,br),6.98(2H,t,J=8.2Hz),7.30(1H,t,J=8.2Hz),9.59(1H,br)
<参考例5>
在氩气氛下,在N-(叔丁氧基羰基)甘氨酸(1.36g,7.74mmol)的二氯甲烷(10mL)溶液中加入1,1-羰基咪唑(1.38g,8.51mmol),以室温搅拌1小时后,加入2,6-二氟苯胺(0.78mL,7.74mmol),以室温搅拌整夜。
利用二氧化硅凝胶柱色谱(15g,己烷︰丙酮=6︰1~3︰1)对蒸馏除去溶剂后的残渣进行精制,以无色晶体物质的形态得到[(2,6-二氟-苯基氨基甲酰基)-甲基]-氨基甲酸叔丁酯(1.73g)。
收率:78%
熔点:119-120℃
1H-NMR(400MHz,CDCl3):δ1.47(9H,s),4.00(2H,d,J=4.6Hz),5.22(1H,br),6.96,(2H,t,J=8.1Hz),7.18-7.27(1H,m),7.74(1H,br)
利用同样的反应获得以下化合物。
·[(1-苯基-乙基氨基甲酰基)-甲基]-氨基甲酸叔丁酯
收率:96%
参考文献:J.Med.Chem.,2011,54,2738-2744.
·[(4-甲基-苄基氨基甲酰基)-甲基]-氨基甲酸叔丁酯
收率:100%
参考文献:ACS Chem.Neurosci.,2010,1,155-164.
·[(4-氯-苯基氨基甲酰基)-甲基]-氨基甲酸叔丁酯
收率:89%
参考文献:US2008-0269280
·[(2-溴-苯基氨基甲酰基)-甲基]-氨基甲酸叔丁酯
收率:68%
熔点:118-119℃
1H-NMR(400MHz,CDCl3):δ1.49(9H,s),3.98(2H,d,J=5.6Hz),5.18(1H,br),6.99(1H,td,J=8.1,1.3Hz),7.32(1H,td,J=8.1,1.3Hz),7.54(1H,dd,J=8.1,1.3Hz),8.37(1H,dd,J=8.1,1.3Hz),8.47(1H,br)13C-NMR(100MHz,CDCl3):δ28.26,45.49,80.67,113.38,121.62,125.33,128.31,132.23,135.16,156.04,167.92
<参考例6>
在氩气氛下,在N-(叔丁氧基羰基)甘氨酸(350mg,2.0mmol)的二氯甲烷(5mL)溶液中加入1,1-羰基二咪唑(357mg,2.2mmol),以室温搅拌1小时后,加入苄基醇(0.21mL,2.0mmol),以室温搅拌整夜。
利用二氧化硅凝胶柱色谱(20g,己烷︰丙酮=10︰1)对蒸馏除去溶剂后的残渣进行精制,得到叔丁氧基羰基氨基乙酸苄酯的无色油状物质(360mg,68%)。
<参考例7>
在苯基乙酸(770mg,5.00mmol)的乙醇(15mL)溶液中加入数滴浓盐酸,整夜加热回流。
之后,以0℃向反应液中加入饱和碳酸氢钠水溶液,直到水槽显示中性。
蒸馏除去乙醇后,利用硫酸钠将用二氯甲烷提取得到的有机层进行干燥,进行过滤,之后蒸馏除去溶剂,得到乙酯体的无色晶体物质(910mg,100%)。
在乙酯体(500mg,2.74mmol)的乙醇(2.0mL)溶液中加入一水合肼(0.13mL,2.74mmol),整夜加热回流。
蒸馏除去溶剂,得到酰肼体的无色晶体物质。
接着,在氩气氛下,在N-苄氧羰基甘氨酸(573mg,2.74mmol)的二氯甲烷(7mL)溶液中加入1,1-羰基二咪唑(488mg,3.01mmol),以室温搅拌1小时后,使用套管(cannula)加入得到的酰肼体的二氯甲烷(3mL)溶液,以室温搅拌整夜。
利用二氧化硅凝胶柱色谱(20g,二氯甲烷︰甲醇=80︰1~30︰1)对蒸馏除去溶剂后的残渣进行精制,得到[N′-[2-(4-氟苯基)乙酰基]肼基氨基甲酰基甲基]氨基甲酸丁酯的无色晶体物(840mg)。
收率:85%
熔点:185-186℃
1H-NMR(400MHz,CDCl3):δ3.45(2H,s),3.65(2H,d,J=5.9Hz),5.01(2H,s),7.12(2H,t,J=8.7Hz),7.31(2H,dd,J=8.7,5.7Hz),7.33-7.34(5H,m),7.51(1H,br),9.92(1H,br),10.08(1H,br)
<参考例8>
在氩气氛下,以0℃向二甲基甲酰胺(1.55mL,20.0mmol)中加入磺酰氯(1.38mL,17.0mmol),搅拌30分钟。
接着,加入4-甲基苯乙烯(1.31mL,10.0mmol),以90℃搅拌4小时。
恢复到室温后,加入冰水(25mL)。
之后,对反应液进行抽滤,用水清洗,得到2-对甲苯基乙烷磺酰氯(2-p-Tolyl-ethanesulfonyl chloride;1.134g,52%)。
<参考例9>
在氩气氛下,在4-羟基苯甲醛(500mg,4.09mmol)的丙酮(5mL)溶液中依次加入碘甲烷(0.76mL,12.27mmol)和碳酸钾(2.26g,16.36mmol),整夜加热回流。
之后,用二氯甲烷(10mL)稀释反应液,进行硅藻土过滤,蒸馏除去溶剂。
利用二氧化硅凝胶柱色谱(20g,己烷︰丙酮=50︰1~30︰1)对残渣进行精制,得到4-甲氧基苯甲醛(439mg,收率:79%)。
参考文献:Tetrahedron,2011,67,8120-8130.
利用同样的反应获得以下化合物。
·2,4-二甲氧基苯甲醛
收率:84%
参考文献:Bioorg.Med.Chem.,2004,13,433-441.
<参考例10>
在氩气氛下,以-78℃在1,3,5,-三氯苯(724mg,4.00mmol)的四氢呋喃(10mL)溶液中加入正丁基锂(2.45mL,4.00mmol),搅拌45分钟。
接着,以-78℃加入二甲基甲酰胺(0.31mL,4.00mmol),搅拌45分钟。
升温到-20℃后,加入饱和氯化铵水溶液(5mL),搅拌5分钟。
之后,利用硫酸钠将用乙酸乙酯提取得到的有机层干燥,过滤后蒸馏除去溶剂。
利用二氧化硅凝胶柱色谱(15g,己烷︰丙酮=50︰1~40︰1)对残渣进行精制,得到无色晶体2,4,6-三氯苯甲醛体(633mg,76%)。参考文献:Synthesis,2008,279-285.
<参考例11>
在氩气氛下,在4-氯苯甲醛(141mg,1.00mmol)的甲苯(5mL)溶液中依次加入丙二酸(156mg,1.50mmol)、吡啶(0.12mL,1.54mmol)、苯胺(0.01mL,0.12mmol),整夜加热回流。
加入10%盐酸水溶液,直到水层显示酸性,利用硫酸钠将用乙酸乙酯提取得到的有机层干燥,过滤后蒸馏除去溶剂。
利用二氧化硅凝胶柱色谱(20g,二氯甲烷︰甲醇=100︰1~40︰1)对残渣进行精制,得到无色晶体3-(4-氯苯基)丙烯酸(162mg,89%)。
参考文献:J.Org.Chem.,2008,73,5766-5775.
同样操作得到以下化合物。
·3-(4-硝基苯基)丙烯酸
收率:100%
参考文献:Org.Biomol.Chem.,2009,7,4062-4066.
·3-(4-氟苯基)丙烯酸
收率:86%
参考文献:Chem.Eur.J.,2000,6,3386-3390.
·3-(2,4-二甲氧基苯基)丙烯酸
收率:95%
参考文献:Synth.Commun.,1980,10,37-42.
·3-(4-异丙基苯基)丙烯酸
收率:90%
参考文献:Synth.Commun.,2002,32,195-201.
·3-(联苯基-4-基)丙烯酸
收率:60%
参考文献:J.Med.Chem.,1993,36,2381-2389.
·3-(2,6-二甲氧基苯基)丙烯酸
收率:100%
参考文献:J.Org.Chem.,1995,60,1981-1984.
·3-(4-三氟甲基苯基)丙烯酸
收率:100%
参考文献:J.Org.Chem.,1999,64,3975-3978.
<参考例12>
(1)在氩气氛下,以0℃在氢化钠(133mg,3.32mmol)的四氢呋喃(5mL)溶液中加入膦酰基乙酸三乙酯(0.66mL,3.32mmol),搅拌30分钟中,使用套管加入2,4,6-三氯苯甲醛(580mg,2.77mmol)的四氢呋喃(5mL)的溶液,以室温搅拌整夜。
蒸馏除去溶剂后加水(10mL),利用硫酸钠将用二氯甲烷提取得到的有机层干燥,过滤后蒸馏除去溶剂。
利用二氧化硅凝胶柱色谱(15g,己烷︰丙酮=90︰1~80︰1)对残渣进行精制,得到无色油状的3-(2,4,6-三氯苯基)丙烯酸乙酯(751mg,97%)。
(2)在3-(2,4,6-三氯苯基)丙烯酸乙酯(751mg,2.69mmol)的甲醇-水(3︰1)混合溶液(20mL)中加入一水合氢氧化钠(226mg,5.38mmol),加热回流2小时。
蒸馏除去溶剂后,加入10%盐酸水溶液直到水层显示酸性,利用硫酸钠将用乙酸乙酯提取得到的有机层干燥,过滤后蒸馏除去溶剂,得到无色晶体3-(2,4,6-三氯苯基)丙烯酸(654mg,97%)。
1H-NMR(400MHz,CDCl3):δ6.64(1H,d,J=16.2Hz),7.41(2H,s),7.82(1H,d,J=16.2Hz)
同样操作得到以下化合物。
·3-(3,5-二溴苯基)丙烯酸
收率:100%
参考文献:WO2004/046122
·3-(2,4,6-三氟苯基)丙烯酸
收率:99%
参考文献:WO2001/092239
<参考例13>
在氩气氛下,在3-(4-氯苯基)丙烯酸(100mg,0.55mmol)的二氯甲烷(3mL)溶液中加入亚硫酰氯(0.05mL,0.66mmol),以室温搅拌整夜。
蒸馏除去溶剂后,重新加入二氯甲烷(3mL),接着依次加入硫氰酸铵(63mg,0.82mmol)、PEG-400(1滴),以室温搅拌2小时。
蒸馏除去溶剂,利用二氧化硅凝胶柱色谱(15g,己烷︰丙酮=50︰1~40︰1)对残渣进行精制,得到无色晶体3-(4-氯苯基)丙烯酰基异硫氰酸酯(105mg,85%)。
1H-NMR(400MHz,CDCl3)δ:6.48(1H,d,J=16.1Hz),7.41(2H,d,J=8.7Hz),7.50(2H,d,J=8.7Hz),7.72(1H,d,J=15.6Hz);Yield:85%.
同样操作得到以下化合物。
·3-(2,4,6-三氯苯基)丙烯酰基 异硫氰酸酯
1H-NMR(400MHz,CDCl3)δ:6.74(1H,d,J=16.1Hz),7.43(2H,s),7.85(1H,d,J=16.1Hz)
收率:80%
·3-(4-氟苯基)丙烯酰基 异硫氰酸酯
1H-NMR(400MHz,CDCl3)δ:6.43(1H,d,J=15.8Hz),7.13(2H,t,J=8.6Hz),7.57(2H,dd,J=8.6,5.3Hz),7.73(1H,d,J=15.8Hz)
收率:88%
·3-(2,4-二甲氧基苯基)丙烯酰基 异硫氰酸酯
1H-NMR(400MHz,CDCl3)δ:3.84(3H,s),3.88(3H,s),6.42-6.53(3H,m),7.46(1H,d,J=16.1Hz),8.00(1H,d,J=16.1Hz)
收率:73%
·3-(2,4-二溴苯基)丙烯酰基 异硫氰酸酯
1H-NMR(400MHz,CDCl3)δ:6.45(1H,d,J=15.8Hz),7.58-7.62(3H,m),7.74(1H,s)
收率:63%
·3-(4-异丙基苯基)丙烯酰基 异硫氰酸酯
1H-NMR(400MHz,CDCl3)δ:1.25(6H,d,J=7.1Hz),2.93(1H,sept,J=7.1Hz),6.45(1H,d,J=15.7Hz),7.27(2H,d,J=8.2Hz),7.48(2H,d,J=8.2Hz),7.73(1H,d,J=15.7Hz)
收率:79%
·3-(联苯基-4-基)丙烯酰基 异硫氰酸酯
1H-NMR(400MHz,CDCl3):δ6.47(1H,d,J=15.6Hz),7.33(1H,t,J=7.4Hz),7.41(2H,t,J=7.4Hz),7.55-7.61(6H,m),7.74(1H,d,J=15.6Hz)
收率:83%
·3-(2,6-二甲氧基苯基)丙烯酰基 异硫氰酸酯
1H-NMR(400MHz,CDCl3)δ:3.89(6H,s),6.55(2H,d,J=8.5Hz),6.99(1H,d,J=15.9Hz),7.32(1H,t,J=8.5Hz),8.23(1H,d,J=15.9Hz)
收率:27%
·3-(2,4,6-三氟苯基)丙烯酰基 异硫氰酸酯
1H-NMR(400MHz,CDCl3):δ6.74-6.79(3H,m),7.78(1H,d,J=16.1Hz)
收率:67%
·3-(4-三氟甲基苯基)丙烯酰基 异硫氰酸酯
1H-NMR(400MHz,CDCl3):δ6.57(1H,d,J=15.9Hz),7.66-7.71(4H,m),7.78(1H,d,J=15.9Hz)
收率:85%
·3-(4-硝基苯基)丙烯酰基 异硫氰酸酯
收率:85%
参考文献:Chem.Pep.Chem.Zvesti,1974,28,693-696.
·3-(4-甲基苯基)丙烯酰基 异硫氰酸酯
收率:60%
参考文献:Chem.Pep.Chem.Zvesti,1969,23,173-180.
<参考例14>
·苯基乙酰基 异硫氰酸酯
在氩气氛下,在乙酰氯(155mg,1mmol)的二氯甲烷(5mL)溶液中依次加入硫氰酸铵(114mg,1.50mmol)、PEG-400(3滴),以室温搅拌2小时。
蒸馏除去溶剂,利用二氧化硅凝胶柱色谱(15g,己烷︰丙酮=50︰1~40︰1)对残渣进行精制,得到无色晶体苯基乙酰基异硫氰酸酯(132mg,75%)。
同样操作得到以下化合物。
·(4-氟苯基)乙酰基 异硫氰酸酯
收率:48%
参考文献:Bioorg.Med.Chem.Lett.,2008,18,1945-1951.
·3-苯基丙酰基 异硫氰酸酯
收率:28%
参考文献:J.Org.Chem.,2008,73,2096-2104.
<参考例15>
·(2,6-二氟苯基)乙酰基 异硫氰酸酯
在氩气氛下,在(2,6-二氟苯基)乙酸(172mg,1.00mmol)的苯(5mL)溶液中加入亚硫酰氯(0.15mL,2.00mmol),整夜加热回流。
蒸馏除去溶剂后,加入二氯甲烷(5mL),接着依次加入硫氰酸铵(114mg,1.50mmol)、PEG-400(4滴),以室温搅拌整夜。
利用二氧化硅凝胶柱色谱(15g,己烷︰丙酮=50︰1~40︰1)对蒸馏除去溶剂后的残渣进行精制,得到无色晶体(2,6-二氟苯基)乙酰基异硫氰酸酯(105mg,49%)。
参考文献:WO2009/125597
<参考例16>
·(环己基)乙酰基 异硫氰酸酯
在氩气氛下,在环己基乙酸(142mg,1.00mmol)的苯(5mL)溶液中加入亚硫酰氯(0.15mL,2.00mmol),整夜加热回流。
蒸馏除去溶剂后,加入二氯甲烷(5mL),接着依次加入硫氰酸铵(114mg,1.50mmol)、PEG-400(4滴),室温搅拌2整夜。
利用二氧化硅凝胶柱色谱(15g,己烷︰丙酮=80︰1~70︰1)对蒸馏除去溶剂后的残渣进行精制,得到无色晶体(环己基)乙酰基异硫氰酸酯(120mg,66%)。
参考文献:WO2007/054831
<参考例17>
在氩气氛下,在2-噻吩乙酸(Thiopheneacetic acid;284mg,2.00mmol)的二氯甲烷(5mL)溶液中加入亚硫酰氯(0.29mL,4.00mmol),整夜加热回流。
蒸馏除去溶剂后,重新加入二氯甲烷(5mL),接着加入硫氰酸铵(228mg,3.00mmol)、聚乙二醇(PEG-400;6drops),以室温搅拌整夜。
利用二氧化硅凝胶柱色谱(15g,己烷︰丙酮=100︰1)对蒸馏除去溶剂后的残渣进行精制,得到无色晶体噻吩-2-基-乙酰氯133mg(36%)。
<参考例18>
在氩气氛下,利用套管以0℃在二胺化合物5a(5.0mmol)的二氯甲烷溶液5mL中加入磺酰氯化合物4a(1.0mmol)的二氯甲烷溶液2mL,以室温搅拌3小时。
之后,加水10mL。
利用硫酸钠将用二氯甲烷提取得到的有机层干燥并过滤。
蒸馏除去溶剂得到胺化合物2a。
利用同样的反应获得以下化合物。
·N-(2-氨基乙基)-4-甲基苯磺酰胺
收率:69%
参考文献:Tetrahedron,2011,67,6206-6213.
·N-(2-氨基乙基)-4-甲氧基苯磺酰胺
收率:39%
参考文献:Zh.Obshch.Khim.,1962,32,887-892.
·N-(2-氨基乙基)-4-溴苯磺酰胺
收率:35%
参考文献:Zh.Obshch.Khim.,1962,32,887-892.
·N-(2-氨基乙基)-4-氯苯磺酰胺
收率:51%
参考文献:J.Med.Chem.,1982,25,1286-1292.
·N-(2-氨基乙基)-4-氟苯磺酰胺
收率:39%
参考文献:Chin.J.Chem.,2011,29,2081-2085.·N-(3-氨基丙基)-4-甲基苯磺酰胺
收率:46%
参考文献:J.Med.Chem.,2012,55,4457-4478.
·N-(3-氨基丙基)-4-甲氧基苯磺酰胺
收率:58%
参考文献:WO98/08822
以下市售品:
·N-(3-氨基丙基)-4-溴苯磺酰胺
·N-(3-氨基丙基)-4-氟苯磺酰胺
<参考例19>
在氩气氛下,在邻苯二胺(500mg,4.62mmol)的四氢呋喃溶液3mL溶液中加入吡啶(0.149mL,1.85mmol),接着利用套管以0℃加入甲苯磺酰氯(294mg,1.54mmol)的四氢呋喃溶液2mL,以室温搅拌4小时。
之后,加水5mL。
利用饱和食盐水5mL对用二氯甲烷提取得到的有机层进行清洗,利用硫酸钠干燥并进行过滤。
利用二氧化硅凝胶柱色谱(15g,己烷︰丙酮=10︰1)对蒸馏除去溶剂后的残渣进行精制,得到N-(2-氨基苯基)-4-甲基苯磺酰胺的无色晶体218mg(收率:54%)。
参考文献:Angew.Chem.Int.Ed.,2007,46,7247-7250.
<参考例20>
在氩气氛下,在苯二胺(487mg,4.50mmol)的四氢呋喃(3mL)溶液中加入吡啶(0.1mL,1.80mmol),接着利用套管以0℃加入4-氯苯磺酰氯(317mg,1.50mmol)的四氢呋喃(2mL)溶液,以室温搅拌4小时。
在蒸馏除去溶剂后的残渣中加水(5mL),利用饱和食盐水(5mL)对用二氯甲烷提取得到的有机层进行清洗,用硫酸钠干燥并进行过滤,之后蒸馏除去溶剂。
使得到的残渣在乙醇-水中重结晶,以无色晶体物质的形态得到2-邻甲苯基-乙磺酸(2-氨基-苯基)-酰胺(384mg,91%)。
1H-NMR(400MHz,CDCl3):δ2.36(3H,s),4.15(2H,br),5.95(1H,br),6.65(td,J=8.1,1.5Hz),6.76(1H,dd,J=8.1,1.5Hz),6.79(1H,d,J=15.4Hz),6.99(1H,dd,J=8.1,1.5Hz),7.07(1H,td,J=8.1,1.5Hz),7.18(2H,d,J=8.2Hz),7.32(2H,d,J=8.2Hz),7.38(1H,d,J=15.4Hz)
利用同样的反应获得以下化合物。
·N-(2-氨基-苯基)-4-氟-苯磺酰胺
收率:61%
参考文献:WO98/54131
·N-(2-氨基-苯基)-4-甲氧基-苯磺酰胺
收率:52%
参考文献:WO98/54131
·N-(2-氨基-苯基)-4-溴-苯磺酰胺
收率:50%
实施例1
(1)在苯氧基乙酸甲酯(102mg,0.61mmol)的甲醇-水(3︰1)混合溶液(4mL)中加入一水合氢氧化锂(52mg,1.23mmol),加热回流2小时。
蒸馏除去溶剂后,加入10%盐酸水溶液,直到水层显示酸性,利用乙酸乙酯进行提取。
用硫酸钠将有机层干燥并进行过滤后,蒸馏除去溶剂,以无色晶体物质的形态得到苯氧基乙酸(92mg)。
(2)在氩气氛下,在[(4-甲氧基-2-甲基-苯基氨基甲酰基)甲基]氨基甲酸叔丁酯(236mg,0.80mmol)的二氯甲烷(3.5mL)溶液中加入三氟乙酸(0.6mL,8.08mmol),以室温搅拌整夜。
之后,以0℃在反应液中加入饱和碳酸氢钠水溶液直到水层显示碱性,利用二氯甲烷进行提取。
用碳酸钾将有机层干燥并进行过滤后,蒸馏除去溶剂,以无色晶体物质的形态得到2-氨基-N-(4-甲氧基-2-甲基苯基)乙酰胺(146mg)。
(3)在氩气氛下,在苯氧基乙酸(78mg,0.52mmol)的二氯甲烷(5mL)溶液中加入1,1-羰基二咪唑(92mg,0.57mmol),以室温搅拌1小时后,利用套管加入2-氨基-N-(4-甲氧基-2-甲基苯基)乙酰胺(100mg,0.52mmol)的二氯甲烷溶液(2mL),以室温搅拌整夜。
蒸馏除去溶剂,利用二氧化硅凝胶柱色谱(15g,己烷︰丙酮=5︰1~3︰1)对得到的残渣进行精制,以无色晶体物质的形态得到N-[(4-甲氧基-2-甲基苯基氨基甲酰基)甲基]-2-苯氧基乙酰胺(113mg)。
<MM-1>
收率:67%
熔点:165-166℃(重结晶溶剂:丙酮)
1H-NMR(400MHz,CDCl3):δ2.19(3H,s),3.76(3H,s),4.16(2H,d,J=5.9Hz),4.57(2H,s),6.72(2H,m),6.92(2H,d,J=7.6Hz),7.01(1H,t,J=7.6Hz),7.30(2H,t,J=7.6Hz),7.38(1H,br),7.52(1H,d,J=9.5Hz),7.62(1H,br)
13C-NMR(100MHz,DMSO-d6):δ17.95,42.06,55.09,66.86,111.15,114.74,115.32,121.20,126.67,128.81,129.50,134.03,156.83,157.68,167.49,168.21
IR(KBr):1668,3258cm-1
MS(EI):m/z328(M+)
实施例2
与实施例1同样操作得到以下化合物。
·2-(4-氯苯氧基)-N-[(4-甲氧基-2-甲基苯基氨基甲酰基)甲基]乙酰胺
<MM-2>
收率:80%
熔点:170-171℃(重结晶溶剂:丙酮)
1H-NMR(400MHz,CDCl3):δ2.20(3H,s),3.76(3H,s),4.16(2H,d,J=5.6Hz),4.53(2H,s),6.71-6.73(2H,m),6.85(2H,d,J=9.0Hz),7.24-7.27(2H,m),7.35(1H,br),7.50(1H,d,J=9.5Hz),7.56(1H,br)
13C-NMR(100MHz,DMSO-d6):δ17.95,42.03,55.09,67.10,111.15,115.32,116.55,124.91,126.68,128.80,129.23,134.05,156.57,156.83,167.45,167.91
IR(KBr):1666,3267cm-1
MS(EI):m/z362(M+)
·2-(4-溴苯氧基)-N-[(4-甲氧基-2-甲基苯基氨基甲酰基)甲基]乙酰胺
<MM-3>
收率:69%
熔点:159-160℃(重结晶溶剂:丙酮)
1H-NMR(400MHz,CDCl3):2.19(3H,s),3.76(3H,s),4.16(2H,d,J=5.6Hz),4.52(2H,s),6.71-6.73(2H,m),6.81(2H,d,J=8.8Hz),7.36(1H,br),7.40(2H,d,J=8.8Hz),7.50(1H,d,J=9.5Hz),7.59(1H,br)
13C-NMR(100MHz,DMSO-d6):δ17.95,55.10,67.03,100.08,111.16,112.63,115.32,117.07,126.69,128.79,132.12,134.05,156.83,157.02,167.44,167.88
IR(KBr):1663,3273cm-1
MS(EI):m/z406(M+)
·2-(4-氯苯氧基)-N-[(4-碘苯基氨基甲酰基)甲基]乙酰胺
<MM-4>
收率:78%
熔点:205-206℃(重结晶溶剂:丙酮)
1H-NMR(400MHz,CDCl3):δ4.13(2H,d,J=5.6Hz),4.54(2H,s),6.86(2H,d,J=9.0Hz),7.24-7.28(3H,m),7.27(2H,d,J=9.0Hz),7.61(2H,d,J=8.8Hz),7.98(1H,br)
13C-NMR(100MHz,DMSO-d6):δ42.42,67.05,86.74,116.56,121.33,124.95,129.23,137.39,138.62,156.52,167.52,167.94
IR(KBr):1663,3294cm-1
MS(EI):m/z444(M+)
·2-(4-溴苯氧基)-N-[(4-碘苯基氨基甲酰基)甲基]乙酰胺
<MM-5>
收率:91%
熔点:211-212℃(重结晶溶剂:丙酮)
1H-NMR(400MHz,CDCl3):δ4.13(2H,d,J=5.6Hz),4.53(2H,s),6.81(2H,d,J=8.8Hz),7.24-7.30(3H,m),7.41(2H,d,J=8.8Hz),7.61(2H,d,J=8.8Hz),7.98(1H,br)
13C-NMR(100MHz,DMSO-d6):δ42.43,66.99,86.75,112.69,117.08,121.34,132.14,137.40,138.63,156.98,167.53,167.93
IR(KBr):1661,3290cm-1
MS(EI):m/z488(M+)
·2-(4-氟苯氧基)-N-[(4-甲氧基-2-甲基苯基氨基甲酰基)甲基]乙酰胺
<MM-6>
收率:82%
熔点:169-170℃(重结晶溶剂:丙酮)
1H-NMR(400MHz,CDCl3):δ2.22(3H,s),3.78(3H,s),4.18(2H,d,J=5.6Hz),4.54(2H,s),6.74-6.75(2H,m),6.89(2H,dd,J=8.9,4.1Hz),7.01(2H,t,J=8.9Hz),7.38(1H,br),7.54(1H,d,J=9.8Hz),7.59(1H,br)
13C-NMR(100MHz,DMSO-d6):δ17.93,42.03,55.08,67.48,111.14,115.31,115.82(d,J=22.3Hz),116.12(d,J=8.3Hz),126.67,128.81,134.03,154.05(d,J=2.5Hz),156.82,156.84(d,J=236.5Hz),167.47,168.09
IR(KBr):3260,1666cm-1
MS(EI):m/z346(M+)
·2-(4-氟苯氧基)-N-[(4-碘苯基氨基甲酰基)甲基]乙酰胺
<MM-7>
收率:96%
熔点:190-191℃(重结晶溶剂:丙酮)
1H-NMR(400MHz,CDCl3):δ4.17(2H,d,J=4.9Hz),4.55(2H,s),6.90(2H,dd,J=8.8,4.0Hz),7.02(2H,t,J=8.8Hz),7.12(1H,br),7.29(2H,d,J=8.5Hz),7.38(1H,br),7.63(2H,d,J=8.5Hz)
13C-NMR(100MHz,DMSO-d6):δ42.41,67.44,86.73,115.85(d,J=23.2Hz),116.14(d,J=8.3Hz),121.34,137.39,138.64,154.02(d,J=2.5Hz),156.87(d,J=236.6Hz),167.55,168.13
IR(KBr):3312,1672cm-1
MS(EI):m/z428(M+)
·2-(4-溴苯氧基)-N-[(4-氟苯基氨基甲酰基)甲基]乙酰胺
<MM-8>
收率:97%
熔点:213-214℃(重结晶溶剂:丙酮)
1H-NMR(400MHz,CDCl3):δ4.13(2H,d,J=5.9Hz),4.53(2H,s),6.82(2H,d,J=8.9Hz),7.00(2H,d,J=8.5Hz),7.31(1H,br),7.40-7.44(2H,m),7.41(2H,d,J=8.9Hz),7.95(1H,br)
13C-NMR(100MHz,DMSO-d6):δ42.28,66.98,112.65,115.28(d,J=22.3Hz),117.07,120.90(d,J=7.4Hz),132.11,135.18(d,J=2.5Hz),156.99,157.96(d,J=239.8Hz),167.24,167.88
IR(KBr):3389,1657cm-1
MS(EI):m/z380(M+)
·2-(4-氟苯氧基)-N-[(4-氟苯基氨基甲酰基)甲基]乙酰胺
<MM-9>
收率:96%
熔点:202-203℃(重结晶溶剂:丙酮)
1H-NMR(400MHz,CDCl3):δ4.14(2H,d,J=5.9Hz),4.53(2H,s),6.88(2H,dd,J=9.3,4.1Hz),6.98-7.02(4H,m),7.34(1H,br),7.43(2H,dd,J=9.0,4.6Hz),7.99(1H,br)
13C-NMR(100MHz,DMSO-d6):δ42.30,67.44,115.33(d,J=22.3Hz),115.87(d,J=23.2Hz),116.14(d,J=8.3Hz),120.92(d,J=7.4Hz),135.22(d,J=1.7Hz),154.04(d,J=1.7Hz),156.88(d,J=236.5Hz),158.00(d,J=239.0Hz),167.32,168.16
IR(KBr):3296,1672cm-1
MS(EI):m/z320(M+)
·N-[(4-溴苯基氨基甲酰基)甲基]-2-(4-氟苯氧基)-乙酰胺
<MM-10>
收率:92%
熔点:192-193℃(重结晶溶剂:丙酮)
1H-NMR(400MHz,CDCl3):δ4.15(2H,d,J=5.6Hz),4.53(2H.s),6.88(2H,dd,J=8.9,4.3Hz),7.00(2H,t,J=8.9Hz),7.38(2H,d,J=9.1Hz),7.39(1H,br),7.42(2H,d,J=9.1Hz),8.22(1H,br)
13C-NMR(100MHz,DMSO-d6):δ42.40,67.40,114.83,115.85(d,J=23.2Hz),116.12(d,J=8.3Hz),121.05,131.56,138.20,154.01(d,J=2.5Hz),156.85(d,J=236.6Hz),167.59,168.16
IR(KBr):1686,3256cm-1
MS(EI):m/z380(M+)
·2-(4-溴苯氧基)-N-[(4-甲氧基苯基氨基甲酰基)甲基]乙酰胺
<MM-11>
收率:79%
熔点:190-191℃(重结晶溶剂:丙酮)
1H-NMR(400MHz,CDCl3):δ3.79(3H,s),4.15(2H,d,J=5.6Hz),4.55(2H,s),6.84(2H,d,J=9.0Hz),6.86(2H,d,J=8.9Hz),7.34(1H,br),7.38(2H,d,J=9.0Hz),7.43(2H,d,J=8.9Hz),7.78(1H,br)
13C-NMR(100MHz,DMSO-d6):δ42.22,55.12,66.98,112.66,113.85,117.07,120.73,131.91,132.14,155.21,156.99,166.80,167.84
IR(KBr):1655,3261cm-1
MS(EI):m/z392(M+)
·2-(4-氟苯氧基)-N-[(4-甲氧基苯基氨基甲酰基)甲基]乙酰胺
<MM-12>
收率:84%
熔点:185-186℃(重结晶溶剂:丙酮)
1H-NMR(400MHz,CDCl3):δ3.80(3H,s),4.16(2H,d,J=5.6Hz),4.55(2H,s),6.86-6.92(2H,m),6.87(2H,d,J=8.9Hz),7.02(2H,t,J=8.5Hz),7.38(1H,br),7.39(2H,d,J=8.9Hz),7.80(1H,br)
13C-NMR(100MHz,DMSO-d6):δ42.24,55.14,67.45,113.87,115.88(d,J=23.2Hz),116.15(d,J=7.4Hz),120.76,131.96,154.05(d,J=1.7Hz),155.24,156.88(d,J=236.5Hz)166.86,168.10
IR(KBr):1659,3279cm-1
MS(EI):m/z332(M+)
·2-(4-溴苯氧基)-N-(环己基氨基甲酰基甲基)乙酰胺
<MM-13>
收率:78%
熔点:210-211℃(重结晶溶剂:丙酮)
1H-NMR(400MHz,CDCl3):δ1.12-1.19(3H,m),1.31-1.38(3H,m),1.53-1.61(1H,m),1.67-1.75(2H,m),1.88-1.93(2H,m),3.76(1H,br),3.96(2H,d,J=5.4Hz),4.51(2H,s),5.64(1H,br),6.83(2H,d,J=9.1Hz),7.42(2H,d,J=9.1Hz)
13C-NMR(100MHz,DMSO-d6):δ24.53,25.17,32.37,41.59,47.53,66.94,112.63,117.03,132.14,156.97,167.19,167.56
IR(KBr):1653,3290cm-1
MS(EI):m/z370(M+)
·N-(环己基氨基甲酰基甲基)-2-(4-氟苯氧基)-乙酰胺
<MM-14>
收率:91%
熔点:184-185℃(重结晶溶剂:丙酮)
1H-NMR(400MHz,CDCl3):δ1.12-1.18(3H,m),1.31-1.40(3H,m),1.53-1.64(1H,m),1.67-1.75(2H,m),1.85-1.95(2H,m),3.78(1H,br),3.96(2H,d,J=5.4Hz),4.50(2H,s),5.68(1H,br),6.89(2H,dd,J=8.8,4.3Hz),7.01(2H,t,J=8.8Hz)
13C-NMR(100MHz,DMSO-d6):δ24.56,25.20,32.40,41.61,47.59,67.42,115.88(d,J=23.2Hz),116.11(d,J=8.3Hz),154.03(d,J=1.7Hz),156.88(d,J=236.5Hz),167.27,167.83
IR(KBr):1653,3292cm-1
MS(EI):m/z308(M+)
·2-(4-溴苯氧基)-N-[(2,6-二氟苯基氨基甲酰基)甲基]乙酰胺
<MM-15>
收率:100%
熔点:173-174℃
1H-NMR(400MHz,CDCl3):δ4.22(2H,d,J=1.5Hz),4.53(2H,s),6.81(2H,d,J=9.0Hz),6.95(2H,t,J=8.4Hz),7.04(1H,br),7.21-7.24(1H,m),7.40(2H,d,J=9.0Hz),7.50(1H,br)
IR(KBr):1661,3261cm-1
·N-(苄基氨基甲酰基甲基)-2-(4-溴苯氧基)-乙酰胺
<MM-16>
收率:98%
熔点:195-196℃(重结晶溶剂:丙酮)
1H-NMR(400MHz,CDCl3):δ4.02(2H,d,J=5.4Hz),4.44(2H,d,J=5.9Hz),4.48(2H,s),6.12(1H,br),6.79(2H,d,J=9.1Hz),6.98(1H,br),7.24-7.35(5H,m),7.38(2H,d,J=9.1Hz)
13C-NMR(100MHz,DMSO-d6):δ41.80,41.99,66.99,112.61,117.04,126.73,127.15,128.21,132.13,139.30,156.99,167.80,168.55
IR(KBr):1653,3277cm-1
MS(EI):m/z376(M+)
·N-(苄基氨基甲酰基甲基)-2-(4-氟苯氧基)-乙酰胺
<MM-17>
收率:88%
熔点:165-166℃(重结晶溶剂:丙酮)
1H-NMR(400MHz,CDCl3):δ4.03(2H,d,J=5.6Hz),4.45(2H,d,J=5.6Hz),4.48(2H,s),6.16(1H,br),6.85(2H,dd,J=8.9,4.1Hz),6.97(2H,t,J=8.9Hz),7.09(1H,br),7.22-7.35(5H,m)
IR(KBr):1655,3263cm-1
·N-[(4-甲氧基-2-甲基苯基氨基甲酰基)甲基]-2-(4-甲氧基苯氧基)-乙酰胺
<MM-18>
收率:94%
熔点:143-144℃(重结晶溶剂:丙酮)
1H-NMR(400MHz,CDCl3):δ2.21(3H,s),3.76(3H,s),3.78(3H,s),4.17(2H,d,J=6.1Hz),4.53(2H,s),6.73-6.75(2H,m),6.84(2H,d,J=9.5Hz),6.88(2H,d,J=9.5Hz),7.39(1H,br),7.53(1H,d,J=9.5Hz),7.64(1H,br)
13C-NMR(100MHz,DMSO-d6):δ17.95,42.01,55.08,55.33,67.61,111.14,114.56,115.31,115.72,126.66,128.81,134.02,151.70,153.82,156.80,167.49,168.41
IR(KBr):1660,3273cm-1
MS(EI):m/z358(M+)
·N-[(4-甲氧基-2-甲基苯基氨基甲酰基)甲基]-2-(3-甲氧基苯氧基)-乙酰胺
<MM-19>
收率:70%
熔点:115-116℃
1H-NMR(400MHz,CDCl3):δ2.21(3H,s),3.78-3.81(6H,m),4.18(2H,d,J=5.9Hz),4.57(2H,s),6.51-6.53(2H,m),6.58(1H,d,J=7.8Hz),6.73-6.75(2H,m),7.21(1H,t,J=7.8Hz),7.38(1H,br),7.52(1H,d,J=9.5Hz),7.65(1H,br)
IR(KBr):1659,3331cm-1
·2-(4-氯苯氧基)-N-[(2,6-二氟苯基氨基甲酰基)甲基]乙酰胺
<MM-20>
收率:68%
熔点:184-185℃
1H-NMR(400MHz,CDCl3):δ4.22(2H,d,J=1.0Hz),4.54(2H,s),6.86(2H,d,J=9.0Hz),6.96(2H,t,J=8.2Hz),7.22-7.26(1H,m),7.26(2H,d,J=9.0Hz),7.30(1H,br),7.50(1H,br)
IR(KBr):1663,3261cm-1
·N-[(2,6-二氟苯基氨基甲酰基)甲基]-2-(4-苯氧基苯氧基)-乙酰胺
<MM-21>
收率:84%
熔点:164-165℃(重结晶溶剂:甲苯)
1H-NMR(400MHz,CDCl3):4.25(2H,d,J=3.2Hz),4.55(2H,s),6.89-7.01(9H,m),7.05(1H,t,J=7.4Hz),7.29(2H,t,J=7.4Hz),7.37(1H,br),7.60(1H,br)
13C-NMR(100MHz,DMSO-d6):δ41.58,67.36,111.88(dd,J=17.8,5.4Hz),114.19(t,J=16.5Hz),116.14,117.47,120.58,122.73,128.06(t,J=10.3Hz),129.92,150.06,154.04,157.73(dd,J=248.1,5.8Hz),157.82,167.91,168.26
R(KBr):1665,3273cm-1
·N-[(2,6-二氟苯基氨基甲酰基)甲基]-2-间甲苯氧基)-乙酰胺
<MM-22>
收率:82%
熔点:161-162℃(重结晶溶剂:甲苯)
1H-NMR(400MHz,CDCl3):δ2.33(3H,s),4.25(2H,s),4.57(2H,s),6.74(1H,d,J=8.3Hz),6.77(1H,s),6.83(1H,d,J=8.3Hz),6.97(2H,t,J=7.9Hz),7.19(1H,t,J=7.9Hz),7.20-7.27(1H,m),7.38(1H,br),7.61(1H,br)
13C-NMR(100MHz,DMSO-d6):δ21.09,41.56,66.80,111.87(dd,J=19.0,5.8Hz),114.19(t,J=16.5Hz),115.44,121.97,128.04(t,J=9.9Hz),128.21,129.25,139.03,157.69,157.73(dd,J=248.1,5.8Hz),167.88,168.30
IR(KBr):1680,3258cm-1
·N-[(2,6-二氟苯基氨基甲酰基)甲基]-2-(4-甲氧基苯氧基)-乙酰胺
<MM-23>
收率:95%
熔点:164-165℃(重结晶溶剂:甲苯)
1H-NMR(400MHz,CDCl3):δ3.74(3H,s),4.23(2H,s),4.52(2H,s),6.82(2H,d,J=9.1Hz),6.86(2H,d,J=9.1Hz),6.95(2H,t,J=8.1Hz),7.24-7.25(1H,m),7.36(1H,br),7.61(1H,br)
13C-NMR(100MHz,DMSO-d6):δ41.54,55.35,67.60,111.88(dd,J=17.8,5.4Hz),114.19(t,J=17.0Hz),114.59,115.75,128.04(t,J=12.0Hz),151.73,153.85,157.72(dd,J=249.4,6.2Hz),167.90,168.46
IR(KBr):1666,3271cm-1
·N-[(2,6-二氟苯基氨基甲酰基)甲基]-2-(4-氟苯氧基)-乙酰胺
<MM-24>
收率:34%
熔点:194-195℃(重结晶溶剂:甲苯)
1H-NMR(400MHz,CDCl3):δ4.27(2H,s),4.54(2H,s),6.89(2H,dd,J=9.1,4.3Hz),6.95-7.03(4H,m),7.22-7.26(1H,m),7.39(1H,br),7.67(1H,br)
IR(KBr):1663,3261cm-1
·2-(4-溴苯氧基)-N-[(2,6-二氟苯基硫代氨基甲酰基)甲基]乙酰胺
<MM-25>
收率:66%
熔点:174-175℃(重结晶溶剂:甲苯)
1H-NMR(400MHz,CDCl3):δ4.57(2H,s),4.59(2H.s),6.84(2H,d,J=9.0Hz),7.00(2H,t,J=7.7Hz),7.33(1H,t,J=7.7Hz),7.43(2H,d,J=9.0Hz),7.62(1H,br),9.46(1H,br)
13C-NMR(100MHz,DMSO-d6):δ48.89,67.03,112.11(dd,J=18.2,4.1Hz),112.63,116.18(t,J=16.5Hz),117.09,129.74(t,J=9.5Hz),132.12,156.99,157.49(dd,J=250.6,5.8Hz),167.99,203.40
IR(KBr):1670,3020,3207cm-1
·N-[(2,6-二氟苯基硫代氨基甲酰基)甲基]-2-(4-甲氧基苯氧基)-乙酰胺
<MM-26>
收率:75%
熔点:160-161℃(重结晶溶剂:甲苯)
1H-NMR(400MHz,CDCl3):δ3.74(3H,s),4.54(2H,s),4.57(2H,d,J=6.1Hz),6.83(2H,d,J=9.5Hz),6.87(2H,d,J=9.5Hz),6.98(2H,t,J=8.1Hz),7.31(1H,t,J=8.1Hz),7.57(1H,br),9.45(1H,br)
13C-NMR(100MHz,DMSO-d6):δ48.90,55.35,67.64,112.13(dd,J=18.6,4.5Hz),114.58,115.75,116.21(t,J=16.5Hz),129.75(t,J=9.9Hz),151.71,153.83,157.52(dd,J=249.8,5.0Hz),168.53,203.48
IR(KBr):1670,3007,3182cm-1
·2-(4-溴苯氧基)-N-[(2-甲基苄基氨基甲酰基)甲基]乙酰胺
<MM-27>
收率:47%
熔点:174-175℃(重结晶溶剂:甲苯)
1H-NMR(400MHz,CDCl3):δ2.30(3H,s),4.01(2H,d,J=5.4Hz),4.44(2H,d,J=5.6Hz),4.46(2H,s),6.06(1H,br),6.79(2H,d,J=9.1Hz),7.14-7.24(5H,m),7.38(2H,d,J=9.1Hz)
IR(KBr):1649,3275cm-1
·N-[(4-溴苄基氨基甲酰基)甲基]-2-(4-溴苯氧基)-乙酰胺
<MM-28>
收率:76%
熔点:208-209℃(重结晶溶剂:丙酮)
1H-NMR(400MHz,CDCl3):δ4.04(2H,d,J=5.4Hz),4.41(2H,d,J=6.1Hz),4.50(2H,s),6.26(1H,br),6.81(2H,d,J=9.0Hz),7.14(2H,d,J=8.5Hz),7.20-7.35(1H,m),7.41(2H,d,J=9.0Hz),7.46(2H,d,J=8.5Hz)
IR(KBr):1655,3271cm-1
·N-[(4-溴-2-氟苄基氨基甲酰基)甲基]-2-(4-溴苯氧基)-乙酰胺
<MM-29>
收率:85%
熔点:179-180℃(重结晶溶剂:甲苯)
1H-NMR(400MHz,CDCl3):δ4.02(2H,d,J=5.6Hz),4.45(2H,d,J=5.9Hz),4.50(2H,s),6.30(1H,br),6.81(2H,d,J=9.0Hz),7.19-7.26(3H,m),7.41(2H,d,J=9.0Hz),7.79(1H,br)
13C-NMR(100MHz,DMSO-d6):δ35.60,41.79,66.96,112.64,117.02,118.38(d,J=24.8Hz),120.07(d,J=9.1Hz),125.62(d,J=14.9Hz),127.37(d,J=3.3Hz),131.04(d,J=5.0Hz),132.12,156.96,159.81(d,J=249.8Hz),167.89,168.86
IR(KBr):1661,3279cm-1
·2-(4-溴苯氧基)-N-[(3-溴苯基氨基甲酰基)甲基]-乙酰胺
<MM-30>
收率:70%
熔点:227-228℃
1H-NMR(400MHz,CDCl3):δ4.13(2H,d,J=5.9Hz),4.53(2H,s),6.81(2H,d,J=9.1Hz),7.16(1H,t,J=8.1Hz),7.22-7.35(2H,m),7.37(1H,d,J=8.1Hz),7.41(2H,d,J=9.1Hz),7.74(1H,s),8.18(1H,br)
13C-NMR(100MHz,DMSO-d6):δ42.45,66.97,112.71,117.08,117.90,121.48,121.57,125.93,130.80,132.15,140.37,156.98,167.77,168.00
IR(KBr):1661,3281cm-1
·N-[(3-溴苯基氨基甲酰基)甲基]-2-(4-甲氧基苯氧基)-乙酰胺
<MM-31>
收率:73%
熔点:174-175℃
1H-NMR(400MHz,CDCl3):δ3.75(3H,s),4.16(2H,d,J=5.6Hz),4.53(2H,s),6.83(2H,d,J=9.3Hz),6.87(2H,d,J=9.3Hz),7.16(1H,t,J=7.8Hz),7.22-7.24(1H,m),7.39(1H,d,J=7.8Hz),7.40(1H,br),7.74(1H,s),8.33(1H,br)
13C-NMR(100MHz,DMSO-d6):δ42.43,55.36,67.59,114.60,115.77,117.90,121.48,121.57,125.92,130.81,140.41,151.70,153.87,167.83,168.53
IR(KBr):1663,3312cm-1
·2-(4-溴苯氧基)-N-[(3-氯苯基氨基甲酰基)甲基]-乙酰胺
<MM-32>
收率:71%
熔点:205-206℃(重结晶溶剂:甲苯)
1H-NMR(400MHz,CDCl3):δ4.14(2H,d,J=5.9Hz),4.54(2H,s),6.82(2H,d,J=9.0Hz),7.09(1H,d,J=8.3Hz),7.21-7.28(2H,m),7.30(1H,d,J=8.3Hz),7.41(2H,d,J=9.0Hz),7.61(1H,s),8.10(1H,br)
13C-NMR(100MHz,DMSO-d6):δ42.42,66.95,112.70,117.07,117.49,118.60,123.01,130.47,132.14,133.08,140.23,156.97,167.77,167.99
IR(KBr):1661,3281cm-1
·2-(4-溴苯氧基)-N-[(3-硝基苯基氨基甲酰基)甲基]-乙酰胺
<MM-33>
收率:77%
熔点:197-198℃
1H-NMR(400MHz,CDCl3):δ4.22(2H,d,J=5.9Hz),4.58(2H,s),6.84(2H,d,J=8.7Hz),7.41(1H,br),7.42(2H,d,J=8.7Hz),7.48(1H,t,J=8.5Hz),7.90(1H,d,J=8.5Hz),7.96(1H,d,J=8.5Hz),8.39(1H,s),8.76(1H,br)
13C-NMR(100MHz,DMSO-d6):δ42.51,66.95,112.69,113.22,117.06,117.81,125.08,130.20,132.13,139.91,147.92,156.96,168.07,168.21
IR(KBr):1676,3265cm-1
·2-(4-苄氧基苯氧基)-N-[(2,6-二氟苯基氨基甲酰基)甲基]-乙酰胺
<MM-34>
收率:82%
熔点:145-146℃
1H-NMR(400MHz,CDCl3):δ4.26(2H,s),4.53(2H,s),5.00(2H,s),6.87(2H,d,J=9.1Hz),6.92(2H,d,J=9.1Hz),6.96(2H,t,J=8.1Hz),7.30-7.42(7H,m),7.66(1H,br)
IR(KBr):1663,3260cm-1
·N-[(4-碘苯基氨基甲酰基)甲基]-2-间甲苯氧基-乙酰胺
<MM-36>
收率:69%
熔点:192-193℃(重结晶溶剂:甲苯)
1H-NMR(400MHz,CDCl3):δ2.34(3H,s),4.16(2H,d,J=5.9Hz),4.57(2H,s),6.74(1H,d,J=7.7Hz),6.77(1H,s),6.86(1H,d,J=7.7Hz),7.20(1H,t,J=7.7Hz),7.26-7.28(2H,m),7.37(1H,br),7.62(2H,J=8.8Hz),8.21(1H,br)
13C-NMR(100MHz,DMSO-d6):δ21.10,42.42,66.75,86.75,111.73,115.40,121.30,121.98,129.23,137.40,138.65,139.02,157.64,167.59,168.31
IR(KBr):1663,3277cm-1
·N-[(4-苄氧基苯基氨基甲酰基)甲基]-2-间甲苯氧基-乙酰胺
收率:96%
熔点:169-170℃
1H-NMR(400MHz,CDCl3):δ2.33(3H,s),4.16(2H,d,J=5.6Hz),4.57(2H,s),5.05(2H,s),6.74(1H,d,J=7.8Hz),6.77(1H,s),6.85(1H,d,J=7.8Hz),6.93(2H,d,J=9.0Hz),7.20(1H,t,J=7.8Hz),7.32-7.43(8H,m),7.91(1H,br)
IR(KBr):1663,3329cm-1
实施例3
在氢氛围下,在2-(4-苄氧基苯氧基)-N-[(2,6-二氟苯基氨基甲酰基)甲基]-乙酰胺(91mg,0.21mmol)的甲醇溶液(10mL)中加入氢氧化钯(5mg),以室温搅拌整夜。
将反应液用硅藻土过滤,之后蒸馏除去溶剂,以无色晶体物质的形态得到N-[(2,6-二氟苯基氨基甲酰基)甲基]-2-(4-羟基苯氧基)-乙酰胺(72mg)。
<MM-35>
收率:100%
熔点:197-198℃
1H-NMR(400MHz,CDCl3):δ3.98(2H,s),4.41(2H,s),6.67(2H,d,J=8.8Hz),6.81(2H,d,J=8.8Hz),7.14(2H,t,J=7.6Hz),7.32(1H,t,J=7.6Hz),8.35(1H,br),9.72(1H,br)
IR(KBr):1680,3261cm-1
实施例4
在氢氛围下,在N-[(4-苄氧基苯基氨基甲酰基)甲基]-2-间甲苯氧基-乙酰胺(200mg,0.49mmol)的甲醇-乙醇(5︰1)混合溶液(60mL)中加入氢氧化钯(10mg),以室温搅拌整夜。
将反应液用硅藻土过滤,之后蒸馏除去溶剂,以无色晶体物质的形态得到N-[(4-羟基苯基氨基甲酰基)甲基]-2-间甲苯氧基-乙酰胺(154mg)。
<MM37>
收率:99%
熔点:186-187℃
1H-NMR(400MHz,DMSO-d6):δ2.27(3H,s),3.90(2H,d,J=5.4Hz),4.51(2H,s),6.68(2H,d,J=8.4Hz),6.77-6.82(3H,m),7.17(1H,t,J=7.7Hz),7.33(2H,d,J=8.4Hz),8.30(1H,br),9.20(1H,br),9.71(1H,m)
13C-NMR(100MHz,DMSO-d6):δ21.13,42.26,66.82,111.78,115.15,115.45,121.04,122.02,129.29,130.43,139.09,153.52,157.72,166.69,168.27
IR(KBr):1663,3339cm-1
实施例5
(1)在氩气氛下,在[(2,6-二氟-苯基氨基甲酰基)-甲基]-氨基甲酸叔丁酯(384mg,1.34mmol)的二氯甲烷(5.7mL)溶液中加入三氟乙酸(1.0mL,13.6mmol),以室温搅拌整夜。
之后以0℃在反应液中加入饱和碳酸氢钠水溶液,直到水层显示碱性。
在水层中加入二氯甲烷,利用碳酸钾将提取得到的有机层干燥,进行过滤。
蒸馏除去溶剂,得到无色晶体2-氨基-N-(2,6-二氟苯基)乙酰胺(122mg,收率:49%)。
(2)在氩气氛下,在2-氨基-N-(2,6-二氟苯基)乙酰胺(114mg,0.61mmol)的二氯甲烷(4mL)溶液中加入二乙胺(0.17mL,1.22mmol),接着以0℃加入苄基氨磺酰氯(114mg,0.67mmol),以室温搅拌整夜。
利用二氧化硅凝胶柱色谱(15g,己烷︰丙酮=4︰1~3︰1)对蒸馏除去溶剂得到的残渣进行精制,得到无色晶体N-(2,6-二氟苯基)-2-苯基甲磺酰胺基-乙酰胺(113mg,DR-1)
收率:54%
熔点:141-142℃(重结晶溶剂:甲苯)
1H-NMR(400MHz,CDCl3):δ3.77(2H,s),4.35(2H,s),5.00(1H,br),6.94(2H,t,J=8.2Hz),7.19-7.24(1H,m),7.37-7.43(6H,m)
实施例6
与实施例5同样操作得到以下化合物。
·N-(2,6-二氟苯基)-2-(甲苯-4-苯基甲磺酰胺基)-乙酰胺
[DR-2]
收率:70%
熔点:129-130℃(重结晶溶剂:甲苯)
1H-NMR(400MHz,CDCl3):δ2.42(3H,s),3.79(2H,s),5.36(1H,br),6.93(2H,t,J=8.2Hz),7.17-7.24(1H,m),7.32(2H,d,J=8.2Hz),7.72(1H,br),7.76(2H,d,J=8.2Hz)
·N-(1-苯基乙基)-2-苯基甲磺酰胺基-乙酰胺
[DR-3]
收率:38%
熔点:147-148℃(重结晶溶剂:甲苯)
1H-NMR(400MHz,CDCl3):δ1.46(3H,d,J=7.1Hz),3.52(2H,s),4.27(2H,s),4.90(1H,br),5.06(1H,quint,J=7.1Hz),6.27(1H,br),7.24-7.35(10H,m)
·N-(1-苯基乙基)-2-(甲苯-4-甲磺酰胺基)-乙酰胺
[DR-4]
收率:59%
1H-NMR(400MHz,CDCl3):δ1.42(3H,d,J=7.1Hz),2.40(3H,s),3.53(2H,s),5.02(1H,quint,J=7.1Hz),5.25(1H,br),6.52(1H,br),7.22-7.32(7H,m),7.70(2H,d,J=8.3Hz)
·苯基甲磺酰胺基乙酸苄酯
[DR-5]
收率:30%
熔点:92-93℃
1H-NMR(400MHz,CDCl3):δ3.71(2H,d,J=5.4Hz),4.30(2H,s),4.69(1H,br),5.15(2H,s),7.30-7.42(10H,m)
·(甲苯-4-磺酰胺基)乙酸苄酯
[DR-6]
收率:70%
Helv.Chim.Acta,1996,79,1843-1862.
·N-(4-甲基苄基)-2-(甲苯-4-磺酰胺基)乙酰胺
[DR-8]
收率:31%
1H-NMR(400MHz,CDCl3):δ2.32(3H,s),2.41(3H,s),3.58(2H,d,J=5.9Hz),4.35(2H,d,J=5.6Hz),5.07(1H,br),6.42(1H,br),7.10(2H,d,J=7.2Hz),7.12(2H,d,J=7.2Hz),7.29(2H,d,J=8.2Hz),7.71(2H,d,J=8.2Hz)
·N-(4-溴苄基)-2-(甲苯-4-磺酰胺基)乙酰胺
收率:50%
熔点:207-208℃(重结晶溶剂:丙酮)
1H-NMR(400MHz,CDCl3):δ2.44(3H,s),3.61(2H,d,J=6.1Hz),4.38(2H,d,J=6.3Hz),5.03(1H,br),6.61(1H,br),7.12(2H,d,J=8.3Hz),7.32(2H,d,J=8.3Hz),7.45(2H,d,J=8.3Hz),7.73(2H,d,J=8.3Hz)
·N-(4-溴-2-氟苄基)-2-(甲苯-4-磺酰胺基)乙酰胺
[DR-11]
收率:64%
熔点:123-124℃
1H-NMR(400MHz,CDCl3):δ2.42(3H,s),3.58(2H,d,J=6.3Hz),4.40(2H,d,J=5.9Hz),5.01(1H,br),6.60(1H,br),7.16(1H,t,J=8.1Hz),7.22(1H,dd,J=8.1,1.5Hz),7.23-7.24(1H,m),7.30(2H,d,J=8.2Hz),7.70(2H,d,J=8.2Hz)
·N-(3-溴苯基)-2-(甲苯-4-磺酰胺基)乙酰胺
[DR-13]
收率:83%
Yingyong Huaxue,1991,8,48-51.
·N-(4-氯苯基)-2-(甲苯-4-磺酰胺基)乙酰胺
[DR-15]
收率:24%
Indian J.Chem.Sect.B,2002,41B,2635-2641.
·N-(3-溴苯基)-2-(4-氯苯磺酰胺基)乙酰胺
[DR-22]
收率:52%
1H-NMR(400MHz,CDCl3):δ3.74(2H,d,J=6.1Hz),5.22(1H,br),7.20(1H,t,J=8.1Hz),7.26-7.30(1H,m),7.37(1H,d,J=8.1Hz),7.54(2H,d,J=8.5Hz),7.74(1H,s),7.84(2H,d,J=8.5Hz),7.93(1H,br)
·N-(3-溴苯基)-2-(4-氟苯磺酰胺基)乙酰胺
[DR-23]
收率:41%
1H-NMR(400MHz,CDCl3):δ3.78(2H,d,J=6.1Hz),5.28(1H,br),7.23(1H,t,J=8.0Hz),7.21-7.33(3H,m),7.41(1H,d,J=8.0Hz),7.78(1H,s),7.96(2H,dd,J=8.7,4.8Hz),8.04(1H,br)
·N-(3-溴苯基)-2-(4-甲氧基-苯磺酰胺基)乙酰胺
[DR-24]
收率:49%
1H-NMR(400MHz,CDCl3):δ3.70(2H,d,J=6.6Hz),3.88(3H,s),5.12(1H,br),7.01(2H,d,J=8.9Hz),7.19(1H,t,J=8.1Hz),7.26-7.28(1H,m),7.39(1H,d,J=8.1Hz),7.73(1H,s),7.83(2H,d,J=8.9Hz),8.16(1H,br)
·N-(4-氯苯基)-2-(4-甲氧基-苯磺酰胺基)乙酰胺
[DR-25]
收率:67%
1H-NMR(400MHz,CDCl3):δ3.70(2H,d,J=6.6Hz),3.87(3H,s),5.14(1H,br),7.01(2H,d,J=8.8Hz),7.29(2H,d,J=8.9Hz),7.45(2H,d,J=8.9Hz),7.82(2H,d,J=8.8Hz),8.18(1H,br)
·N-(4-氯苯基)-2-(4-氟苯磺酰胺基)乙酰胺
[DR-26]
收率:54%
1H-NMR(400MHz,CDCl3):δ3.74(2H,d,J=6.3Hz),5.19(1H,br),7.22-7.32(4H,m),7.44(2H,d,J=8.8Hz),7.92(2H,dd,J=9.0,4.9Hz),7.98(1H,br)
·N-(4-氯苯基)-2-(4-氯苯磺酰胺基)乙酰胺
[DR-27]
收率:56%
Indian J.Exp.Biol.,1966,4,190-1.
·N-(2-溴苯基)-2-(4-氟苯磺酰胺基)乙酰胺
[DR-28]
收率:27%
1H-NMR(400MHz,CDCl3):δ3.83(2H,d,J=6.1Hz),5.27(1H,br),7.02(1H,t,J=7.9Hz),7.22(2H,t,J=8.5Hz),7.32(1H,t,J=7.9Hz),7.55(1H,d,J=7.9Hz),7.94(2H,dd,J=8.5,5.1Hz),8.23(1H,d,J=7.9Hz),8.37(1H,br)
·N-(2-溴苯基)-2-(4-氯苯磺酰胺基)乙酰胺
[DR-29]
收率:29%
1H-NMR(400MHz,CDCl3):δ3.83(2H,d,J=6.1Hz),5.43(1H,br),7.02(1H,t,J=8.1Hz),7.31(1H,t,J=8.1Hz),7.51(2H,d,J=8.7Hz),7.54(1H,d,J=8.1Hz),7.85(2H,d,J=8.7Hz),8.21(1H,d,J=8.1Hz),8.37(1H,br)
实施例7
(1)在氩气氛下,在[(3-溴-苯基氨基甲酰基)-甲基]-氨基甲酸叔丁酯(717mg,2.18mmol)的二氯甲烷(9mL)溶液中加入三氟乙酸(1.6mL,22.07mmol),以室温搅拌整夜。
之后以0℃在反应液中加入饱和碳酸氢钠水溶液,直到水层显示碱性。
在水层中加入二氯甲烷,用碳酸钾将提得到的有机层干燥,并进行过滤。
蒸馏除去溶剂,得到无色晶体2-氨基-N-(3-溴苯基)乙酰胺(421mg,收率:84%)。
(2)在氩气氛下,在2-氨基-N-(3-溴苯基)乙酰胺(80mg,0.33mmol)的二氯甲烷(5mL)溶液中加入三乙胺(0.17mL,1.22mmol)、DMAP(41mg,0.33mmol),接着以0℃加入苄基氨磺酰氯(69mg0.36mmol),以室温搅拌整夜。
利用二氧化硅凝胶柱色谱(15g,己烷︰丙酮=6︰1~4︰1)对蒸馏除去溶剂得到的残渣进行精制,得到无色晶体N-(3-溴苯基)-2-苯基甲磺酰胺基-乙酰胺(41mg,DR-12)。
收率:31%
熔点:215-216℃(重结晶溶剂:甲苯)
1H-NMR(400MHz,CDCl3):δ3.69(2H,d,J=6.3Hz),4.38(2H,s),4.84(1H,br),7.17-7.27(3H,m),7.35-7.45(5H,m),7.75(1H,s),7.80(1H,br)
实施例8
与实施例7同样操作得到以下化合物。
·N-(4-氯苯基)-2-苯基甲磺酰胺基-乙酰胺
[DR-14]
收率:28%
熔点:200-201℃
1H-NMR(400MHz,CDCl3):δ3.69(2H,d,J=6.3Hz),4.38(2H,s),4.84(1H,br),7.42-7.52(9H,m),7.81(1H,br)
·N-(3-氯苯基)-2-苯基甲磺酰胺基-乙酰胺
[DR-16]
收率:45%
1H-NMR(400MHz,CDCl3):δ3.67(2H,d,J=6.3Hz),4.36(2H,s),4.84(1H,br),7.10(1H,d,J=7.6Hz),7.20-7.32(2H,m),7.35-7.45(5H,m),7.60(1H,s),7.81(1H,br)
·N-(3-氯苯基)-2-(甲苯-4-磺酰胺基)-乙酰胺
[DR-17]
收率:82%
Yingyong Huaxue,1991,8,48-51.
·N-(3-硝基苯基)-2-(甲苯-4-磺酰胺基)-乙酰胺
[DR-18]
收率:55%
Yingyong Huaxue,1991,8,48-51.
·N-(4-苄氧基苯基)-2-(甲苯-4-磺酰胺基)-乙酰胺
[DR-20]
收率:86%
1H-NMR(400MHz,CDCl3):δ2.43(3H,s),3.70(2H,d,J=5.9Hz),5.04(2H,s),5.19(1H,br),6.93(2H,d,J=8.8Hz),7.34-7.43(9H,m),7.77(2H,d,J=8.1Hz),7.93(1H,br)
·2-(4-氟苯磺酰胺基)-N-(4-甲基苄基)-乙酰胺
[DR-21]
收率:37%
1H-NMR(400MHz,CDCl3):δ2.34(3H,s),3.63(2H,s),4.36(2H,d,J=5.9Hz),6.25(1H,br),7.10(2H,d,J=8.2Hz),7.14(2H,d,J=8.2Hz),7.15-7.21(3H,m),7.87(2H,dd,J=8.7,5.0Hz)
实施例9
(1)在氢氛围下,在[N′-[2-(4-氟苯基)乙酰基]肼基氨基甲酰基甲基]氨基甲酸丁酯(298mg,0.83mmol)的甲醇溶液(30mL)中加入氢氧化钯(5mg),以室温搅拌整夜。
将反应液用硅藻土过滤后,蒸馏除去溶剂,得到无色晶体2-氨基-N′-(2-(4-氟苯基)乙酰基)乙酰肼(233mg,收率100%)。
(2)在氩气氛下,2-氨基-N′-(2-(4-氟苯基)乙酰基)乙酰肼(68mg,0.30mmol)的二氯甲烷(5mL)溶液中加入三乙胺(0.084mL,0.60mmol)、DMAP(37mg,0.30mmol),接着以0℃加入甲苯磺酰氯(63mg,0.33mmol),以室温搅拌整夜。
利用二氧化硅凝胶柱色谱(15g,己烷︰丙酮=2︰1~1.5︰1)对蒸馏除去溶剂得到的残渣进行精制,得到无色晶体N-(2-{N′-[2-(4-氟苯基)乙酰基]肼基}-2-氧乙基)-4-甲基-苯磺酰胺(82mg,DR-19)。
收率:71%
1H-NMR(400MHz,CDCl3):δ2.44(3H,s),3.59(2H,s),4.81(2H,s),7.05(2H,t,J=8.7Hz),7.10(1H,br),7.10-7.26(4H,m),7.36(2H,d,J=8.2Hz),7.72(2H,d,J=8.2Hz)
(1)在氩气氛下,在Boc体(144mg,0.44mmol)的二氯甲烷(2mL)溶液中加入四氢呋喃(1.6mL,2.37mmol),以室温搅拌整夜。
之后,以0℃在反应液中加入饱和碳酸氢钠水溶液,直到水层显示碱性,利用碳酸钾将用二氯甲烷提取后得到的有机层干燥并进行过滤,蒸馏除去溶剂,以无色晶体物质的形态得到胺体(98mg,98%)。
(2)在氩气氛下,在胺体(98mg,0.43mmol)的二氯甲烷(5mL)溶液中加入三乙胺(0.12mL,0.86mmol),以0℃加入磺酰氯体(102mg,0.47mmol),以室温搅拌整夜。
利用二氧化硅凝胶柱色谱(15g,己烷︰丙酮=8︰1~5︰1)对蒸馏除去溶剂得到的残渣进行精制,得到N-(2-溴-苯基)-2-(2-甲苯基-乙磺酰胺基)-乙酰胺(DR-30)的无色晶体75mg(收率43%)。
1H-NMR(400MHz,CDCl3):δ2.39(3H,s),3.92(2H,d,J=6.1Hz),5.12(1H,br),6.74(1H,d,J=15.2Hz),7.01(1H,t,J=7.9Hz),7.21(2H,d,J=8.2Hz),7.30(1H,t,J=7.9Hz),7.38(2H,d,J=8.2Hz),7.53(1H,d,J=7.9Hz),7.54(1H,d,J=15.2Hz),8.28(1H,d,J=7.9Hz),8.53(1H,br);
熔点:132-133℃
实施例10
与实施例9同样操作得到以下化合物。
·N-(4-溴-苯基)-2-(2-甲苯基-乙磺酰胺基)-乙酰胺
(DR-31)
收率:83%
1H-NMR(400MHz,CDCl3):δ2.41(3H,s),3.74(2H,d,J=4.4Hz),4.39(2H,d,J=5.9Hz),5.07(1H,br),6.58(1H,br),6.66(1H,d,J=15.5Hz),7.09(2H,d,J=8.1Hz),7.23(2H,d,J=7.8Hz),7.36-7.38(4H,m),7.51(1H,d,J=15.5Hz)
熔点:200-201℃
·N-(4-甲氧基苯基-苯基)-2-(2-甲苯基-乙磺酰胺基)-乙酰胺
(DR-32)
收率:35%
1H-NMR(500MHz,CDCl3):δ2.39(3H,s),3.79(3H,s),3.83(2H,d,J=4.6Hz),5.14(1H,br),6.70(1H,d,J=15.5Hz),6.85(2H,d,J=9.2Hz),7.21(2H,d,J=8.0Hz),7.37-7.39(4H,m),7.52(1H,d,J=15.5Hz),7.93(1H,br)
熔点:145-146℃
·N-(4-溴-苯基)-2-(2-甲苯基-乙磺酰胺基)-乙酰胺
(DR-33)
收率:65%
1H-NMR(500MHz,CDCl3):δ2.39(3H,s),3.83(2H,d,J=6.3Hz),5.22(1H,br),6.69(1H,d,J=15.2Hz),7.21(2H,d,J=8.0Hz),7.36(2H,d,J=8.0Hz),7.39-7.43(4H,m),7.51(1H,d,J=15.2Hz),8.19(1H,br)
熔点:216-219℃
·N-(4-溴-2-氟-苯基)-2-(2-甲苯基-乙磺酰胺基)-乙酰胺
(DR-34)
收率:65%
1H-NMR(500MHz,CDCl3):δ2.40(3H,s),3.73(2H,d,J=6.3Hz),4.44(2H,d,J=6.3Hz),5.01(1H,br),6.58(1H,br),6.65(1H,d,J=15.5Hz),7.15-7.20(2H,m),7.22(2H,d,J=8.0Hz),7.25-7.30(1H,m),7.36(2H,d,J=8.0Hz),7.47(1H,d,J=15.5Hz);13C-NMR(125MHz,DMSO-d6):21.02,35.64(d,J=4.8Hz),44.95,118.32(d,J=23.9Hz),119.99(d,J=9.6Hz),125.46(d,J=15.6Hz),125.64,127.28(d,J=3.6Hz),128.36,129.54,130.05,130.80(d,J=4.8Hz),139.20,140.44,159.73(d,J=249.5Hz),168.53
熔点:161-162℃
·N-(4-苄氧基-苯基)-2-(2-甲苯基-乙磺酰胺基)-乙酰胺
(DR-35)
收率:66%
1H-NMR(400MHz,CDCl3):δ2.36(3H,s),3.80(2H,d,J=6.1Hz),5.00(2H,s),5.29(1H,br),6.68(1H,d,J=15.4Hz),6.88(2H,d,J=9.0Hz),7.17(2H,d,J=7.8Hz),7.25-7.45(9H,m),7.49(1H,d,J=15.4Hz),8.02(1H,br)
13C-NMR(125MHz,DMSO-d6):δ20.99,45.59,69.33,114.79,120.80,125.89,127.64,127.77,128.31,128.39,129.51,130.07,131.90,137.13,139.05,140.35,154.38,166.45
熔点:178-179℃
实施例11
(1)在氩气氛下,在通式4的羧酸(1mmol)的乙醇(3mL)溶液中加入浓盐酸(1滴),整夜加热回流。
蒸馏除去溶剂后,加入饱和碳酸氢钠水溶液,直到水层显示碱性,用二氯甲烷进行提取。
用硫酸钠将有机层干燥并进行过滤后,蒸馏除去溶剂,得到通式4a的乙酯体。
(2)在氩气氛下,在通式4a的乙酯体(1mmol)的乙醇(0.5mL)溶液中加入一水合肼(0.05mL,1mmo),加热回流整夜,得到通式3的肼体。
接着蒸馏除去溶剂,之后,利用套管加入通式2a的异硫氰酸酯体(1mmol)的二氯甲烷(5mL)溶液,以室温搅拌整夜。
对反应液进行抽滤,得到通式1a的硫脲体。
·3-(4-氯苯基)-N-[N′-(2-噻吩-2-基-乙酰基)肼基硫代羰基]丙烯酰胺
(LW-1)
收率:64%
熔点:232-233℃(重结晶溶剂:乙醇)
1H-NMR(400MHz,DMSO-d6):δ3.85(2H,s),6.95-7.01(3H,m),7.38(1H,dd,J=5.0,1.3Hz),7.53(2H,d,J=8.5Hz),7.64(2H,d,J=8.5Hz),7.73(1H,d,J=15.9Hz),11.16(1H,br),11.66(1H,br),12.57(1H,br)13C-NMR(100MHz,DMSO-d6):δ33.90,120.18,125.18,126.65,126.67,129.20,129.90,132.97,135.26,136.19,143.14,165.56,166.26,176.63
IR(KBr):3211,1684,1655,1630cm-1
MS(EI):m/z379(M+)
·N-[N′-(2-噻吩-2-基-乙酰基)肼基硫代羰基]-3-(2,4,6-三氯苯基)-丙烯酰胺
(LW-2)
收率:81%
熔点:219-220℃(重结晶溶剂:己烷-丙酮)
1H-NMR(400MHz,DMSO-d6):δ3.86(2H,s),6.95-6.98(2H,m),7.14(1H,d,J=16.1Hz),7.38(1H,dd,J=5.0,1.3Hz),7.72(1H,d,J=16.1Hz),7.81(2H,s),11.2(1H,br),11.9(1H,br),12.5(1H,br)
13C-NMR(100MHz,DMSO-d6):δ33.89,125.18,126.63,126.65,128.05,129.00,130.17,134.61,134.88,136.16,136.68,164.59,166.29,176.44
IR(KBr):3196,1682,1653,1624cm-1
MS(EI):m/z447(M+)
·3-(4-硝基苯基)-N-[N′-(2-噻吩-2-基-乙酰基)肼基硫代羰基]丙烯酰胺
(LW-3)
收率:60%
熔点:222-223℃(重结晶溶剂:己烷-丙酮)
1H-NMR(400MHz,DMSO-d6)δ:3.88(2H,s),6.97-7.00(2H,m),7.17(1H,d,J=16.3Hz),7.40(1H,dd,J=5.1,1.5Hz),7.86(1H,d,J=16.3Hz),7.89(2H,d,J=8.9Hz),8.32(2H,d,J=8.9Hz),11.20(1H,br),11.78(1H,br),12.56(1H,br)
13C-NMR(100MHz,DMSO-d6)δ:33.89,123.72,124.25,125.19,126.66,126.67,129.25,136.17,140.38,141.79,148.16,165.00,166.28,176.46
IR(KBr):3244,1682,1655,1522,1342cm-1
MS(EI):m/z390(M+)
·N-[N′-(2-噻吩-2-基-乙酰基)肼基硫代羰基]-3-对甲苯基丙烯酰胺
(LW-4)
收率:77%
熔点:212-213℃(重结晶溶剂:乙醇)
1H-NMR(400MHz,DMSO-d6):δ2.33(3H,s),3.85(2H,s),6.92-6.98(3H,m),7.27(2H,d,J=7.9Hz)7.38(1H,dd,J=5.1,1.0Hz),7.51(2H,d,J=7.9Hz),7.69(1H,d,J=15.9Hz),11.14(1H,br),11.60(1H,br),12.59(1H,br)
13C-NMR(100MHz,DMSO-d6):δ21.09,33.92,118.26,125.20,126.66,126.69,128.30,129.75,131.32,136.22,140.95,144.69,165.96,166.26,176.69
IR(KBr):3227,1684,1661,1630cm-1
MS(EI):m/z359(M+)
·3-(4-氟苯基)-N-[N′-(2-噻吩-2-基-乙酰基)肼基硫代羰基]丙烯酰胺
(LW-5)
收率:89%
熔点:215-216℃(重结晶溶剂:丙酮)
1H-NMR(400MHz,DMSO-d6):δ3.85(2H,s),6.93(1H,d,J=15.9Hz),6.96-6.99(2H,m),7.31(2H,t,J=8.8Hz),7.38(1H,dd,J=4.9,1.5Hz),7.69(2H,dd,J=8.8,5.6Hz),7.74(1H,d,J=15.9Hz),11.15(1H,br),11.64(1H,br),12.58(1H,br)
13C-NMR(100MHz,DMSO-d6):δ33.93,116.25(d,J=22.3Hz),119.25,125.23,126.69,126.72,130.63(d,J=8.3Hz),130.73(d,J=3.3Hz),136.22,143.42,163.46(d,J=248.9Hz),165.73,166.31,176.78
IR(KBr):3186,1680,1651,1628cm-1
MS(EI):m/z363(M+)
·3-(2,4-二甲氧基苯基)-N-[N′-(2-噻吩-2-基-乙酰基)肼基硫代羰基]丙烯酰胺
(LW-6)
收率:70%
熔点:207-208℃(重结晶溶剂:甲醇)
1H-NMR(600MHz DMSO-d6)δ:3.82(3H,s),3.85(2H,s),3.88(3H,s),6.62(2H,m),6.97(3H,m),7.38(1H,dd,J=5.1,1.5Hz),7.47(1H,d,J=9.5Hz),7.81(1H,d,J=15.8Hz),11.11(1H,br),11.56(1H,br),12.68(1H,br)
13C-NMR(150MHz,DMSO-d6)δ:33.89,55.54,55.72,98.45,106.33,115.42,116.66,125.15,126.61,126.65,130.97,136.22,140.07,159.98,163.05,166.19,166.80,176.94
IR(KBr):3225,1670,1606,1531,1215,1132.1cm-1
MS(EI):m/z405(M+)
·3-(3,5-二溴苯基)-N-[N′-(2-噻吩-2-基-乙酰基)肼基硫代羰基]丙烯酰胺
(LW-7)
收率:81%
熔点:212-213℃(重结晶溶剂:己烷-丙酮)
1H-NMR(400MHz,DMSO-d6):δ3.85(2H,s),6.95-6.98(2H,s),7.06(1H,d,J=15.9Hz),7.38(1H,dd,J=4.9,1.5Hz),7.67(1H,d,J=15.9Hz),7.84(2H,d,J=1.5Hz),7.92(1H,d,J=1.5Hz),11.17(1H,br),11.59(1H,br),12.48(1H,br)
13C-NMR(100MHz,DMSO-d6)δ:33.91,122.77,123.13,125.22,126.70,129.69,129.80,134.89,136.19,138.31,141.07,165.00,166.34,176.59
IR(KBr):3184,1686,1663,1632cm-1
MS(EI):m/z501(M+)
·3-(4-异丙基苯基)-N-[N′-(2-噻吩-2-基-乙酰基)肼基硫代羰基]丙烯酰胺
(LW-8)
收率:50%
熔点:201-202℃(重结晶溶剂:乙酸乙酯)
1H-NMR(400MHz,DMSO-d6):δ1.20(6H,d,J=6.8Hz),2.91(1H,sept,J=6.8Hz),3.85(2H,s),6.93-6.98(3H,m),7.34(2H,d,J=8.1Hz),7.38(1H,dd,J=5.0,1.3Hz),7.54(2H,d,J=8.1Hz),7.70(1H,d,J=15.9Hz),11.14(1H,br),11.62(1H,br),12.59(1H,br)
13C-NMR(100MHz,DMSO-d6):δ23.56,33.40,33.89,118.37,125.18,126.64,126.67,127.12,128.40,131.73,136.20,144.63,151.64,165.92,166.24,176.78
MS(EI):m/z387(M+)
·3-联苯基-4-基-N-[N′-(2-噻吩-2-基-乙酰基)肼基硫代羰基]丙烯酰胺
(LW-9)
收率:85%
熔点:231-232℃
1H-NMR(400MHz,DMSO-d6):δ3.86(2H,s),6.96-6.99(2H,m),7.04(1H,d,J=15.9Hz),7.38-7.41(2H,m),7.48(2H,t,J=7.6Hz),7.70-7.80(7H,m),11.16(1H,br),11.66(1H,br),12.61(1H,br)
13C-NMR(100MHz,DMSO-d6):δ33.91,119.26,125.19,126.68,126.72,127.30,128.08,128.94,129.05,131.31,133.13,136.21,139.07,142.26,144.13,165.79,166.27,176.74
MS(EI):m/z421(M+)
·3-(2,6-二甲氧基苯基)-N-[N′-(2-噻吩-2-基-乙酰基)肼基硫代羰基]丙烯酰胺
(LW-10)
收率:59%
熔点:220-221℃(重结晶溶剂:己烷-丙酮)
1H-NMR(400MHz,DMSO-d6):δ3.87(8H,s),6.71(2H,d,J=8.3Hz),6.96-6.98(2H,m),7.34-7.38(3H,m),8.06(1H,d,J=15.9Hz),11.12(1H,br),11.67(1H,br),12.73(1H,br)
13C-NMR(100MHz,DMSO-d6):δ33.90,55.92,104.07,110.99,120.95,125.18,126.62,126.67,132.55,135.32,136.23,159.82,166.17,167.53,176.86;
IR(KBr):3219,1670,1653,1611cm-1
MS(EI):m/z405(M+)
·N-[N′-(2-噻吩-2-基-乙酰基)肼基硫代羰基]-3-(2,4,6-三氟苯基)-丙烯酰胺
(LW-11)
收率:69%
熔点:207-208℃
1H-NMR(400MHz,DMSO-d6):δ3.85(2H,s),6.96-6.98(2H,m),7.20(1H,d,J=16.0Hz),7.36-7.40(3H,m),7.60(1H,d,J=16.0Hz),11.17(1H,br),11.87(1H,br),12.57(1H,br)
13C-NMR(100MHz,DMSO-d6):δ33.90,101.73(td,J=26.9,2.5Hz),108.66(td,J=15.3,5.0Hz),124.64(td,J=8.4,3.0Hz),125.19,126.65,126.68,129.11,136.19,161.35(dt,J=254.7,7.9Hz),161.42(dt,J=254.7,8.1Hz),165.39,166.27,176.44
IR(KBr):3190,1684,1653,1624cm-1
MS(EI):m/z399(M+)
·3-(4-氟苯基)-N-[N′-苯基乙酰基肼基硫代羰基]丙烯酰胺
(LW-12)
收率:89%
熔点:212-213℃
1H-NMR(400MHz,DMSO-d6)δ:3.62(2H,s),6.93(1H,d,J=15.7Hz),7.25-7.32(7H,m),7.69(2H,dd,J=8.8,5.6Hz),7.73(1H,d,J=15.7Hz),11.10(1H,s),11.62(1H,s),12.56(1H,s)
13C-NMR(100MHz,DMSO-d6)δ:39.57,116.20(d,J=21.5Hz),119.25,126.61,128.25,129.20,130.57(d,J=9.1Hz),130.71(d,J=3.3Hz),135.26,143.33,163.41(d,J=248.9Hz),165.66,167.29,176.77
MS(EI):m/z357(M+)
·N-[N′-(2-噻吩-2-基-乙酰基)肼基硫代羰基]-3-(4-三氟甲基苯基)-丙烯酰胺
(LW-13)
收率:83%
熔点:224-225℃
1H-NMR(400MHz,DMSO-d6):δ3.86(2H,s),6.95-6.99(2H,m),7.11(1H,d,J=15.9Hz),7.38(1H,dd,J=4.9,1.5Hz),7.76-7.83(5H,m),11.17(1H,br),11.72(1H,br),12.53(1H,br)
13C-NMR(100MHz,DMSO-d6):δ33.93,122.34,124.00(q,J=272.4Hz),125.22,126.02(q,J=4.1Hz),126.70,127.83,128.86,130.24(q,J=32.0Hz),136.19,138.03(q,J=1.7Hz),142.66,165.28,166.34,176.62
IR(KBr):1636,1661,1684,3196cm-1
MS(EI):m/z413(M+)
·N-(N′-苯基乙酰基-肼基硫代羰基)-3-(2,4,6-三氟苯基)-丙烯酰胺
(LW-14)
收率:75%
熔点:210-211℃
1H-NMR(400MHz,DMSO-d6)δ:3.62(2H,s),7.19(1H,d,J=16.1Hz),7.23-7.40(7H,m),7.59(1H,d,J=16.1Hz),11.13(1H,br),11.86(1H,br),12.53(1H,br)
13C-NMR(100MHz,DMSO-d6)δ:39.54,101.72(td,J=27.3,3.3Hz),108.64(td,J=16.1,4.1Hz),124.67,126.60,128.25,129.07,129.18,135.25,160.01(dd,J=12.8,9.9Hz),162.63(dd,J=12.8,9.9Hz),165.35,167.28,176.47
MS(EI):m/z393(M+)
·3-(3,5-二溴苯基)-N-[N′-苯基乙酰基-肼基硫代羰基]丙烯酰胺
(LW-15)
收率:70%
熔点:192-193℃
1H-NMR(400MHz,DMSO-d6)δ:3.62(2H,s),7.06(1H,d,J=15.9Hz),7.23-7.32(5H,m),7.66(1H,d,J=15.9Hz),7.84(2H,s),7.92(1H,s),11.13(1H,br),11.57(1H,br),12.47(1H,br)
13C-NMR(100MHz,DMSO-d6)δ:39.59,122.79,123.12,126.66,128.30,129.24,129.80,134.88,135.26,138.32,141.06,164.99,167.42,176.69
MS(EI):m/z495(M+)
·3-(4-氟苯基)-N-[N′-(噻吩-2-羰基)-肼基硫代羰基]丙烯酰胺
(LW-16)
收率:85%
熔点:217-218℃
1H-NMR(400MHz,DMSO-d6)δ:6.98(1H,d,J=15.7Hz),7.21(1H,t,J=4.5Hz),7.32(2H,t,J=8.7Hz),7.69-7.72(2H,m),7.77(1H,d,J=15.7Hz),7.87(1H,d,J=4.5Hz),7.90(1H,d,J=4.5Hz),11.10(1H,br),11.67(1H,br),12.14(1H,br)
13C-NMR(100MHz,DMSO-d6)δ:116.24(d,J=22.3Hz),119.41,128.21,129.60,130.63(d,J=9.1Hz),130.76(d,J=3.3Hz),132.00,136.63,143.47,159.48,163.45(d,J=248.9Hz),165.44,177.93
MS(EI):m/z349(M+)
·3-(2,6-二甲氧基苯基)-N-[N′-苯基乙酰基-肼基硫代羰基]丙烯酰胺
(LW-17)
收率:73%
熔点:211-212℃
1H-NMR(400MHz,DMSO-d6)δ:3.62(2H,s),3.89(6H,s),6.71(2H,d,J=8.3Hz),7.25-7.39(7H,m),8.05(1H,d,J=15.9Hz),11.07(1H,s),11.65(1H,s),12.70(1H,br)
13C-NMR(100MHz,DMSO-d6)δ:39.59,55.94,104.09,111.02,121.00,126.63,128.29,129.21,132.57,135.19,135.31,159.84,167.26,167.53,177.00
MS(EI):m/z399(M+)
·3-(2,6-二甲氧基苯基)-N-[N′-(噻吩-2-羰基)-肼基硫代羰基]丙烯酰胺
(LW-19)
收率:26%
熔点:209-210℃
1H-NMR(400MHz,DMSO-d6):δ3.88(6H,s),6.72(2H,d,J=8.5Hz),7.21(1H,t,J=5.1Hz),7.37-7.42(2H,m),7.84-7.90(2H,m),8.09(1H,d,J=15.9Hz),11.07(1H,br),11.68(1H,br),12.14(1H,br)
MS(EI):m/z391(M+)
·3-(2,6-二溴苯基)-N-[N′-(噻吩-2-羰基)-肼基硫代羰基]丙烯酰胺
(LW-20)
收率:59%
熔点:217-218℃
1H-NMR(400MHz,DMSO-d6)δ:7.11(1H,d,J=15.6Hz),7.21(1H,t,J=4.3Hz),7.70(1H,d,J=15.6Hz),7.86-7.93(5H,m),11.11(1H,br),11.62(1H,br),12.06(1H,br);13C-NMR(100MHz,DMSO-d6)δ:122.90,123.11,128.20,129.62,129.80,132.022,134.88,136.59,138.33,141.16,159.51,164.73,181.07
MS(EI):m/z487(M+)
·3-(3,5-二溴苯基)-N-[N′-[2-(4-氟苯基)乙酰基]-肼基硫代羰基]丙烯酰胺
(LW-21)
收率:28%
熔点:195-196℃
1H-NMR(400MHz,DMSO-d6)δ:3.61(2H,s),7.06(1H,d,J=16.0Hz),7.11-7.35(4H,m),7.66(1H,d,J=16.0Hz),7.84(2H,s),7.92(1H,s),11.11(1H,br),11.56(1H,br),12.44(1H,br)
13C-NMR(100MHz,DMSO-d6)δ:30.88,115.05(d,J=21.5Hz),122.79,123.16(d,J=2.5Hz),128.35,129.28,129.78,129.86,131.11,134.98(d,J=8.3Hz),139.75(d,J=282.9Hz),151.38,176.13,180.47
MS(EI):m/z515(M+)
·N-(N′-苯甲酰基-肼基硫代羰基)-3-(3,5-二溴苯基)-丙烯酰胺
(LW-23)
收率:44%
熔点:224-225℃
1H-NMR(400MHz,DMSO-d6)δ:7.11(1H,d,J=15.7Hz),7.52(2H,t,J=7.4Hz),7.60(1H,t,J=7.4Hz),7.71(1H,d,J=15.7Hz),7.87(2H,s),7.90(2H,d,J=7.4Hz),7.93(1H,s),11.10(1H,br),11.63(1H,br),12.18(1H,br)
13C-NMR(100MHz,DMSO-d6)δ:122.89,123.12,127.65,128.51,129.80,132.02,132.10,134.88,138.33,141.13,164.56,164.83,180.46
·3-(3,5-二溴苯基)-N-[N′-(2-间甲苯基)乙酰基]-肼基硫代羰基]丙烯酰胺
(LW-24)
收率:76%
熔点:203-204℃
1H-NMR(400MHz,DMSO-d6)δ:2.28(3H,s),3.57(2H,s),7.04-7.20(5H,m),7.66(1H,d,J=15.9Hz),7.84(2H,s),7.91(1H,s),11.10(1H,br),11.55(1H,br),12.48(1H,br)
13C-NMR(100MHz,DMSO-d6)δ:20.97,122.78,123.12,126.29,127.26,128.18,129.79,129.84,134.88,135.11,137.31,138.31,141.04,164.97,167.40,176.58
·3-(3,5-二溴苯基)-N-[N′-[2-(3-甲氧基苯基)乙酰基]-肼基硫代羰基]丙烯酰胺
(LW-26)
收率:69%
熔点:202-203℃
1H-NMR(400MHz,DMSO-d6)δ:3.58(2H,s),3.74(3H,s),6.81(1H,d,J=7.9Hz),6.89(1H,d,J=7.9Hz),6.92(1H,s),7.06(1H,d,J=16.0Hz),7.21(1H,t,J=7.9Hz),7.67(1H,d,J=16.0Hz),7.83-7.84(2H,m),7.92(1H,s),11.10(1H,br),11.56(1H,br),12.45(1H,br)
13C-NMR(100MHz,DMSO-d6)δ:39.63,54.98,112.17,114.82,121.48,122.78,123.11,129.27,129.78,134.87,136.69,138.30,141.02,159.16,164.95,167.23,176.72
·3-(3,5-二溴苯基)-N-[N′-(3-苯基-丙酰基)-肼基硫代羰基]丙烯酰胺
(LW-31)
收率:23%
熔点:213-214℃
1H-NMR(400MHz,DMSO-d6)δ:2.57(2H,t,J=7.8Hz),2.87(2H,t,J=7.8Hz),7.06(1H,d,J=16.0Hz),7.18-7.28(5H,m),7.67(1H,d,J=16.0Hz),7.84(2H,d,J=1.5Hz),7.92(1H,t,J=1.5Hz),10.98(1H,br),11.54(1H,br),12.47(1H,br)
13C-NMR(100MHz;DMSO-d6)δ:30.57,34.46,122.80,123.10,125.99,128.22,128.30,129.76,132.25,138.30,140.80,154.67,168.68,176.29,180.24
MS(EI):m/z511(M+)
实施例12
(1)在氩气氛下,在通式5的羧酸(1mmol)的乙醇(3mL)溶液中加入浓盐酸(1滴),整夜加热回流。
蒸馏除去溶剂后,加入饱和碳酸氢钠水溶液,直到水层显示碱性,用二氯甲烷进行提取。
用硫酸钠将有机层干燥并进行过滤,之后蒸馏除去溶剂,得到通式5a的乙酯体。
(2)在氩气氛下,在通式4a的乙酯体(1mmol)的乙醇(0.5mL)溶液中加入一水合肼(0.05mL,1mmo),加热回流整夜,得到通式3a的肼体。
接着在蒸馏除去溶剂后,利用套管加入通式2b的异硫氰酸酯体(1mmol)的二氯甲烷(5mL)溶液,以室温搅拌整夜。
对反应液进行抽滤,得到通式1b的硫脲体。
·2-苯基-N-[N′-(2-噻吩-2-基-乙酰基)肼基硫代羰基]乙酰胺
(LW-18)
收率:63%
熔点:161-162℃
1H-NMR(400MHz,DMSO-d6)δ:3.74(2H,s),3.81(2H,s),6.93-6.95(2H,m),7.24-7.37(6H,m),11.06(1H,br),11.73(1H,br),12.30(1H,br)
13C-NMR(100MHz,DMSO-d6)δ:33.94,42.11,125.24,126.70,126.74,127.08,128.32,128.51,129.41,134.30,166.39,167.43,176.90
MS(EI):m/z333(M+)
·N-[N′-[2-(4-氟苯基)乙酰基]肼基硫代羰基]-2-苯基-乙酰胺
(LW-22)
收率:55%
熔点:182-183℃
1H-NMR(400MHz,DMSO-d6)δ:3.57(2H,s),3.74(2H,s),7.11(2H,t,J=8.7H),7.20-7.40(7H,m),10.10(1H,br),11.02(1H,br),11.73(1H,br)
13C-NMR(100MHz,DMSO-d6)δ:38.64,42.07,114.85(d,J=21.5Hz),126.51,127.01,128.23,128.45,129.04,129.37,131.06(d,J=8.3Hz),131.43(d,J=2.5Hz),135.01(d,J=286.9Hz),167.33,172.57,177.11
·2-苯基-N-[N′-(2-间甲苯基-乙酰基]肼基硫代羰基]-乙酰胺
(LW-25)
收率:24%
熔点:149-150℃
1H-NMR(400MHz,DMSO-d6)δ:2.26(3H,s),3.53(2H,s),3.74(2H,s),7.09-7.29(9H,m),11.01(1H,br),11.72(1H,br),12.28(1H,br)
·2-苯基-N-(N′-苯基乙酰基]肼基硫代羰基]-乙酰胺
(LW-27)
收率:34%
·N-[N′-[2-(2,6-二氟苯基)乙酰基]肼基硫代羰基]-2-苯基-乙酰胺
(LW-28)
收率:88%
熔点:174-175℃
1H-NMR(400MHz,DMSO-d6)δ:3.67(2H,s),3.74(2H,s),7.07(2H,t,J=7.4Hz),7.22-7.40(6H,m),11.07(1H,br),11.73(1H,br),12.23(1H,br)
·N-[N′-[2-(3,5-二氟苯基)乙酰基]肼基硫代羰基]-2-苯基-乙酰胺
(LW-29)
收率:4%
熔点:178-179℃
1H-NMR(400MHz,DMSO-d6)δ:3.74(2H,s),4.03(2H,s),7.03-7.12(3H,m),7.23-7.34(5H,m),11.02(1H,br),11.74(1H,br),12.18(1H,br)
13C-NMR(100MHz,DMSO-d6)δ:26.73,42.06,110.77(d,J=20.7Hz),111.26(d,J=25.6Hz),127.00,128.44,129.35,134.29,159.86(d,J=8.3Hz),162.31(d,J=6.3Hz),165.60,172.53,177.32
·2-苯基-N-(N′-(3-苯基-异丙酰基]肼基硫代羰基]-乙酰胺
(LW-30)
收率:41%
熔点:88-90℃
1H-NMR(400MHz,DMSO-d6)δ:2.52(2H,m),2.83(2H,m),3.74(2H,s),7.16-7.30(10H,m),10.80(1H,br),11.70(1H,br),12.28(1H,br)
MS(EI):m/z341(M+)
·2-(4-氟苯基)-N-(N′-苯基乙酰基]肼基硫代羰基]-乙酰胺
(LW-32)
收率:35%
熔点:178-179℃
1H-NMR(400MHz,DMSO-d6)δ:3.57(2H,s),3.74(2H,s),7.12-7.32(8H,m),11.03(1H,br),11.72(1H,br),12.28(1H,br)
13C-NMR(100MHz,DMSO-d6)δ:38.60,41.08,115.03(t,J=20.3Hz),128.22,129.15,130.38(d,J=2.5Hz),131.01(d,J=7.9Hz),131.32(d,J=7.9Hz),161.32(d,J=242.3Hz),167.24,172.38,176.98
MS(EI):m/z363(M+)
·2-(2,4-二氟苯基)-N-[N′[2-(4-氟苯基)乙酰基]肼基硫代羰基]-乙酰胺
(LW-33)
收率:59%
熔点:186-187℃
1H-NMR(400MHz,DMSO-d6)δ:3.57(2H,s),3.88(2H,s),7.08-7.14(4H,m),7.30-7.40(3H,m),11.03(1H,br),11.86(1H,br),12.09(1H,br)
13C-NMR(100MHz,DMSO-d6)δ:29.27,30.70,38.62,111.34(dd,J=5.8,19.0Hz),114.95(d,J=20.7Hz),129.83(t,J=10.3Hz),131.03(d,J=8.3Hz),131.40(d,J=3.3Hz),159.81(t,J=10.3Hz),162.25(t,J=8.3Hz),167.31,170.28,176.85
MS(EI):m/z381(M+)
实施例13
(1)在氩气氛下,在通式4的羧酸(1mmol)的乙醇(3mL)溶液中加入浓盐酸(1滴),整夜加热回流。
蒸馏除去溶剂后,加入饱和碳酸氢钠水溶液,直到水层显示碱性,用二氯甲烷进行提取。
用硫酸钠将有机层干燥并进行过滤,之后蒸馏除去溶剂,得到通式4a的乙酯体。
(2)在氩气氛下,在通式4a的乙酯体(1mmol)的乙醇(0.5mL)溶液中加入一水合肼(0.05mL,1mmo),加热回流整夜,得到通式3的肼体。
接着,在蒸馏除去溶剂后,利用套管加入通式2c的异硫氰酸酯体(1mmol)的二氯甲烷(5mL)溶液,以室温搅拌整夜。对反应液进行抽滤,得到通式1c的硫脲体。
·2-环己基-N-[N′[2-(4-氟苯基)乙酰基]肼基硫代羰基]-乙酰胺
(LW-34)
收率:62%
熔点:132-133℃
1H-NMR(400MHz,DMSO-d6)δ:0.93-1.92(5H,m),2.27(2H,d,J=6.8Hz),3.58(2H,s),7.13(2H,t,J=8.8Hz),7.30-7.40(2H,m),11.04(1H,br),11.46(1H,br),12.42(1H,br)
13C-NMR(100MHz,DMSO-d6)δ:24.48,25.66,32.24,34.55,38.60,42.93,114.96(d,J=21.5Hz),131.04(d,J=8.3Hz),131.43(d,J=2.5Hz),163.90(d,J=282.9Hz),167.33,174.15,176.75
MS(EI):m/z351(M+)
·N-[N′-[2-(4-氟-苯基)-乙酰基]肼基硫代羰基]-2-噻吩-2-基-乙酰胺
(LW-35)
收率:28%
1H-NMR(500MHz,DMSO-d6)δ:3.57(2H,s),3.98(2H,s),6.96-7.00(2H,m),7.12(2H,t,J=8.7Hz),7.33(2H,dd,J=8.7,5.7Hz),7.41(1H,dd,J=3.8,2.6Hz),11.03(1H,br),11.74(1H,br),12.18(1H,br)·N-[N′-[2-(4-氟-苯基)-乙酰基]肼基硫代羰基]-3-苯基-丙酰胺
(LW-36)
收率:42%
1H-NMR(500MHz,DMSO-d6)δ:2.72(2H,t,J=7.5Hz),2.83(2H,t,J=7.5Hz),3.58(2H,s),7.13(2H,t,J=9.0Hz),7.17(1H,td,J=7.4,1.7Hz),7.21(2H,dd,J=7.4,1.7Hz),7.27(2H,td,J=7.4,1.7Hz),7.34(2H,dd,J=9.0,5.6Hz),11.02(1H,br),11.52(1H,br),12.33(1H,br)
实施例14
·4-甲基-N-[2-(3-苯基脲基)乙基]苯磺酰胺
(ED-1)
在N-(2-氨基乙基)-4-甲基苯磺酰胺(100mg,0.47mmol)的二氯甲烷溶液5mL中加入异氰酸苯酯(0.051mL,0.47mmol),以室温搅拌整夜。
利用二氧化硅凝胶柱色谱(15g,己烷︰丙酮=10︰1~1︰1)对蒸馏除去溶剂后得到的残渣进行精制,得到无色晶体4-甲基-N-[2-(3-苯基脲基)乙基]苯磺酰胺89mg(收率57%)。
1H-NMR(400MHz,CDCl3):δ2.38(3H,s),3.06(2H,t,J=5.4Hz),3.34(2H,t,J=5.4Hz),5.17(1H,br),5.40(1H,br),6.51(1H,br),7.07(1H,t,J=7.0Hz),7.24-7.31(6H,m),7.72(2H,d,J=8.1Hz)
13C-NMR(125MHz,DMSO-d6):δ20.92,38.82,42.82,117.65,121.05,126.55,128.62,129.63,137.30,140.40,142.64,155.15
IR(KBr):1161,1325,1593,1645,3302cm-1
MS(EI):m/z333(M+)
熔点:154-155℃(重结晶溶剂:甲苯)
实施例15
与实施例14同样操作得到以下化合物。
·N-[2-[3-(4-氟苯基)脲基]乙基]-4-甲基-苯磺酰胺
(ED-3)
收率:88%
1H-NMR(400MHz,CDCl3):δ2.40(3H,s),3.07(2H,t,J=4.8Hz),3.35(2H,t,J=4.8Hz),5.12(1H,br),5.33(1H,br),6.45(1H,br),6.97(2H,t,J=8.2Hz),7.24-7.29(4H,m),7.72(2H,d,J=7.8Hz)
13C-NMR(125MHz,DMSO-d6):δ20.92,38.88,42.81,115.07(d,J=21.6Hz),119.27(d,J=8.4Hz),126.56,129.64,136.78(d,J=2.4Hz),137.33,142.65,155.22,156.91(d,J=237.5Hz)
IR(KBr):1165,1323,1508,1645,3314cm-1
MS(EI):m/z 351(M+)
熔点:161-162℃(重结晶溶剂:甲苯)
·N-[2-[3-(3,4-二氯苯基)脲基]乙基]-4-甲基-苯磺酰胺
(ED-4)
收率:62%
1H-NMR(400MHz,CDCl3):δ2.40(3H,s),3.07(2H,t,J=4.9Hz),3.37(2H,t,J=4.9Hz),5.52(2H,m),7.01(1H,br),7.10(1H,dd,J=8.7,2.4Hz),7.22-7.27(1H,m),7.28(2H,d,J=8.1Hz),7.48(1H,d,J=2.4Hz),7.71(2H,d,J=8.1Hz)
13C-NMR(125MHz,DMSO-d6):δ20.89,38.90,42.56,117.68,118.66,122.24,126.54,129.61,130.37,130.90,137.30,140.65,142.61,154.76
IR(KBr):1157,1319,1541,1674,3393cm-1
MS(EI):m/z401(M+)
熔点:154-155℃
·N-[2-[3-(2-甲氧基苯基)脲基]乙基]-4-甲基-苯磺酰胺
(ED-5)
收率:89%
1H-NMR(400MHz,CDCl3):δ2.39(3H,s),3.10(2H,t,J=5.6Hz),3.37(2H,t,J=5.6Hz),3.85(3H,s),5.10(1H,br),5.33(1H,br),6.80(1H,br),6.86(1H,dd,J=7.8,1.6Hz),6.94(1H,td,J=7.8,1.6Hz),7.01(1H,td,J=7.8,1.6Hz),7.25-7.27(2H,m),7.74(2H,d,J=8.3Hz),7.92(1H,dd,J=7.8,1.6Hz)
13C-NMR(125MHz,DMSO-d6):δ20.92,38.86,42.94,55.61,110.53,118.04,120.45,121.04,126.58,129.38,129.63,137.34,142.65,147.34,155.22
IR(KBr):1155,1321,1572,1647,3277cm-1
MS(EI):m/z363(M+)
熔点:184-185℃
·N-[2-[3-(2-甲氧基苯基)硫脲基]乙基]-4-甲基-苯磺酰胺
(ED-6)
收率:73%
1H-NMR(400MHz,CDCl3):δ2.41(3H,s),3.20(2H,t,J=5.5Hz),3.78(2H,t,J=5.5Hz),3.88(3H,s),6.49(1H,br),6.99-7.03(2H,m),7.26-7.30(5H,m),7.59(1H,br),7.71(2H,d,J=8.3Hz)
13C-NMR(125MHz,CDCl3):δ21.43,42.43,44.48,55.74,111.97,121.10,124.93,125.40,126.95,127.80,129.71,136.40,143.50,152.46,180.92
MS(EI):m/z379(M+)
·N-[2-[3-(3-甲氧基苯基)脲基]乙基]-4-甲基-苯磺酰胺
(ED-7)
收率:97%
1H-NMR(400MHz,CDCl3):δ2.38(3H,s),3.04(2H,t,J=5.1Hz),3.33(2H,t,J=5.1Hz),3.74(3H,s),6.58(1H,d,J=7.8Hz),6.78(1H,d,J=7.8Hz),6.99(1H,s),7.05(1H,br),7.13(1H,t,J=7.8Hz),7.20-7.30(2H,m),7.72(2H,d,J=8.3Hz)
13C-NMR(125MHz,DMSO-d6):δ20.92,38.83,42.82,54.82,103.47,106.47,110.04,126.56,129.37,129.65,137.32,141.66,142.66,155.10,159.65
IR(KBr):1163,1329,1560,1655,3350cm-1
MS(EI):m/z363(M+)
熔点:136-137℃
·N-[2-[3-(2-乙氧基苯基)脲基]乙基]-4-甲基-苯磺酰胺
(ED-8)
收率:40%
1H-NMR(400MHz,CDCl3):δ1.45(3H,t,J=7.1Hz),2.39(3H,s),3.11(2H,t,J=5.4Hz),3.38(2H,t,J=5.4Hz),4.09(2H,q,J=7.1Hz),6.88(1H,d,J=7.1Hz),6.93(1H,t,J=7.1Hz),7.00(1H,t,J=7.1Hz),7.26-7.31(2H,m),7.51(1H,br),7.74(2H,d,J=8.1Hz),7.88(1H,d,J=7.1Hz)
13C-NMR(125MHz,DMSO-d6):δ14.68,20.92,38.86,42.89,63.81,111.56,118.04,120.36,121.00,126.56,129.55,129.63,137.30,142.64,146.39,155.12
MS(EI):m/z377(M+)
熔点:129-130℃
·N-[2-[3-(2,4-二氯苯基)脲基]乙基]-4-甲基-苯磺酰胺
(ED-10)
收率:90%
1H-NMR(400MHz,CDCl3):δ2.39(3H,s),3.11(2H,t,J=4.8Hz),3.37(2H,t,J=4.8Hz),5.11(1H,br),5.33(1H,br),6.73(1H,br),7.18-7.32(4H,m),7.72(2H,d,J=7.8Hz),8.08(1H,d,J=8.8Hz)
13C-NMR(125MHz,DMSO-d6):δ20.91,38.92,42.62,121.55,121.78,125.17,126.56,127.44,128.36,129.61,135.89,137.28,142.63,154.61
MS(EI):m/z401(M+)
熔点:161-162℃(重结晶溶剂:甲苯)
·4-甲基-N-[2-(3-间甲苯基脲基)乙基]-苯磺酰胺
(ED-11)
收率:53%
1H-NMR(400MHz,CDCl3):δ2.26(3H,s),2.37(3H,s),3.03(2H,t,J=5.0Hz),3.32(2H,t,J=5.0Hz),6.84(1H,d,J=7.6Hz),7.02(1H,d,J=7.6Hz),7.07(1H,br),7.12(1H,t,J=7.6Hz),7.24-7.30(5H,m),7.71(2H,d,J=8.1Hz)
13C-NMR(125MHz,DMSO-d6):δ20.96,21.26,38.81,42.86,114.89,118.25,121.84,126.57,128.47,129.62,137.33,137.71,140.30,142.67,155.18
熔点:114-115℃(重结晶溶剂:甲苯).
·4-甲基-N-[2-(3-邻甲苯基脲基)乙基]-苯磺酰胺
(ED-12)
收率:80%
1H-NMR(400MHz,CDCl3):δ2.26(3H,s),2.40(3H,s),3.14(2H,t,J=4.8Hz),3.73(2H,t,J=4.8Hz),4.14(1H,br),6.16(1H,br),7.13-7.26(5H,m),7.27(2H,d,J=7.8Hz),7.68(2H,d,J=7.8Hz)
13C-NMR(125MHz,DMSO-d6):δ17.68,21.03,40.03,41.71,126.34,126.49,127.71,129.67,129.69,130.69,134.73,136.72,137.33,142.67,181.13
熔点:131-132℃
·N-[2-[3-(2-甲氧基-5-甲基苯基)硫脲基]乙基]-4-甲基-苯磺酰胺
(ED-13)
收率:83%
1H-NMR(400MHz,CDCl3):δ2.29(3H,s),2.39(3H,s),3.19(2H,t,J=5.1Hz),3.75(2H,t,J=5.1Hz),3.82(3H,s),6.86(1H,d,J=7.3Hz),7.00-7.15(2H,m),7.20-7.26(3H,m),7.27(2H,d,J=8.1Hz),7.70(2H,d,J=8.1Hz)
13C-NMR(125MHz,DMSO-d6):δ20.27,20.96,41.71,43.32,55.60,111.53,126.26,126.41,126.57,126.80,128.78,129.69,137.33,142.67,149.99,180.59
熔点:130-131℃
·N-[2-[3-(2-氯-苯基)硫脲基]乙基]-4-甲基-苯磺酰胺
(ED-15)
收率:99%
1H-NMR(400MHz,CDCl3):δ2.40(3H,s),3.18(2H,t,J=5.1Hz),3.79(2H,t,J=5.1Hz),6.63(1H,br),7.20-7.27(3H,m),7.28(2H,d,J=7.6Hz),7.34(1H,t,J=7.4Hz),7.40-7.52(2H,m),7.70(2H,d,J=7.6Hz)
13C-NMR(125MHz,CDCl3):δ21.45,42.28,44.65,126.91,127.59,127.90,128.05,129.71,129.73,130.34,133.54,136.14,143.69,181.16
·N-[2-[3-(3,4-二氯-苯基)脲基]乙基]-4-甲氧基-苯磺酰胺
(ED-16)
收率:70%
1H-NMR(400MHz,CDCl3):δ3.07(2H,t,J=5.1Hz),3.38(2H,t,J=5.1Hz),3.84(3H,s),6.90(3H,m),7.12(1H,dd,J=9.0,1.2Hz),7.20-7.30(2H,m),7.37(1H,br),7.51(1H,d,J=1.2Hz),7.77(2H,d,J=8.3Hz)
13C-NMR(125MHz,DMSO-d6):δ38.89,42.55,55.60,114.36,117.71,118.63,122.22,128.70,130.38,130.92,131.83,140.68,154.80,162.13
熔点:150-151℃
·4-溴-N-[2-[3-(3,4-二氯-苯基)脲基]乙基]-苯磺酰胺
(ED-17)
收率:45%
1H-NMR(400MHz,CDCl3):δ3.12(2H,t,J=5.6Hz),3.40(2H,t,J=5.6Hz),7.00(1H,br),7.14(1H,dd,J=8.8,2.6Hz),7.31(1H,d,J=8.8Hz),7.35(1H,br),7.42(1H,br),7.53(1H,d,J=2.6Hz),7.65(2H,d,J=8.7Hz),7.72(2H,d,J=8.7Hz)
13C-NMR(100MHz,DMSO-d6):δ42.51,54.90,117.69,118.66,122.24,126.21,128.53,130.41,130.90,132.29,139.53,140.62,154.75
MS(EI):m/z465(M+)
熔点:129-130℃
·4-氯-N-[2-[3-(3,4-二氯-苯基)脲基]乙基]-苯磺酰胺
(ED-18)
收率:14%
1H-NMR(400MHz,CDCl3):δ3.08(2H,t,J=5.1Hz),3.37(2H,t,J=5.1Hz),5.43(1H,br),5.73(1H,br),6.94(1H,br),7.10(1H,dd,J=8.4,2.3Hz),7.21-7.27(1H,m),7.46(2H,d,J=8.5Hz),7.49(1H,d,J=2.3Hz),7.77(2H,d,J=8.5Hz)
13C-NMR(125MHz,丙酮-d6):δ40.25,44.30,118.62,120.07,129.90,129.53,130.07,131.14,132.43,138.77,140.52,141.51,155.94
熔点:139-140℃
·N-[2-[3-(3,4-二氯-苯基)脲基]乙基]-4-氟-苯磺酰胺
(ED-19)
收率:67%
1H-NMR(400MHz,CDCl3):δ3.11(2H,t,J=5.3Hz),3.19(2H,t,J=5.3Hz),6.67(1H,br),6.98(1H,br),7.13(1H,dd,J=8.6,2.2Hz),7.18(2H,t,J=8.7Hz),7.30(1H,d,J=8.6Hz),7.40(1H,br),7.52(1H,d,J=2.2Hz),7.86(2H,dd,J=8.7,5.0Hz)
13C-NMR(125MHz,DMSO-d6):δ38.97,42.55,116.34(d,J=19.2Hz),117.71,118.71,122.29,129.50(d,J=9.6Hz),130.38,130.92,136.60(d,J=3.6Hz),140.61,154.80,164.11(d,J=249.5Hz)
熔点:153-154℃
·N-[2-[3-(4-溴-2-氯-苯基)脲基]乙基]-4-甲基-苯磺酰胺
(ED-20)
收率:76%
1H-NMR(400MHz,CDCl3):δ2.41(3H,s),3.12(2H,t,J=5.3Hz),3.41(2H,t,J=5.3Hz),6.79(1H,br),7.00(1H,br),7.23(1H,br),7.29(2H,d,J=8.1Hz),7.33(1H,dd,J=8.8,2.3Hz),7.46(1H,d,J=2.3Hz),7.74(2H,d,J=8.1Hz),8.02(1H,d,J=8.8Hz)
13C-NMR(125MHz,DMSO-d6):δ21.11,38.89,42.78,112.75,122.06,126.71,126.72,129.77,130.46,131.14,136.41,137.48,142.82,154.72
熔点:164-165℃
·N-[2-[3-(3,4-二氯-苯基)脲基]丙基]-4-甲基-苯磺酰胺
(ED-21)
收率:86%
1H-NMR(500MHz,CDCl3):δ1.68(2H,quint,J=5.4Hz),2.40(3H,s),2.99(2H,t,J=5.4Hz),3.36(2H,t,J=5.4Hz),5.30(1H,br),5.42(1H,br),6.91(1H,br),7.15(1H,dd,J=8.7,2.5Hz),7.24-7.28(2H,m),7.30(1H,d,J=8.7Hz),7.55(1H,d,J=2.5Hz),7.72(2H,d,J=8.6Hz)
13C-NMR(125MHz,DMSO-d6):δ20.96,29.73,38.97,40.34,117.64,118.71,122.14,126.49,129.54,130.31,130.92,137.48,140.76,142.59,154.88
熔点:157-158℃
·4-溴-N-[3-[3-(3,4-二氯-苯基)脲基]丙基]-苯磺酰胺
(ED-22)
收率:80%
1H-NMR(500MHz,CDCl3):δ1.70(2H,quint,J=6.0Hz),3.00(2H,t,J=6.0Hz),3.39(2H,t,J=6.0Hz),4.95(1H,br),5.55(1H,br),6.40(1H,br),7.13(1H,dd,J=9.0,2.5Hz),7.35(1H,d,J=9.0Hz),7.54(1H,d,J=2.5Hz),7.60(2H,d,J=8.6Hz),7.71(2H,d,J=8.6Hz)
13C-NMR(125MHz,DMSO-d6):δ29.73,36.52,40.34,117.64,118.71,122.22,126.18,128.55,130.38,130.92,132.29,139.69,140.76,154.88
熔点:163-164℃
·N-[3-[3-(3,4-二氯-苯基)脲基]丙基]-4-氟-苯磺酰胺
(ED-23)
收率:82%
1H-NMR(500MHz,CDCl3):δ1.70(2H,quint,J=6.0Hz),2.99(2H,t,J=6.0Hz),3.37(2H,t,J=6.0Hz),6.80(1H,br),6.92(1H,br),7.13(1H,dd,J=8.6,2.9Hz),7.15(2H,t,J=8.5Hz),7.24-7.30(1H,m),7.33(1H,d,J=8.6Hz),7.53(1H,d,J=2.9Hz),7.85(2H,dd,J=8.5,4.8Hz)
13C-NMR(125MHz,DMSO-d6):δ29.73,36.60,40.34,116.34(d,J=19.2Hz),117.71,118.63,122.14,129.43(d,J=9.6Hz),130.38,130.92,136.79(d,J=2.8Hz),140.76,154.88,164.03(d,J=249.5Hz)
熔点:120-121℃
·N-[3-[3-(3,4-二氯-苯基)脲基]丙基]-4-甲氧基-苯磺酰胺
(ED-24)
收率:64%
1H-NMR(500MHz,CDCl3):δ1.70(2H,quint,J=6.0Hz),2.98(2H,t,J=6.0Hz),3.38(2H,t,J=6.0Hz),3.84(3H,s),6.80(1H,br),6.90(1H,br),6.91(2H,d,J=8.6Hz),7.16(1H,dd,J=8.6,2.3Hz),7.32(1H,d,J=8.6Hz),7.42(1H,br),7.56(1H,d,J=2.3Hz),7.76(2H,d,J=8.6Hz)
13C-NMR(125MHz,DMSO-d6):δ29.21,36.08,39.74,55.00,113.76,117.12,118.11,121.62,128.10,129.86,130.39,131.46,140.24,154.35,161.53
熔点:124-125℃
实施例16
代替实施例14中的异氰酸苯酯,使用○○○○,得到以下化合物。
·N-[2-[3-(3-甲氧基-丙基)硫脲基)乙基]-4-甲基-苯磺酰胺
(ED-14)
收率:99%
1H-NMR(400MHz,CDCl3):δ1.85(2H,quint,J=5.2Hz),2.40(3H,s),3.15(2H,t,J=4.5Hz),3.33(3H,s),3.45-3.55(4H,m),3.69(2H,t,J=4.5Hz),7.29(2H,d,J=8.2Hz),7.72(2H,d,J=8.2Hz)
13C-NMR(125MHz,CDCl3):δ21.45,28.55,42.66,43.96,53.73,58.61,70.59,126.91,129.73,136.21,143.54,181.69
实施例17
代替实施例14中的异氰酸苯酯,使用甲苯磺酰基异氰酸酯,得到以下化合物。
·4-甲基-N-[[2-(4-甲基苯基磺酰胺基)乙基]氨基甲酰基]苯磺酰胺
(ED-2)
收率:80%
1H-NMR(400MHz,CDCl3):δ2.43(3H,s),2.44(3H,s),3.04(2H,t,J=5.7Hz),3.33(2H,t,J=5.7Hz),5.08(1H,br),6.70(1H,br),7.30(2H,d,J=8.3Hz),7.35(2H,d,J=8.5Hz),7.71(2H,d,J=8.3Hz),7.82(2H,d,J=8.5Hz),7.94(1H,br)
13C-NMR(125MHz,DMSO-d6):δ20.96,21.02,38.91,42.08,126.51,127.21,129.43,129.67,137.22,137.35,142.71,143.61,151.41
IR(KBr):1155,1327,1522,1692,3328cm-1
熔点:163-164℃
·2-甲基-N-[[2-(4-甲基苯基磺酰胺基)乙基]氨基甲酰基]苯磺酰胺
(ED-9)
收率:14%
1H-NMR(400MHz,CDCl3):δ2.41(3H,s),2.62(3H,s),3.00(2H,t,J=5.8Hz),3.31(2H,t,J=5.8Hz),5.30(1H,br),6.62(1H,br),7.28(2H,d,J=8.1Hz),7.32(1H,d,J=7.6Hz),7.36(1H,t,J=7.6Hz),7.51(1H,t,J=7.6Hz),7.69(2H,d,J=8.1Hz),8.01(1H,d,J=7.6Hz),8.60(1H,br)
13C-NMR(125MHz,CDCl3):δ14.11,21.51,39.84,42.81,126.44,127.01,129.72,129.83,132.73,133.67,136.38,137.38,137.44,143.64,152.44
熔点:134-135℃
实施例18
代替实施例14中的烷基氨基体,使用氨基苯基体,得到以下化合物。
·N-[2-[3-(3,4-二氯苯基)脲基]苯基]-4-甲基-苯磺酰胺
(ED-25)
收率:75%
1H-NMR(500MHz,CDCl3):δ2.40(3H,s),6.68(1H,dd,J=7.8,1.2Hz),6.92(1H,td,J=7.8,1.2Hz),7.06(1H,br),7.10(1H,br),7.18(1H,dd,J=9.0,2.5Hz),7.20-7.27(3H,m),7.30(1H,d,J=9.0Hz),7.57(1H,br),7.58(1H,d,J=2.5Hz),7.64(2H,d,J=8.6Hz),7.79(1H,dd,J=7.8,1.2Hz)
13C-NMR(100MHz,DMSO-d6):δ21.00,118.14,119.16,121.27,122.41,123.10,125.35,127.20,127.32,127.61,129.52,130.63,131.11,136.26,136.46,140.08,143.30,152.18
熔点:204-205℃
·N-[2-[3-(4-氟苯基)脲基]苯基]-4-甲基-苯磺酰胺
(ED-26)
收率:99%
1H-NMR(500MHz,CDCl3):δ2.41(3H,s),6.38(1H,br),6.80(1H,br),6.92-7.16(3H,m),7.19(1H,td,J=7.8,1.3Hz),7.23-7.35(4H,m),7.48(1H,td,J=7.8,1.3Hz),7.76(2H,d,J=8.0Hz),7.87(1H,dd,J=7.8,1.3Hz),8.30(1H,br)
13C-NMR(125MHz,DMSO-d6):δ20.96,115.04,115.27(d,J=19.2Hz),121.00,121.99,123.36,125.12,127.21(d,J=9.6Hz),127.56,129.54,136.03,136.41,136.91(d,J=3.0Hz),143.28,152.74,157.36(d,J=239.9Hz)
熔点:180-181℃
·4-溴-N-[2-[3-(3,4-二氯-苯基)-脲基]苯基]-苯磺酰胺
(ED-27)
收率:97%
1H-NMR(400MHz,CDCl3):δ6.69(1H,dd,J=8.1,1.5Hz),6.96(1H,td,J=8.1,1.5Hz),7.06(1H,br),7.10(1H,br),7.20(1H,dd,J=8.7,2.4Hz),7.21-7.25(1H,m),7.32(1H,d,J=8.7Hz),7.42(1H,br),7.55-7.58(4H,m),7.59(1H,d,J=2.4Hz),7.72(1H,dd,J=8.1,1.5Hz)
13C-NMR(125MHz,DMSO-d6):δ118.17,119.21,121.48,122.61,123.15,124.98,126.93,127.47,127.89,129.14,130.61,131.12,132.20,136.49,138.36,139.98,152.13
熔点:211-212℃
·4-氯-N-[2-[3-(3,4-二氯-苯基)-脲基]苯基]-苯磺酰胺
(ED-28)
收率:83%
1H-NMR(400MHz,CDCl3):δ6.68(1H,dd,J=7.6,1.5Hz),6.94(1H,td,J=7.6,1.5Hz),7.15(1H,dd,J=8.8,2.4Hz),7.20(1H,td,J=7.6,1.5Hz),7.22-7.27(2H,m),7.29(1H,d,J=8.8Hz),7.41(2H,d,J=8.8Hz),7.48(1H,br),7.55(1H,d,J=2.4Hz),7.65-7.69(3H,m)
13C-NMR(125MHz,DMSO-d6):δ118.17,119.21,121.48,122.60,123.15,125.00,127.48,127.89,129.07,129.27,130.60,131.12,136.50,137.93,139.98,140.06,152.15
熔点:199-200℃
·N-[2-[3-(3,4-二氯-苯基)-脲基]苯基]-4-氟-苯磺酰胺
(ED-29)
收率:96%
1H-NMR(400MHz,CDCl3):δ6.61(1H,dd,J=8.1,1.5Hz),6.92(1H,td,J=8.1,1.5Hz),7.00(1H,br),7.13(2H,t,J=8.5Hz),7.18-7.25(3H,m),7.31(1H,d,J=8.5Hz),7.52(1H,br),7.60(1H,d,J=2.4Hz),7.74(2H,dd,J=8.5,7.0Hz),7.78(1H,dd,J=8.1,1.5Hz)
13C-NMR(125MHz,DMSO-d6):δ116.31(d,J=22.8Hz),118.16,119.20,121.35,122.51,123.16,125.08,127.46,127.85,130.25(d,J=9.6Hz),130.62,131.12,135.36,136.57,140.01,152.18,164.43(d,J=251.9Hz)
熔点:203-204℃
·4-甲基-N-[2-[3-(3-苯基)-脲基]苯基]-苯磺酰胺
(ED-30)
收率:85%
1H-NMR(400MHz,CDCl3):δ2.34(3H,s),6.70(1H,br),6.83(1H,dd,J=8.1,1.5Hz),6.95(1H,td,J=8.1,1.5Hz),7.12-7.22(5H,m),7.25-7.34(5H,m),7.58(2H,d,J=8.3Hz),7.66(1H,dd,J=8.1,1.5Hz)
13C-NMR(125MHz,DMSO-d6):δ20.99,115.89,117.90,118.15,120.94,121.84,121.91,125.07,127.18,128.81,129.51,136.43,139.82,140.87,143.27,152.46
熔点:83-84℃
·N-[2-[3-(3,4-二氯-苯基)-脲基]苯基]-4-甲氧基-苯磺酰胺
(ED-31)
收率:93%
1H-NMR(400MHz,CDCl3):δ3.80(3H,s),6.66(1H,dd,J=8.1,1.5Hz),6.86(2H,d,J=8.9Hz),6.88(1H,td,J=8.1,1.5Hz),7.13(1H,dd,J=8.5,2.4Hz),7.18(1H,td,J=8.1,1.5Hz),7.23-7.25(2H,m),7.29(1H,br),7.54(1H,d,J=2.4Hz),7.61(1H,br),7.66(2H,d,J=8.9Hz),7.76(1H,dd,J=8.1,1.5Hz)
13C-NMR(125MHz,DMSO-d6):δ55.57,114.18,118.15,119.16,121.14,122.38,123.09,125.48,127.38,127.54,129.37,130.62,130.64,131.09,136.46,140.06,152.18,162.51
熔点:129-130℃
·N-[2-[3-(3,4-二氯-苯基)-脲基]苯基]-4-甲基-苯磺酰胺
(ED-32)
收率:59%
1H-NMR(400MHz,CDCl3):δ2.33(3H,s),3.77(3H,s)6.63(1H,dd,J=8.1,1.5Hz),6.77-6.82(3H,m),6.84(1H,dd,J=8.2,1.9Hz),6.94(1H,td,J=8.1,1.5Hz),7.02(1H,t,J=1.9Hz),7.11-7.20(4H,m),7.33(1H,br),7.58(2H,d,J=8.5Hz),7.72(1H,dd,J=8.1,1.5Hz)
13C-NMR(125MHz,DMSO-d6):δ21.00,54.88,103.87,107.32,110.46,115.89,116.80,121.94,125.10,127.20,127.55,129.51,129.58,136.43,136.92,141.08,143.28,152.40,159.70
熔点:84-85℃
·N-[2-[3-(2-甲氧基-苯基)-脲基]苯基]-4-甲基-苯磺酰胺
(ED-33)
收率:68%
1H-NMR(400MHz,CDCl3):δ2.29(3H,s),3.83(3H,s),6.86(1H,dd,J=8.1,1.5Hz),6.93-7.00(5H,m),7.13-7.23(5H,m),7.56(1H,dd,J=8.1,1.5Hz),7.57(2H,d,J=8.3Hz),7.99(1H,dd,J=8.1,1.7Hz)
13C-NMR(125MHz,DMSO-d6):δ20.96,55.73,110.81,119.21,120.46,121.84,122.11,122.39,126.13,126.64,126.95,127.03,128.53,129.47,135.86,136.85,143.13,148.18,152.77
熔点:105-106℃
·4-溴-N-[2-[3-(2,4-二氯-苯基)-脲基]苯基]-苯磺酰胺
(ED-34)
收率:96%
1H-NMR(400MHz,CDCl3):δ6.90(1H,br),7.01(1H,dd,J=8.1,1.5Hz),7.08(1H,td,J=8.1,1.5Hz),7.19(1H,br),7.20-7.26(3H,m),7.35(1H,d,J=2.4Hz),7.51(2H,d,J=8.8Hz),7.55(2H,d,J=8.8Hz),7.57(1H,dd,J=8.1,1.5Hz),8.06(1H,d,J=9.0Hz)
13C-NMR(125MHz,DMSO-d6):δ122.14,122.92,123.28,123.40,125.78,126.45,126.81,127.19,127.52,127.60,128.62,129.01,132.17,135.20,135.98,138.74,152.34
熔点:209-210℃
·N-[2-[3-(2,4-二氯-苯基)-脲基]苯基]-4-氟-苯磺酰胺
(ED-35)
收率:95%
1H-NMR(400MHz,CDCl3):δ6.92(1H,dd,J=8.1,1.5Hz),6.93(1H,br),7.02-7.08(3H,m),7.14(1H,br),7.21-7.25(2H,m),7.32(1H,br),7.34(1H,d,J=2.2Hz),7.63(1H,dd,J=8.1,1.5Hz),7.72(2H,dd,J=8.8,4.9Hz),8.07(1H,d,J=9.0Hz)
13C-NMR(125MHz,DMSO-d6):δ116.27(d,J=22.8Hz),122.07,122.85,123.31,123.46,125.91,126.51,127.21,127.52,127.56,128.64,130.12(d,J=9.6Hz),135.23,135.77(d,J=2.4Hz),136.07,152.42,164.39(d,J=250.7Hz)
熔点:201-202℃
·4-氯-N-[2-[3-(2,4-二氯-苯基)-脲基]苯基]-苯磺酰胺
(ED-36)
收率:75%
1H-NMR(400MHz,CDCl3):δ6.94(1H,br),6.99(1H,dd,J=8.1,1.5Hz),7.07(1H,td,J=8.1,1.5Hz),7.20-7.30(4H,m),7.34(1H,d,J=2.4Hz),7.35(2H,d,J=8.8Hz),7.58(1H,dd,J=8.1,1.5Hz),7.63(2H,d,J=8.8Hz),8.06(1H,d,J=9.0Hz)
13C-NMR(125MHz,DMSO-d6):δ122.17,122.92,123.27,123.41,125.83,126.47,127.21,127.50,127.58,128.60,128.93,129.22,135.20,135.96,137.82,138.33,152.36
熔点:201-202℃
·2-对甲苯基-乙磺酸[2-[3-(2,4-二氯-苯基)-脲基]苯基]-酰胺
(ED-37)
收率:74%
1H-NMR(400MHz,CDCl3):δ2.34(3H,s),3.49(1H,br),6.79(1H,d,J=15.9Hz),7.03(1H,td,J=8.1,1.5Hz),7.10-7.30(8H,m),7.36(1H,d,J=15.9Hz),7.43(1H,br),7.53(1H,d,J=2.4Hz),7.60(1H,br),7.72(1H,dd,J=8.1,1.5Hz)
13C-NMR(125MHz,DMSO-d6):δ20.98,118.13,119.18,121.42,122.76,123.08,124.75,125.57,127.67,128.43,128.88,129.45,129.65,130.51,131.02,136.29,139.98,140.64,140.99,152.20
熔点:182-183℃
产业上的可利用性
本发明的非肽性酰胺衍生物具有丝氨酸消旋酶抑制活性,能够作为用于预防、治疗NMDAR的过度活化所伴有的病症和神经变性疾患的药物。并且,也能够作为解析神经系统中的丝氨酸消旋酶的功能的研究试药。
Claims (17)
1.一种丝氨酸消旋酶抑制剂,其特征在于:
以选自下述通式[MM_1]、[DR_1]、[DR′_1]、[LW_1]和[ED_1]的任意化合物组中的一个以上的化合物作为有效成分,
其中,通式[MM_1]表示苯氧基-(N-取代氨基甲酰基甲基)-乙酰胺衍生物,
式[MM_1]中,R1m表示选自氢原子、卤原子、烷基、烷氧基和可以被保护的羟基中的一个以上的原子或取代基;R2m表示可以具有取代基的芳基、芳烷基或环烷基;Xm表示氧原子或硫原子,
通式[DR_1]表示N-(取代)-2-(取代氨磺酰氨基)-乙酰胺衍生物,
式[DR_1]中,R1d表示选自氢原子、卤原子、烷基、烷氧基和可以被保护的羟基中的一个以上的原子或取代基;R2d表示可以具有取代基的芳基、芳烷基或芳基乙酰胺基;Xd表示氧原子或亚氨基;nd表示0或1,
通式[DR′_1]表示N-(取代)-2-(取代氨磺酰氨基)-乙酰胺衍生物,
式[DR′_1]中,R1d′表示选自氢原子、卤原子、烷基、烷氧基和可以被保护的羟基中的一个以上的原子或取代基;R2d′表示可以具有取代基的芳基、芳烷基或芳基乙酰胺基;Xd′表示氧原子或亚氨基,
通式[LW_1]表示N-[(酰基)肼基硫代羰基]-乙酰胺衍生物,
式[LW_1]中,R1w表示可以具有取代基的苯乙烯基、苄基或环己基甲基;R2w表示可以具有取代基的芳基、含有氧原子或硫原子作为成环原子的杂环基;nw表示0、1或2,
通式[ED_1]表示苯磺酰胺衍生物,
式[ED_1]中,R1e相同或不同,表示选自氢原子、卤原子、烷基、烷氧基中的1个以上的原子或取代基;R2e表示可以具有取代基的苯基或甲苯磺酰基;Ae表示亚烷基或亚苯基。
2.一种丝氨酸消旋酶抑制剂,其特征在于:
以下述通式[MM_1]所示的苯氧基-(N-取代氨基甲酰基甲基)-乙酰胺衍生物作为有效成分,
式中,R1m表示选自氢原子、卤原子、烷基、烷氧基和可以被保护的羟基中的一个以上的原子或取代基;R2m表示可以具有取代基的芳基、芳烷基或环烷基;Xm表示氧原子或硫原子。
3.一种下述通式[MM_2]所示的苯氧基-(N-取代氨基甲酰基甲基)-乙酰胺衍生物,
式中,R1m表示选自氢原子、卤原子、烷基、烷氧基和可以被保护的羟基中的一个以上的原子或取代基;R2Am表示可以具有选自卤原子、烷基、烷氧基、硝基和可以被保护的羟基中的1~2个原子或取代基作为取代基的芳基、芳烷基或环烷基;Xm表示氧原子或硫原子。
4.一种丝氨酸消旋酶抑制剂,其特征在于:
以下述通式[DR_1]所示的N-(取代)-2-(取代氨磺酰氨基)-乙酰胺衍生物作为有效成分,
式中,R1d表示选自氢原子、卤原子、烷基、烷氧基和可以被保护的羟基中的一个以上的原子或取代基;R2d表示可以具有取代基的芳基、芳烷基或芳基乙酰胺基;Xd表示氧原子或亚氨基;nd表示0或1。
5.一种下述通式[DR_1a]所示的N-(取代)-2-(取代氨磺酰氨基)-乙酰胺衍生物,
式中、R1d表示选自氢原子、卤原子、烷基、烷氧基和可以被保护的羟基中的一个以上的原子或取代基;R2d表示可以具有取代基的芳基、芳烷基或芳基乙酰胺基;Xd表示氧原子或亚氨基。
6.一种下述通式[DR_1b]所示的N-(取代)-2-(取代氨磺酰氨基)-乙酰胺衍生物,
式中,R1d表示选自氢原子、卤原子、烷基、烷氧基和可以被保护的羟基中的一个以上的原子或取代基;R2ad表示可以具有取代基的苄基或可以具有取代基的芳基乙酰胺基。
7.一种丝氨酸消旋酶抑制剂,其特征在于:
以下述通式[DR′_1]所示的N-(取代)-2-(取代氨磺酰氨基)-乙酰胺衍生物作为有效成分,
式中,R1d′表示选自氢原子、卤原子、烷基、烷氧基和可以被保护的羟基中的一个以上的原子或取代基;R2d′表示可以具有取代基的芳基、芳烷基或芳基乙酰胺基;Xd′表示氧原子或亚氨基。
8.下述通式[DR′_1]所示的N-(取代)-2-(取代氨磺酰氨基)-乙酰胺衍生物,
式中,R1d′表示选自氢原子、卤原子、烷基、烷氧基和可以被保护的羟基中的一个以上的原子或取代基;R2d′表示可以具有取代基的芳基、芳烷基或芳基乙酰胺基;Xd′表示氧原子或亚氨基。
9.一种丝氨酸消旋酶抑制剂,其特征在于:
以下述通式[LW_1]所示的N-[(酰基)肼基硫代羰基]-乙酰胺衍生物作为有效成分,
式中,R1w表示可以具有取代基的苯乙烯基、苄基或环己基甲基;R2w表示可以具有取代基的芳基、含有氧原子或硫原子作为成环原子的杂环基;nw表示0、1或2。
10.一种下述通式[LW_1d]所示的N-[(酰基)肼基硫代羰基]-乙酰胺衍生物,
式中,R13w表示卤原子;R12w、R14w、R15w和R16w相同或不同,表示选自氢原子、卤原子、烷基、烷氧基、硝基中的一个以上的原子或取代基;R2bw表示可以具有取代基的芳基、含有氧原子或硫原子作为成环原子的杂环基。
11.一种下述通式[LW_1e]所示的N-[(酰基)肼基硫代羰基]-乙酰胺衍生物,
式中,R2cw表示可以具有取代基含有氧原子或氧原子作为成环原子的杂环基,取代基R12w~R16w表示以下的组合:
(1)R12w、R14w和R16w为氢原子,R13w和R15w为卤原子;
(2)R13w、R14w和R15w为氢原子,R12w和R16w为烷氧基。
12.一种下述通式[LW_1g]所示的N-[(酰基)肼基硫代羰基]-乙酰胺衍生物,
式中,R1aw表示选自卤原子、烷基、烷氧基、硝基和可以被保护的羟基中的一个以上的原子或取代基;取代基R22w~R26w表示以下的组合:
(1)R24w为卤原子,R22w、R23w、R25w和R26w为氢原子;
(2)R23w为烷基,R22w、R24w、R25w和R26w为氢原子;
(3)R22w和R26w为卤原子,R23w、R24w和R26w为氢原子;
(4)R23w和R25w为卤原子;R22w、R24w和R26w为氢原子。
13.一种下述通式[LW_1c]所示的N-[(酰基)肼基硫代羰基]-乙酰胺衍生物,
式中,R2w表示可以具有取代基的芳基、含有氧原子或氧原子作为成环原子的杂环基;nw表示0、1或2。
14.一种丝氨酸消旋酶抑制剂,其特征在于:
以下述通式[ED_1]所示的苯磺酰胺衍生物作为有效成分,
式中,R1e相同或不同,表示选自氢原子、卤原子、烷基、烷氧基中的一个以上的原子或取代基;R2e表示可以具有取代基的苯基或甲苯磺酰基;Ae表示亚烷基或亚苯基。
15.一种下述通式[ED_1aa]所示的苯磺酰胺衍生物,
式中,R11e表示氢原子、烷基或烷氧基;R21e表示氢原子、卤原子或烷基;R22e表示氢原子或卤原子;R23e表示氢原子或卤原子;R24e表示氢原子、烷基或烷氧基;Xe表示氧原子或硫原子;ne表示整数2或3,
但是,不包括R11e为烷基、R21e和R23e为卤原子、R22e和R24e为氢卤原子、Xe为氧原子、ne为2的情况。
16.一种下述通式[ED_1ab]所示的苯磺酰胺衍生物,
式中,R11e表示氢原子、烷基或烷氧基;R25e和R25e相同或不同,表示氢原子或烷基;ne表示整数2或3。
17.一种下述通式[ED_1ba]所示的苯磺酰胺衍生物,
式中,R11e表示氢原子、烷基或烷氧基;R22e和R23e相同或不同,表示氢原子或烷基。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012-015233 | 2012-01-27 | ||
JP2012015233 | 2012-01-27 | ||
JP2012-037977 | 2012-02-23 | ||
JP2012037977 | 2012-02-23 | ||
JP2012-049955 | 2012-03-07 | ||
JP2012049955 | 2012-03-07 | ||
JP2012-135591 | 2012-06-15 | ||
JP2012135591 | 2012-06-15 | ||
PCT/JP2013/051385 WO2013111798A1 (ja) | 2012-01-27 | 2013-01-24 | セリンラセマーゼ阻害剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104220058A true CN104220058A (zh) | 2014-12-17 |
Family
ID=48873511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380017021.8A Pending CN104220058A (zh) | 2012-01-27 | 2013-01-24 | 丝氨酸消旋酶抑制剂 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9216954B2 (zh) |
EP (1) | EP2808014A4 (zh) |
JP (1) | JP6037396B2 (zh) |
KR (1) | KR20150000875A (zh) |
CN (1) | CN104220058A (zh) |
CA (1) | CA2863006A1 (zh) |
TW (1) | TW201339126A (zh) |
WO (1) | WO2013111798A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113100233A (zh) * | 2021-04-19 | 2021-07-13 | 中国农业科学院植物保护研究所 | 芳甲羟肟酸及其衍生物作为几丁质脱乙酰基酶抑制剂及植物抗真菌剂的应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9518011B2 (en) | 2012-11-21 | 2016-12-13 | Nippon Soda Co., Ltd. | Recording material produced using non-phenol compound |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2780876B2 (ja) * | 1994-12-15 | 1998-07-30 | アンリツ株式会社 | 微結晶化半導体薄膜を用いる温度センサシステム |
BR9713186A (pt) | 1996-08-28 | 1999-11-03 | Procter & Gamble | Inibidores de metaloprotease 1,3-diheterocìclicos |
CA2374641A1 (en) | 1999-05-24 | 2000-11-30 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
US20030212262A1 (en) * | 2000-04-04 | 2003-11-13 | Connolly Thomas M | Human serine racemase |
KR20030007797A (ko) | 2000-05-31 | 2003-01-23 | 워너-램버트 캄파니 | 바이시클릭 시클로헥실아민 및 nmda 수용체길항제로서의 그의 용도 |
US20020127605A1 (en) * | 2000-11-28 | 2002-09-12 | Hamilton Gregory S. | Bisubstituted carbocyclic cyclophilin binding compounds and their use |
WO2004046122A2 (en) | 2002-11-16 | 2004-06-03 | Oxford Glycosciences (Uk) Ltd | Benzoxazole, benzthiazole and benzimidazole acid derivatives and their use as heparanase inhibitors |
JP2007527412A (ja) * | 2003-10-24 | 2007-09-27 | エグゼリクシス, インコーポレイテッド | Taoキナーゼモジュレーターおよび使用方法 |
CA2608726C (en) | 2005-05-20 | 2013-07-09 | Methylgene Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
WO2007053794A2 (en) | 2005-10-21 | 2007-05-10 | Bezwada Biomedical Llc | Functionalized phenolic compounds and absorbable therefrom |
EP2049490A1 (en) | 2006-06-09 | 2009-04-22 | Astra Zeneca AB | N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl]-l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors |
JP4857071B2 (ja) * | 2006-10-12 | 2012-01-18 | 潤平 笹部 | 筋萎縮性側策硬化症(als)の検出方法 |
US7786157B2 (en) | 2007-03-16 | 2010-08-31 | Chemocentryx, Inc. | OXO-imidazolidines as modulators of chemokine receptors |
EP2219646A4 (en) * | 2007-12-21 | 2010-12-22 | Univ Rochester | PROCESS FOR EXTENDING THE LIFE OF EUKARYOTIC ORGANISMS |
CN101998951B (zh) | 2008-04-10 | 2013-07-17 | 大鹏药品工业株式会社 | 酰基硫脲化合物或其盐及其用途 |
FR2930552B1 (fr) * | 2008-04-24 | 2012-10-12 | Centre Nat Rech Scient | N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog |
AU2009326259A1 (en) | 2008-12-08 | 2011-07-28 | Boehringer Ingelheim International Gmbh | Compounds for treating cancer |
US9034857B2 (en) * | 2010-03-24 | 2015-05-19 | Health Research, Inc. | Methods for reducing superoxide anions in eukaryotic organisms |
WO2011139636A1 (en) * | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small molecule inhibitors of functions of the hiv-1 matrix protein |
KR20110137941A (ko) * | 2010-06-18 | 2011-12-26 | (주) 에빅스젠 | 신규한 티오우레아 또는 우레아 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 aids 예방 또는 치료용 약학 조성물 |
-
2013
- 2013-01-24 EP EP13741215.1A patent/EP2808014A4/en not_active Withdrawn
- 2013-01-24 JP JP2013555295A patent/JP6037396B2/ja not_active Expired - Fee Related
- 2013-01-24 CN CN201380017021.8A patent/CN104220058A/zh active Pending
- 2013-01-24 US US14/375,006 patent/US9216954B2/en not_active Expired - Fee Related
- 2013-01-24 CA CA2863006A patent/CA2863006A1/en not_active Abandoned
- 2013-01-24 WO PCT/JP2013/051385 patent/WO2013111798A1/ja active Application Filing
- 2013-01-24 KR KR1020147023788A patent/KR20150000875A/ko not_active Withdrawn
- 2013-01-25 TW TW102102801A patent/TW201339126A/zh unknown
Non-Patent Citations (1)
Title |
---|
冯小明 等: "2-芳酰氨基-5-(5-苄基四唑-2-亚甲基)-1,3,4-噻二唑的合成", 《有机化学》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113100233A (zh) * | 2021-04-19 | 2021-07-13 | 中国农业科学院植物保护研究所 | 芳甲羟肟酸及其衍生物作为几丁质脱乙酰基酶抑制剂及植物抗真菌剂的应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2013111798A1 (ja) | 2013-08-01 |
EP2808014A4 (en) | 2016-01-13 |
JPWO2013111798A1 (ja) | 2015-05-11 |
US9216954B2 (en) | 2015-12-22 |
EP2808014A1 (en) | 2014-12-03 |
CA2863006A1 (en) | 2013-08-01 |
US20140371291A1 (en) | 2014-12-18 |
TW201339126A (zh) | 2013-10-01 |
JP6037396B2 (ja) | 2016-12-07 |
KR20150000875A (ko) | 2015-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Toth et al. | Sulfonimidamide analogs of oncolytic sulfonylureas, 1 | |
RU2275360C2 (ru) | Ортозамещенные азотсодержащие бисарильные соединения для применения в качестве ингибиторов калиевого канала, а также содержащие их фармацевтические композиции | |
AU2006272837B2 (en) | N-(arylamino)-sulfonamide inhibitors of MEK | |
US6492362B1 (en) | Compounds and compositions as cathepsin S inhibitors | |
RU2424227C2 (ru) | Антагонист рецептора s1p3 | |
US20030225099A1 (en) | Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | |
AU2008203531A1 (en) | Sulfonamides as potassium channel blockers | |
KR101872553B1 (ko) | Trpm8 수용체 길항제들 | |
HRP20020264A2 (en) | 2'-substituted 1,1'-biphenyl-2-carbonamides, method for the production thereof, use thereof as a medicament and pharmaceutical preparations containing said compounds | |
KR101194968B1 (ko) | Ptp 1-b 저해제로서의 1,1’-(1,2-에틴디일)비스-벤젠유도체 | |
JP4885393B2 (ja) | 医薬として活性なスルホニル・ヒドラジド誘導体 | |
KR101493717B1 (ko) | 알킬아민 유도체 | |
AU2007253424B2 (en) | (2R)-2-[(4-sulfonyl)aminophenyl]propanamides and pharmaceutical compositions containing them | |
CN102516152B (zh) | 一种α-二氟羰基取代的手性叔醇类化合物及其合成方法和应用 | |
ITBO20090078A1 (it) | Composti per il trattamento del tumore alla prostata e procedimenti per la loro sintesi | |
CN104220058A (zh) | 丝氨酸消旋酶抑制剂 | |
CN109134391A (zh) | 一种酰基磺酰胺类衍生物及其制备方法与应用 | |
JP4486254B2 (ja) | 2,5−置換されたベンゼンスルホニル尿素および−チオ尿素、それらの製法、それらの使用およびそれらを含有する医薬製剤 | |
CN1137519A (zh) | 取代的苯磺酰脲和苯磺酰硫脲、其制备方法、其用作制备药用制剂及含它们的药用制剂 | |
KR20050089070A (ko) | 로타마제 억제용 화합물 | |
RU2184110C2 (ru) | Производные нитрометилтиобензола, способ их получения (варианты) и фармацевтическая композиция | |
RU2233840C2 (ru) | Новые производные липоевой кислоты, способ их получения (варианты), фармацевтическая композиция | |
WO2006047302A1 (en) | Bissulfonamide compounds as agonists of galr1, compositions, and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20141217 |